Search this site

The Nelson Advisors Guide for Founders to HealthTech and MedTech Success in 2026: 10 European Case Studies Executive summary Europe has quietly become one of the most productive regions on earth for building health and medical technology companies of genuine scale. Over the past decade a cohort of founders has turned the continent's structural disadvantages, fragmented markets, multiple regulators, conservative public payers, slow procurement, into the very foundations of durable, defendable businesses. This guide examines ten of them in depth. The companies profiled here are deliberately varied. They span pure software platforms (Doctolib, Ada Health, Kry/Livi), deep-science instrumentation (Oxford Nanopore), surgical robotics (CMR Surgical), applied genomics and AI biology (SOPHiA GENETICS, Owkin), clinical-AI infrastructure (Corti), tech-enabled care delivery (Cera) and preventive consumer medicine (Neko Health). Between them they have raised well over five billion euros from grants, venture capital, private equity, strategic pharmaceutical partners and the public markets. Some are now profitable; several are not; one cautionary comparator in this report went bankrupt after a multi-billion-dollar valuation. Three themes run through every case. First, the most defendable moats in European health technology are built not from clever algorithms but from proprietary data, regulatory clearance and entrenchment in the workflows of clinicians and payers, assets that take years to accumulate and are extremely hard to copy. Second, the distinction between being “AI-native” and an “AI enabler” matters far less than founders assume: what matters is whether AI is layered on top of a genuine distribution and data advantage. Third, the 2022–24 funding winter separated the survivors from the casualties almost entirely on the basis of capital discipline and proximity to whoever actually pays for healthcare. This is not a ranking. It is a working reference for founders and boards: a set of strategies, tactics, funding journeys, critical decisions and hard-won lessons drawn from companies that have already walked the path you are on. Read it as a map of what has worked, what has nearly killed otherwise excellent businesses, and where the genuinely defensible value in this market sits in 2026. How to read this guide ▸ Each case study opens with a fact box (HQ, founders, funding, valuation, AI posture) followed by analysis of strategy, scalability, moat, risks, critical decisions and lessons. ▸ Funding figures are drawn from company announcements and reputable reporting to mid-2026; private valuations are last-round marks and may be stale. Treat them as directional, not audited. ▸ Cross-cutting chapters after the case studies synthesise the patterns: AI-native versus AI-enabler, moat construction, the funding map, and the risks that have sunk well-capitalised peers. The 2026 landscape: why these lessons matter now Founders entering HealthTech and MedTech in 2026 face a market that looks superficially similar to 2021 but behaves completely differently. The exuberant capital of the pandemic era has gone; in its place is a more demanding investor base that wants evidence of clinical impact, a credible path to profitability and a defensible position before it writes large cheques. At the same time, the underlying demand has never been stronger. Ageing populations, chronic disease burden, workforce shortages across European health systems and the maturation of artificial intelligence have combined to make health one of the few categories where technology can simultaneously cut cost and improve outcomes. The opportunity is therefore real, but the bar is higher. The companies in this report succeeded not because they rode a hype cycle but because they solved a structural problem for a payer, a clinician or a patient and then made that solution progressively harder to displace. Understanding how they did it and where comparable companies failed, is the single most useful preparation a founder can do. A simple framework: scalable, sustainable, defendable Throughout this guide we assess each company against three properties that, in our advisory work, separate enduring health-technology businesses from those that raise large rounds and then stall. • Scalable — can the business add revenue faster than it adds cost? Software platforms scale through near-zero marginal cost; hardware and care businesses scale through repeatable unit models, manufacturing capacity or acquisition roll-ups. The question is always: what is the unit, and does the next unit get cheaper? • Sustainable — does the business have a route to funding itself? In a market where reimbursement is slow and capital is expensive, the survivors are those with recurring revenue, demonstrated unit economics and the discipline to reach profitability before the money runs out. • Defendable — once the business works, how hard is it to copy? In health the durable moats are proprietary longitudinal data, regulatory clearance, entrenchment in clinical workflows, patent estates and trusted brand. Features are not moats; the assets that take years to build are. With that framework in mind, we turn to the ten companies. Why these ten companies These ten were not chosen as a definitive ranking of the best European health-technology companies, nor as an investment recommendation. They were selected because, between them, they illustrate the full range of strategies, business models, funding paths and moats a founder is likely to consider, also because each has progressed far enough to offer real, tested lessons rather than early promise. The selection deliberately spans the spectrum from pure software to deep science. Doctolib, Ada Health and Kry/Livi represent software-led platforms and digital care. Oxford Nanopore and CMR Surgical represent capital-intensive deep-science hardware. SOPHiA GENETICS and Owkin sit at the data-and-AI layer of genomics and drug discovery. Corti represents pure clinical-AI infrastructure. Cera represents technology-enabled care delivery, and Neko Health represents consumer-facing preventive medicine. The set also spans the funding journey, from companies still private and venture-backed, through those that took strategic capital from industry partners, to two that have weathered the public markets — and several European geographies, with companies anchored in France, the United Kingdom, Switzerland, Germany, Sweden and Denmark. Just as importantly, the cohort spans outcomes. Some are profitable; several are not; valuations have risen for some and fallen sharply for others. We have resisted the temptation to present only unambiguous successes, because the most useful lessons frequently lie in the tensions, a brilliant business with a punished share price, a category creator still searching for profitability, an AI pioneer confronting a new paradigm. Read together, they form a more honest map of the territory than a list of winners would. Part One: Ten European case studies The ten companies are grouped loosely from broad software platforms through to deep science and consumer medicine. Each can be read independently. 1. Doctolib — the operating system for European healthcare HQ / country Paris, France (major hub in Berlin) Founded 2013 Founders Stanislas Niox-Château (CEO) and co-founders Sub-sector Practice-management SaaS, e-booking and teleconsultation Funding to date ~€790m+ private; never IPO’d (Series F €500m, 2022) Key backers Accel, General Atlantic, Eurazeo, Bpifrance Valuation ~€5.8bn / $6.4bn (2022, reportedly held flat in 2025) AI posture AI enabler — marketplace first, AI layered on from 2024 What it does and why it matters Doctolib is the closest thing Europe has to an operating system for healthcare. Patients use it to find a practitioner, book an appointment and run a video consultation; the much more valuable side of the business sells practice-management software, scheduling, records, billing and, increasingly, AI tools, to doctors, clinics and hospitals. Founded in Paris in 2013 by Stanislas Niox-Château, it now serves more than 135,000 healthcare professionals and is the most valuable startup France has produced. Its significance for founders is that it demonstrates how to build a category-defining platform in a regulated, fragmented, trust-sensitive market and how distribution, not technology, became the moat. Strategy and tactics Doctolib executed a textbook land-and-expand vertical-SaaS strategy. It began with the single sharp problem of appointment booking, then layered teleconsultation, full practice management, payments and AI on top, increasing revenue per practitioner over time. Crucially, growth was driven by a large human field-sales force that built density city by city, signing up doctors in person to overcome the trust barrier that gates technology adoption in medicine. This created a two-sided flywheel: more doctors made the platform more useful to patients, and more patient demand pulled in more doctors. The company’s decision to run COVID-19 vaccination booking for the French state in 2020–21 cemented both its brand and its status as quasi-national infrastructure. Scalable, sustainable, defendable The model is highly scalable: subscriptions of roughly €109–€229 per practitioner per month carry high gross margins and low marginal cost once local density is achieved. On sustainability, 2024 annual recurring revenue reached €348m, up 22.5%, while losses were cut 38% to €53.8m, putting breakeven within reach. Defensibility comes from per-geography network effects, the high switching costs of being a practice’s system of record, GDPR-compliant health-data hosting, and a deep brand of trust. AI-native versus AI-enabler Doctolib is an AI enabler, not an AI-native company. It was built as a marketplace and bolted AI on from 2024 — an ambient-transcription Consultation Assistant (built on Azure OpenAI and the acquisition of Typeless) and an AI phone assistant in 2025. The instructive point is that its AI is valuable precisely because it sits on top of an existing network, distribution and a decade of appointment and clinical data. AI is the layer; the moat is underneath it. Risks and critical decisions The principal risks are recurring data-privacy and regulatory scrutiny, including controversy over using anonymised patient data to train AI, a continued path to profitability and roughly 80% revenue concentration in France. Three critical decisions defined the company: choosing a heavy human field-sales model over pure product-led growth; stepping up to run national vaccination booking; and the decisive 2024 pivot to position itself as an AI clinical platform ahead of a possible 2026–27 IPO. Founder lessons from Doctolib ▸ In regulated verticals, owning the system of record and the local network beats winning on features. ▸ Boots-on-the-ground sales can itself be a moat when trust gates adoption. ▸ A crisis (COVID) can be a catalyst that converts a product into infrastructure. ▸ AI is a layer on top of distribution and data — not a substitute for them. 2. Oxford Nanopore Technologies — owning a new sequencing category HQ / country Oxford, United Kingdom (LSE: ONT) Founded 2005 (University of Oxford spin-out) Founders Hagan Bayley, Gordon Sanghera, Spike Willcocks Sub-sector Genomics instrumentation and consumables (sequencing) Funding to date >$1.1bn pre-IPO; ~£350m raised at 2021 IPO Key backers IP Group, Invesco, Temasek, Nikon, Wellington Valuation ~£1.2bn market cap (2026), down ~75% from IPO peak AI posture AI-enabled deep tech — ML basecalling on a physics moat What it does and why it matters Oxford Nanopore sells a fundamentally different way to read genetic material. Its sequencers pass single DNA or RNA molecules through protein nanopores and read the resulting electrical signal in real time, enabling portable, long-read sequencing, from the USB-stick-sized MinION to the high-throughput PromethION. Spun out of the University of Oxford in 2005 around Professor Hagan Bayley’s chemistry, it created and still leads a sequencing category distinct from the dominant short-read, sequencing-by-synthesis approach. It matters to founders as the archetype of patient, deep-science company building: more than $1.1Bn raised over roughly sixteen years before a landmark IPO, and a moat rooted in physics, biochemistry and intellectual property rather than software alone. Strategy and tactics The strategy was to build one scalable sensing platform, “analysis of anything, by anyone, anywhere” and ladder products from the entry-level Flongle up to PromethION. Tactics included democratising access and seeding academic users with grant programmes (the platform now underpins more than 14,000 publications), continuous accuracy improvements, and a deliberate move up into higher-margin Clinical and BioPharma segments. From 2025 the company showed new discipline, sunsetting weaker products to focus on its profitability path. Scalable, sustainable, defendable Scalability comes from a common sensor across the entire product line and a razor-and-razor-blade model: consumable flow cells and reagents generate recurring revenue tied to the installed base. FY2025 revenue reached £223.9m, up around 24% at constant currency, with Clinical growing roughly 60%. With about £302m of cash at year-end 2025 and guidance for adjusted EBITDA breakeven in 2027, the business is funding its own path to sustainability. Defensibility rests on a deep, litigated patent estate covering pores, enzymes and electronics. AI-native versus AI-enabler Oxford Nanopore is best described as AI-enabled deep tech. The core invention is physical and biochemical, but its Dorado basecaller uses neural networks to convert raw electrical signal into sequence in real time, and machine learning is now used to design novel pore proteins. AI is mission-critical software, but it sits on a moat made of physics and biology, the inverse of a pure-software AI company. Risks and critical decisions The clearest risk is illustrated by the share price: down roughly 75% from its IPO peak, a reminder that a blockbuster listing is a milestone, not a finish line. The company also has meaningful exposure to US federal research funding and is in litigation with BGI/MGI. Three critical decisions shaped it: spinning out around nanopore science in 2005 as a contrarian long-horizon bet; re-engineering its pore chemistry after Illumina’s 2016 patent suit (switching to a CsgG pore) to defuse the litigation; and choosing a London listing in 2021. Founder lessons from Oxford Nanopore ▸ Own a category rather than fight an incumbent head-on. ▸ Razor-and-blade economics turn hardware sales into recurring revenue. ▸ Patents are a living asset — be prepared to re-engineer around your own IP under litigation. ▸ Deep science needs deep, patient capital; a spectacular IPO is the start of public-market discipline, not the end of the journey. 3. CMR Surgical — challenging a monopoly in surgical robotics HQ / country Cambridge, United Kingdom Founded 2014 (as Cambridge Medical Robotics) Founders Mark Slack, Luke Hares, Martin Frost, Paul Roberts, Keith Marshall Sub-sector Surgical robotics (minimally invasive soft-tissue surgery) Funding to date ~$1.4–$1.5bn private (Series D $600m, 2021) Key backers SoftBank Vision Fund 2, Ally Bridge, Tencent, GE Healthcare Valuation $3bn (2021); explored a sale up to ~$4bn in 2025 AI posture AI enabler — mechatronics core, AI/data features added What it does and why it matters CMR Surgical makes Versius, a modular, portable robotic-assisted surgery system that competes directly with Intuitive Surgical’s dominant da Vinci. Where da Vinci is a single large console-and-cart, Versius uses small, independent bedside arm carts that fit existing operating theatres and can be moved between them. Founded in Cambridge in 2014, Versius has now been used in more than 30,000 procedures across 30-plus countries. It matters because it is a credible European challenger to one of medtech’s most entrenched monopolies — and a live lesson in the capital intensity and patience that hardware in medicine demands. Strategy and tactics The strategy was to win as the challenger by competing on cost, footprint and accessibility rather than trying to out-feature the incumbent. Tactically, CMR commercialised internationally first, across Europe, Latin America, Asia and Australia, becoming the second most-adopted soft-tissue robot outside the US before tackling the American market. It built recurring revenue through single-use instruments, service contracts and its Versius Connect data ecosystem, and invested in its own manufacturing capacity in Ely. Scalable, sustainable, defendable Scalability rests on a razor-and-blade model (system plus single-use instruments plus service) and purpose-built manufacturing capacity of around 500 systems a year. The defensibility is real but shallower than the incumbent’s: surgeon and theatre switching costs, multi-jurisdiction regulatory clearances and a growing procedure dataset, set against Intuitive’s roughly 60% global share, 9,000-plus installed systems and around 85% recurring revenue. CMR’s edge is economics and form factor, not scale. AI-native versus AI-enabler CMR is firmly an AI enabler, not AI-native. The core value is mechatronics, robotics and surgeon ergonomics; the robot is teleoperated, not autonomous. AI and data features, procedure analytics, the digital ecosystem, near-infrared imaging, are add-ons layered onto excellent hardware. Risks and critical decisions The risks are formidable: a dominant incumbent, deep-pocketed new US entrants (Medtronic’s Hugo, J&J’s Ottava), high cash intensity, slow surgical sales cycles, a 2025 reliance on debt and a valuation that has been flat since 2021. Three critical decisions stand out: the founding bet on a modular, portable architecture; the decision to internationalise before entering the US; and new leadership’s high-conviction call to scrap the planned first-generation US launch and wait for the cleared Versius Plus, vindicated by FDA clearance in December 2025. Founder lessons from CMR Surgical ▸ Against an entrenched incumbent, differentiate on architecture and economics — don’t try to out-feature them. ▸ Sequence your markets: prove the product in less-defended geographies before the hardest one. ▸ Build recurring revenue into hardware from day one. ▸ Be willing to delay a flagship launch for the right product — and respect that hardware in medicine is brutally capital-intensive. 4. SOPHiA GENETICS — owning the genomic data layer HQ / country Lausanne, Switzerland / Boston, USA (NASDAQ: SOPH) Founded 2011 (EPFL spin-out) Founders Jurgi Camblong, Pierre Hutter, Lars Steinmetz Sub-sector Genomic data analytics / clinical bioinformatics SaaS Funding to date ~$250m pre-IPO; $234M gross at 2021 NASDAQ IPO Key backers Balderton, Generation IM, aMoon, Hitachi Ventures Valuation ~$330–360M market cap (2026), down ~70% from IPO AI posture AI-native within its niche (proprietary ML is the product) What it does and why it matters SOPHiA GENETICS sells SOPHiA DDM, a cloud-based, AI-powered platform that helps hospitals and laboratories analyse and interpret complex genomic and multimodal data for precision medicine, principally in oncology. It sits one layer above the sequencing hardware companies, turning raw sequencer output into clinically actionable insight. Founded in 2011 as an EPFL spin-out, its platform has analysed more than 2.5 million cases across some 70 countries. It matters as a rare European deep-tech company that listed on NASDAQ, and as a case study in owning the data and analytics layer of a value chain rather than the hardware. Strategy and tactics The strategy is a decentralised “data-as-a-network” model: hospitals sequence locally and analyse in SOPHiA’s cloud, so each analysis enriches a shared dataset that improves the algorithms for everyone. Tactics include classic land-and-expand SaaS economics, licensing marquee assays (notably Memorial Sloan Kettering’s MSK-ACCESS and MSK-IMPACT), a 2026 joint venture with MSK in multimodal precision oncology, and monetising the platform with biopharma partners. Scalable, sustainable, defendable The cloud SaaS model is scalable with improving margins (adjusted gross margin around 74%), and revenue reaccelerated to roughly $77m in FY2025, up about 19%. It is not yet self-sustaining, net losses remain large, with adjusted EBITDA breakeven targeted by end-2026. Defensibility comes from a genuine data network effect, a dataset of more than two million genomic profiles, around 31 patents and deep clinical integration that creates high switching costs. AI-native versus AI-enabler SOPHiA is AI-native within its niche: proprietary machine learning is the product, not an add-on. It is, however, an applied AI company for genomics rather than a frontier-model builder, a useful distinction for founders, because applied, domain-specific AI on proprietary data is often more defensible than generic model capability. Risks and critical decisions Risks include persistent losses, a stock down around 70% from IPO, intellectual-property litigation (a European dispute with Guardant Health) and a leadership transition. Three critical decisions defined it: building a decentralised analytics layer rather than a centralised lab; listing on NASDAQ with a dual Swiss-Boston identity; and going all-in on multimodal oncology through the MSK alliance, alongside a deliberate founder-to-CEO succession in 2026. Founder lessons from SOPHiA GENETICS ▸ Own the data layer, not just the workflow — a data network effect compounds with every customer. ▸ Partner with the prestige incumbent (MSK) for instant clinical credibility. ▸ A great moat does not guarantee a great stock; unit economics must eventually deliver. ▸ Plan IPO timing, venue and founder succession deliberately, not reactively. 5. Owkin — strategic capital and an AI-biology moat HQ / country Paris, France / New York, USA Founded 2016 Founders Thomas Clozel (CEO), Gilles Wainrib (President/CSO) Sub-sector AI for drug discovery, biomarkers and trial optimisation Funding to date ~$300m+ equity (Sanofi $180m equity + $90m alliance, 2021) Key backers Sanofi, Bristol Myers Squibb, GV (Google Ventures), Bpifrance Valuation ~$1bn unicorn (last mark; likely stale) AI posture Clearly AI-native — founded around ML on patient data What it does and why it matters Owkin is a French-American “TechBio” company that applies AI and federated learning to hospital data to discover drug targets and biomarkers, optimise clinical trials and build diagnostics. Federated learning lets it train models across hospital datasets without the data ever leaving the institution, a privacy-preserving approach that unlocked access to data others could not touch. It became a unicorn in 2021. It matters as the clearest example in this report of strategic capital: rather than raising plain venture money, Owkin sold equity to the pharmaceutical giants whose problems it solves. Strategy and tactics The strategy is to secure privacy-preserving access to multimodal hospital data, train biology-specialised AI on it, and monetise through pharma partnerships and its own diagnostics and pipeline. Tactically, the defining move was Sanofi’s November 2021 investment of $180m in equity plus $90m for a three-year R&D alliance, the round that made Owkin a unicorn, followed by a deal with Bristol Myers Squibb. From 2025 the company pivoted toward a more scalable platform and licensing model built around an agentic AI co-pilot and a foundational biology model, and spun out its diagnostics business. Scalable, sustainable, defendable Scalability improves markedly with the shift from bespoke services to a licensable software platform. Sustainability is trending the right way, revenue around $86m and roughly doubling, with about $200m of cash and shrinking losses, though the business remains pre-profit and capital-intensive. Defensibility rests on a decade of hospital trust and data access (including a proprietary multi-omics cancer atlas), federated-learning IP and credibility, and embedded relationships with pharma partners who are also shareholders. AI-native versus AI-enabler Owkin is unambiguously AI-native, it was founded around machine learning on patient data and is now building foundational biological models. For founders this case shows both the upside and the dependency of being AI-native: the technology is the company, which makes the data and partnerships that feed it existential. Risks and critical decisions Risks include admitted over-hiring after its mega-rounds, concentration in a few large partners, a potentially stale billion-dollar valuation (down-round risk), an unproven drug pipeline and a frontier-model arms race against far larger players. Three critical decisions defined it: taking Sanofi’s strategic equity and alliance over pure VC; pivoting from services toward a licensable platform; and spinning out diagnostics to refocus the core. Founder lessons from Owkin ▸ Strategic capital — equity plus data plus credibility from an industry partner — can beat plain VC, but it adds dependency. ▸ A regulated-industry data moat is built slowly and is correspondingly hard to copy. ▸ Be honest about over-hiring after mega-rounds; capital can mask a lack of focus. ▸ Evolve from bespoke services toward scalable software, and divest non-core assets to stay focused. The Nelson Advisors Guide for Founders to HealthTech and MedTech Success in 2026: 10 European Case Studies 6. Ada Health — turning regulation into a moat HQ / country Berlin, Germany Founded 2011 (consumer app launched 2016) Founders Claire Novorol, Martin Hirsch, Daniel Nathrath (CEO) Sub-sector AI symptom assessment, triage and care navigation Funding to date ~$190m+ (Series B $90m, 2021; €30m venture debt 2023) Key backers Access Industries, Leaps by Bayer, Samsung Catalyst Fund Valuation ~$600m last reported (2022); likely repriced lower AI posture AI-native, but pre-LLM expert-system AI What it does and why it matters Ada Health builds an AI-powered symptom assessment, triage and care-navigation platform. A consumer app launched in 2016 lets users describe symptoms and receive a probabilistic assessment and guidance on what to do next; by late 2024 it had handled more than 35 Million assessments. Founded in Berlin (and not to be confused with the unrelated Canadian customer-service company Ada Support), it is one of Europe’s most-used digital triage tools. It matters as a case study in converting regulatory clearance into a durable moat, and in the difficult art of monetising a free consumer health product. Strategy and tactics The central strategic move was a pivot from a free consumer app, which built brand, reach and a vast dataset, to an enterprise and B2B2C model, selling “Ada Assess” to health systems, payers, pharma and governments including Bayer, Novartis, Pfizer and US health systems. After the 2022 downturn the company repositioned hard around profitability and clinical credibility, and used venture debt to extend runway with less dilution. Scalable, sustainable, defendable The product is highly scalable: software-only AI triage with near-zero marginal cost, available in multiple languages. On sustainability, the company stated it reached profitability at the end of 2023 with 260% year-on-year revenue growth, driven by enterprise contracts. Defensibility comes from a physician-curated medical knowledge base, EU-MDR Class IIa certification and ISO 13485, a trusted consumer brand and 35 million-plus structured real-world assessments. AI-native versus AI-enabler Ada is AI-native but in a specific, instructive sense: it was built around a proprietary probabilistic medical-reasoning engine, not a bolt-on, yet that engine predates the generative-LLM wave. Large language models are now both a competitive threat and a strategic question for the company, illustrating that being AI-native at one moment does not guarantee defensibility against the next paradigm shift. Risks and critical decisions Risks include LLM-driven disruption (ChatGPT, Google and others), medical-advice liability, thin consumer monetisation and enterprise concentration. Three critical decisions defined it: the early pivot from a doctor-facing network to a consumer symptom checker; the later pivot to a monetised enterprise model prioritising profitability after 2022; and the early investment in EU-MDR certification, which turned a compliance cost into a competitive moat. Founder lessons from Ada Health ▸ In regulated markets, certification and clinical validation are a durable moat, not just a cost. ▸ A free consumer product can be a data-and-brand engine — but it rarely funds deep tech. Find the enterprise payer. ▸ In a downturn, choose profitability over vanity growth. ▸ Being AI-native at one moment is not permanent defensibility — you must actively renew it against paradigm shifts such as LLMs. 7. Kry / Livi — discipline and the hybrid care model HQ / country Stockholm, Sweden (Livi in UK and France) Founded 2014 Founders Johannes Schildt (CEO), Josefin Landgård and co-founders Sub-sector Digital-first primary care / telehealth (hybrid) Funding to date ~$700m total (Series D ~$300m, 2021); no IPO Key backers Accel, Index Ventures, Ontario Teachers’, CPP Investments, Fidelity Valuation ~$2bn last mark (2021); likely stale post-repricing AI posture AI adopter — clinical-ops company, AI as a margin lever What it does and why it matters Kry, branded Livi in the UK and France, is a digital-first primary care company offering app-based video consultations alongside owned physical clinics, a hybrid “phygital” model across Northern Europe. Founded in Stockholm in 2014, it now serves more than seven million patients with over 1,300 clinicians. It matters above all as a survival story: Kry came through the telehealth crash that bankrupted Babylon Health, and did so through capital discipline rather than momentum. Strategy and tactics The strategy combined digital and physical care, the app as a funnel, owned clinics for higher-value and chronic care, with multi-country expansion built on genuine localisation rather than copy-paste (per-visit payment in Sweden versus free-at-point-of-use in the NHS). Tactics included expanding wallet share into mental health, weight management and occupational health, acquiring clinics, and anchoring revenue to public payers with a cost-saving argument of roughly 40% versus in-person care. Scalable, sustainable, defendable The model proved scalable, the patient base grew roughly a hundredfold in five years and AI now cuts clinician administrative time by around 30%. On sustainability, all of its markets were individually profitable by end-2024, with group profit deliberately delayed to fund generative-AI investment; FY2024 revenue was around €220m, up 13%. Defensibility comes from an employed clinician network (quality control versus US-style marketplaces), public-payer and government contracts, multi-country regulatory know-how and owned clinic assets. AI-native versus AI-enabler Kry is an AI adopter, not AI-native. It was built as a telehealth and clinical-operations company, with AI layered in for efficiency. Tellingly, its CEO has publicly framed generative AI as an overhead that is delaying group profitability, a candid view of AI as a margin lever rather than the core product. Risks and critical decisions Risks include the commoditisation of video consultation (now a feature inside larger platforms such as Doctolib), roughly 78% revenue concentration in Sweden, and dependence on reimbursement policy. Three critical decisions defined it: the 2022 pivot from hyper-growth to profitability, cutting around 400 jobs and exiting the German consumer market — which arguably saved the company; the hybrid owned-clinic strategy; and the deliberate decision to delay group profitability to fund AI. Founder lessons from Kry / Livi ▸ Multi-country health expansion needs real localisation, not copy-paste. ▸ Discipline beats momentum in a downturn — Kry survived where Babylon failed. ▸ Own the hard, defensible parts (employed clinicians, clinics), and anchor to whoever actually pays. ▸ Treat AI as a margin lever and be transparent with investors about the trade-off. 8. Cera — a data moat from owning care delivery HQ / country London, United Kingdom Founded 2015–16 Founders Dr Ben Maruthappu (CEO), Marek Sacha Sub-sector Digital-first home healthcare / care delivery Funding to date ~$571m (£450m) across ~13 rounds; latest >$150m, 2025 Key backers Kairos, BDT & MSD Partners, Schroders Capital, Vanderbilt Endowment Valuation Unicorn (>$1bn) as of 2025; exact figure undisclosed AI posture AI enabler evolving to AI-led — care operator first What it does and why it matters Cera is Europe’s largest digital-first home healthcare provider, delivering AI-powered care, nursing and telehealth in patients’ homes as an alternative to hospital and residential care. Founded in 2015–16 by NHS doctor Ben Maruthappu after his mother received fragmented post-fracture care, it employs more than 10,000 carers and nurses, works with over 150 local authorities and around two-thirds of NHS Integrated Care Systems. It matters because, unusually for the sector, Cera is profitable, and because its decision to own care delivery created a proprietary data moat that pure-software rivals cannot replicate. Strategy and tactics The strategy is to replace expensive hospital and residential beds with technology-enabled care at home. Cera built an actual care-delivery business, it employs carers and layered a proprietary digital platform on top, using AI to predict deterioration and falls from daily carer-collected data and intervene early (it claims to predict up to around 80% of deterioration and cut hospitalisations by roughly a third). It grows by acquiring and rolling up fragmented home-care agencies and anchors revenue on recurring public-sector contracts. Scalable, sustainable, defendable Scalability comes from combining software with an acquisition roll-up across a highly fragmented market. On sustainability, Cera reported being EBITDA-positive in 2023 and free-cash-flow positive in 2024, exceptionally rare for a healthtech scale-up, which de-risked its 2025 unicorn round of more than $150M. Defensibility rests on the proprietary longitudinal dataset generated by millions of daily home visits, deep entrenchment with NHS and local-authority commissioners, and scale as the UK’s largest operator. AI-native versus AI-enabler Cera is an AI enabler evolving toward AI-led. Its core business is physical care delivery; AI is layered on to optimise it through predictive risk, scheduling and documentation. It markets itself as “AI-led home healthcare,” but the underlying model is operational first and algorithmic second and that operational layer is precisely what generates the data the AI needs. Risks and critical decisions Risks include heavy dependence on public-sector budgets and contract renewals, margin pressure in low-margin care, labour intensity and wage inflation, scrutiny of its AI claims, and integration risk from acquisitions. Three critical decisions defined it: building a care operator rather than a pure software platform; anchoring on public-sector contracts for defensive recurring revenue; and prioritising profitability over pure growth, which gave it negotiating leverage and resilience. Founder lessons from Cera ▸ Owning the full delivery stack creates a proprietary data moat that software-only rivals lack. ▸ In healthcare, demonstrable cost savings to the payer is the strongest sales argument. ▸ Reaching profitability buys leverage and resilience in a sector littered with cash-burning failures. ▸ Roll-up of a fragmented market can be a legitimate scaling engine — if integration is disciplined. 9. Corti — AI infrastructure for healthcare HQ / country Copenhagen, Denmark Founded 2014–16 Founders Andreas Cleve (CEO), Lars Maaløe (CTO) and co-founders Sub-sector Clinical-AI infrastructure / ambient clinical intelligence Funding to date ~$103m (Series B $60m, 2023) Key backers Prosus Ventures, Atomico, Eurazeo, EIFO Valuation Undisclosed AI posture Genuinely AI-native — healthcare-specific foundation models What it does and why it matters Corti builds healthcare-specialised AI infrastructure, foundation models and APIs for speech-to-text, text generation, agentic workflows and clinical documentation, that act as a real-time co-pilot during clinical conversations. It first became known for AI that detects cardiac arrest during emergency calls. Founded in Copenhagen, its technology now powers applications serving more than 100 Million patients a year and over a million interactions a week, including in the NHS. It matters as one of the clearest AI-native companies in this report, and as a model for scaling through infrastructure rather than selling a single product. Strategy and tactics Corti’s defining strategic move was to pivot from selling a finished co-pilot to becoming AI infrastructure for healthcare developers, opening its API to the world in 2025 and launching healthcare-specific foundation models trained exclusively on healthcare data, explicitly positioned against general-purpose LLMs as safer and more suitable for clinical use. Tactics include an API and SDK platform play, partnerships with EHR vendors and virtual-care platforms, and aggressive US expansion. Scalable, sustainable, defendable The platform model is highly scalable: others build on Corti, multiplying its reach (it reported a roughly fortyfold increase in projects built on its platform over two quarters). Sustainability is less proven, reported revenue of around $13M in 2025 is modest against the capital raised, so the infrastructure pivot must monetise. Defensibility comes from nearly a decade of peer-reviewed research and proprietary clinical training data drawn from millions of real patient interactions, a safety and trust advantage in a domain where general models are risky. AI-native versus AI-enabler Corti is genuinely AI-native: the entire company is built around proprietary healthcare AI models, and AI is the product rather than an add-on. It is the strongest example in this report of a company whose moat is domain-specific AI, although, importantly, the moat is the proprietary clinical data and published evidence, not the model architecture itself. Risks and critical decisions Risks include intense competition from well-funded rivals (Microsoft/Nuance DAX, Abridge, Suki, Nabla) and from general-purpose LLM providers moving into healthcare, clinical-safety and liability burdens, long enterprise sales cycles and modest revenue relative to capital. Three critical decisions defined it: the life-or-death origin in cardiac-arrest detection that built clinical credibility and data; the 2024–25 pivot to an open API and foundation-model business; and the deliberate choice to build healthcare-specific models rather than fine-tune general LLMs. Founder lessons from Corti ▸ In clinical AI, proprietary domain data and published evidence are the moat — not the model architecture. ▸ Specialisation can beat general-purpose incumbents on safety and trust. ▸ Becoming infrastructure that others build on can scale reach far faster than selling one product. ▸ Watch the gap between reach and revenue: an infrastructure pivot must ultimately monetise. 10. Neko Health — brand, hardware and preventive medicine HQ / country Stockholm, Sweden Founded 2018 (publicly launched 2023) Founders Hjalmar Nilsonne (CEO), Daniel Ek (chairman) Sub-sector Preventive health / consumer medtech (hardware + AI + clinics) Funding to date ~$325m+ (Series B $260m at ~$1.8bn, 2025) Key backers Lightspeed, General Catalyst, Lakestar, Atomico Valuation ~$1.8bn (January 2025) AI posture Hardware-and-AI-native — proprietary scanner plus AI analysis What it does and why it matters Neko Health operates AI-powered, non-invasive full-body scanning clinics that capture millions of data points, skin and moles, cardiovascular and metabolic markers, in minutes, for early detection and prevention. Co-founded in 2018 by Hjalmar Nilsonne and Spotify’s Daniel Ek, it scanned roughly 10,000 patients across Stockholm and London by early 2025, with a waitlist that grew past 100,000. It matters as a high-conviction bet on shifting healthcare from treatment to prevention, and as a study in how a trusted founder brand and a premium consumer experience can generate demand at remarkable speed. Strategy and tactics The strategy is to make preventive, broad-spectrum screening fast, affordable, convenient and consumer-friendly. Tactics include building proprietary scanning hardware and AI analysis in-house (vertical integration), a premium consumer-pay model with a curated, retail-quality clinic experience, demand generation through waitlists and Ek’s brand halo, deliberate one-market-at-a-time geographic rollout, and reinvestment in diagnostics to widen what the scans can detect. Scalable, sustainable, defendable Scalability comes from a repeatable clinic-plus-standardised-hardware unit model, where each new clinic replicates a proven format. Sustainability is supported by direct consumer revenue (around £299 per scan), reducing reliance on slow public payers, though the model is capital-intensive. Defensibility rests on proprietary scanner hardware and IP, a strong consumer brand, and a fast-growing longitudinal dataset that improves the AI with every scan, a data network effect. AI-native versus AI-enabler Neko is best described as hardware-and-AI-native. It was built around proprietary scanning hardware and AI from day one, with AI interpreting the data. It is not a pure-software AI company, but AI is core to the product, sitting between Cera’s adopter stance and Corti’s pure AI-native model. Risks and critical decisions The defining risk is clinical: preventive whole-body screening attracts overdiagnosis and false-positive criticism from clinicians, and faces variable regulation across markets including the US FDA. The model is also capital-intensive and reliant on out-of-pocket demand. Three critical decisions stand out: building proprietary scanning hardware in-house rather than assembling off-the-shelf devices; choosing a consumer-pay premium model over chasing public payers first; and a deliberate, evidence-led geographic expansion rather than blitz-scaling. Founder lessons from Neko Health ▸ A trusted founder brand and a premium experience can build demand extraordinarily fast in healthcare. ▸ Owning the hardware creates a durable moat and proprietary data. ▸ Preventive screening lives or dies on clinical evidence and avoiding overdiagnosis — earn regulator and clinician trust early. ▸ Consumer-pay can sidestep slow public payers, but it is capital-intensive and demand-sensitive. The Nelson Advisors Guide for Founders to HealthTech and MedTech Success in 2026: 10 European Case Studies Part Two: The patterns that decide success AI-native versus AI enablers: a distinction founders over-weight It has become fashionable to divide health-technology companies into the “AI-native”, built from the ground up around machine learning, and “AI enablers” that adopt AI to improve an existing business. Our ten companies map cleanly onto a spectrum. Owkin and Corti are genuinely AI-native, with foundational models at their core. SOPHiA and Ada are AI-native within their niches, built around proprietary engines, though Ada’s predates the LLM era. Neko is hardware-and-AI-native. Oxford Nanopore is AI-enabled deep tech, with neural-network basecalling on a physics moat. And Doctolib, CMR Surgical and Cera are AI enablers, platforms, robots and care operations with AI layered on top. The striking conclusion is that the AI-native label correlates poorly with durability. Several of the most defendable businesses here, Doctolib, Cera, CMR, are emphatically not AI-native, while at least one cautionary tale in the next chapter was an AI-native company whose AI was over-hyped. What consistently matters is not whether AI is the origin of the company but whether AI sits on top of a genuine, hard-to-copy advantage in data, distribution, regulation or hardware. This has a direct implication for founders. The right question is not “am I an AI company?” but “what is my durable advantage, and does AI compound it?” In every successful case here, the AI is valuable precisely because it is fed by proprietary data or embedded in a workflow the company already owns. Where AI is the only differentiator, it is rarely a moat: in 2026, general-purpose models are cheap, capable and improving fast, and a thin AI wrapper is the most easily disrupted position in the market. How European health technology moats are actually built Across all ten companies, four moat types recur, almost always in combination. Understanding which ones you are building and how long each takes, is central to a defensible strategy. • Proprietary, longitudinal data. The single most common moat. SOPHiA’s two-million-profile dataset, Cera’s daily home-visit data, Corti’s clinical interactions, Owkin’s federated hospital data and Neko’s scan dataset all improve their products with scale and cannot be bought off the shelf. The key insight: data moats are usually a by-product of owning a workflow or delivery channel, not a thing acquired directly. • Regulatory clearance and clinical validation. Ada’s EU-MDR certification, CMR’s FDA De Novo and 510(k) clearances and Oxford Nanopore’s clinical validation are assets, not just compliance. They take years and capital to obtain, which is exactly what makes them defensible against fast followers. • Workflow entrenchment and switching costs. Doctolib as a practice’s system of record, Kry’s employed-clinician network, CMR’s trained surgeons and Cera’s commissioner relationships all make the company painful to rip out once embedded. In health, where safety and continuity matter, switching costs are unusually high. • Intellectual property and deep science. Oxford Nanopore’s litigated patent estate and CMR’s modular-architecture IP protect genuinely hard engineering. This moat is strongest where the underlying science is difficult and patient capital has funded a long lead. The pattern is that the strongest companies stack several of these. Doctolib combines network effects, switching costs, data and brand; Oxford Nanopore combines IP, razor-and-blade economics and an ecosystem of published users. A single moat can be eroded; a stack of complementary moats is what produces durability. Founders should map their intended moats explicitly and ask, for each, how many years and how much capital a well-funded competitor would need to replicate it. The funding map: grants, venture, private equity and public markets The capital journeys of these ten companies reveal as much about strategy as their products do. Several lessons stand out for founders planning their own financing. Grants and non-dilutive capital play a real but limited role. Oxford Nanopore benefited from early NIH and Innovate UK support and Owkin from French sovereign backing through Bpifrance, but in every case grants were catalytic seed money, not the engine. For deep-science companies they de-risk the earliest, least investable phase; founders should pursue them aggressively but not mistake them for a business model. Venture capital remains the dominant fuel, and the rounds here are large: Doctolib’s €500m Series F, CMR’s $600m Series D led by SoftBank, Kry’s ~$300m Series D, Neko’s $260m Series B. The clear pattern is that hardware and deep science (Oxford Nanopore raised over $1.1bn before listing; CMR around $1.4–$1.5bn) require far more capital and patience than software. Founders in capital-intensive categories must plan for a decade-long financing arc and choose investors who can sustain it. Strategic and quasi-private-equity capital is a distinctive European feature. Owkin’s decision to sell equity to Sanofi and Bristol Myers Squibb, the customers whose problems it solves, brought data, credibility and distribution alongside money, at the cost of dependency. Eurazeo’s lead of Doctolib’s 2022 round and pension funds such as Ontario Teachers’ and CPP Investments backing Kry show how growth and PE-style capital now anchor the late-stage European market. The public markets are the hardest lesson. Of the two companies here that listed, Oxford Nanopore and SOPHiA, both saw their shares fall roughly 70–75% from peak despite sound underlying businesses. The message is not that listing is wrong, but that an IPO is the beginning of public-market discipline and a milestone valuation must then be grown into, not celebrated as an exit. Risks and rewards: lessons from the casualties Every company in this report carries real risk, regulatory scrutiny, payer dependence, capital intensity, competition from better-funded incumbents and, for the AI-natives, the relentless advance of general-purpose models. But the sharpest lessons come from the companies that failed, and three cautionary cases should be studied by every founder. • Babylon Health. The headline collapse. An AI symptom-checker and telehealth company valued at $4.2bn at its 2021 SPAC listing, bankrupt and sold for parts by 2023. It over-hyped AI that was reportedly closer to a decision tree, took on a ruinous US value-based-care model that paid out almost as much in medical claims as it earned, and expanded recklessly across the UK, US and Africa before reaching profitability. • Pear Therapeutics. The first FDA-cleared prescription digital therapeutics company, bankrupt in 2023 with assets auctioned for a few million dollars. The lesson is brutal: regulatory clearance does not equal reimbursement. Payers would not pay, so there was no viable revenue model despite a validated product. • Olive AI. A healthcare-automation unicorn that raised around $400m at a $4bn valuation and wound down in 2023. It over-promised on AI-driven savings, expanded too fast and failed to deliver — destroying trust and capital. The common thread is unmistakable: inflated AI claims without clinical evidence, ignoring the reimbursement and payer reality, and scaling before proving unit economics. These are precisely the traps the survivors in this report avoided. Kry pivoted to discipline where Babylon chased growth. Cera and Ada reached profitability where Olive burned cash. Neko is deliberately building clinical evidence to avoid the over diagnosis critique. The reward for getting this right is enormous, the companies here have created billions in value and, in several cases, genuine improvements in care, but the asymmetry is severe, and the graveyard is full of well-funded companies that confused a large round for a durable business. The critical decisions that recur Reading across thirty-odd critical decisions made by these founders, a handful recur often enough to count as patterns worth internalising. • Choosing distribution as a moat. Doctolib’s human field sales and Kry’s employed clinicians were expensive, unfashionable choices that became the moat. • Sequencing markets deliberately. CMR proved Versius internationally before the US; Neko expanded one city at a time; Kry localised rather than copy-pasting. • Owning the hard part. Cera owns care delivery, Neko owns the hardware, Owkin owns the data access, each chose the difficult, defensible layer over the easy, copyable one. • Pivoting decisively under pressure. Ada and Kry pivoted to profitability in the 2022 downturn; Owkin and Corti pivoted from services to scalable platforms; CMR delayed a launch for the right product. • Treating regulation and IP as strategy. Ada’s certification, CMR’s clearances and Oxford Nanopore’s re-engineering around a patent suit were all offensive moves, not defensive chores. Commercial models: who pays and how you reach them If the moat determines whether a company survives, the commercial model determines how fast it grows and how much capital it consumes along the way. The ten companies here use markedly different routes to revenue, and the choice of model is one of the most consequential a founder makes. Three broad commercial archetypes appear. The first is recurring software subscription, used by Doctolib and Ada Health, where practitioners or enterprises pay a monthly or annual fee. This model carries the highest gross margins and the cleanest scalability, but it requires solving the cold-start problem of adoption in a conservative profession, which is why Doctolib invested so heavily in human sales. The second is the razor-and-blade hardware model, used by Oxford Nanopore and CMR Surgical, where an installed base of instruments drives recurring consumable and service revenue. This model produces durable, sticky revenue but demands enormous upfront capital and long sales cycles. The third is service or care-delivery revenue, used by Cera and Kry, where the company is paid per episode of care, usually by a public payer; margins are thinner and the business is operationally heavy, but the revenue is recurring, defensive and anchored to genuine demand. Cutting across these is the question of who pays. In Europe the dominant payer is the state, national health systems, regional authorities and statutory insurers, which shapes everything. Public payers are slow to procure and price-sensitive, but once won they provide stable, large-volume, recurring demand and a powerful reference. Cera’s cost-saving argument to the NHS, Kry’s roughly 40% cost advantage over in-person care, and Doctolib’s role in national vaccination booking all turned public-payer alignment into a growth engine. The contrasting route is consumer-pay, chosen by Neko Health, which sidesteps slow procurement entirely but trades it for the need to generate consumer demand and the capital intensity of a clinic network. Owkin and Corti, meanwhile, sell to enterprises, pharmaceutical companies and health systems, where contracts are large but sales cycles are long and concentration risk is real. The lesson for founders is to choose the commercial model that matches both the product and the appetite of available capital, and then to design the company around its payer from day one. The companies that struggled were frequently those that built a product first and discovered the payer later, Pear Therapeutics being the starkest example, with a cleared product and no one willing to pay for it. The European advantage: constraints that became strengths It is tempting to view Europe’s fragmentation, regulatory density and conservative payers purely as handicaps relative to the larger, more homogeneous US market. The companies in this report suggest a more nuanced picture: several of the continent’s apparent disadvantages, handled well, became sources of durable competitive strength. Fragmentation forced discipline. Because there is no single European market, companies such as Kry, Doctolib and CMR Surgical had to master genuine localisation, different languages, reimbursement systems, regulators and clinical cultures. That is harder and slower than scaling across fifty US states, but the resulting multi-country regulatory and operational know-how is itself a moat that new entrants cannot quickly replicate. The very friction that slowed these companies down also protected them once they had crossed it. Strong public health systems created uniquely valuable data and demand. Europe’s universal, largely single-payer systems generate longitudinal, population-scale clinical data and a coherent buyer with a direct interest in cost reduction. Owkin’s access to leading oncology hospitals, Cera’s entrenchment with NHS commissioners, SOPHiA’s network of clinical institutions and Corti’s reach into the NHS were all enabled by the structure of European healthcare. The same systems that are slow to buy are, once aligned, extraordinary sources of data and stable demand. World-class science and a deepening talent base supplied the raw material. Oxford Nanopore emerged from the University of Oxford, SOPHiA from EPFL, Owkin from the French AI research ecosystem and Corti from Danish machine-learning research. Europe’s universities and research institutions remain a genuine comparative advantage in deep-science health technology, and a maturing pool of operators, many of whom cut their teeth at the first wave of European technology champions, increasingly supplies the commercial talent that was historically the weak link. None of this makes Europe an easy place to build. Capital is still thinner at the latest stages, exits are harder, and the public-market reception for Oxford Nanopore and SOPHiA was punishing. But the founders who treated Europe’s constraints as design parameters rather than obstacles built companies that are, in several respects, more defensible than a faster-moving US equivalent would have been. Timing, sequencing and the discipline of focus A final pattern deserves its own treatment because it appears, in some form, in almost every successful case and almost every failure: the discipline of sequencing, doing the right things in the right order and the courage to stay focused under the pressure to expand. The casualties shared a failure of sequencing. Babylon Health scaled across three continents and into a complex US value-based-care model before it had proven profitability anywhere; Olive AI broadened its product line before it had reliably delivered the savings it promised on a narrower one. The survivors did the opposite. CMR Surgical refused to enter the US until it had a cleared, competitive product, even scrapping a planned launch to wait. Neko Health expanded one city at a time, building clinical evidence as it went. Kry cut roughly four hundred jobs and exited Germany in 2022 to concentrate on markets it could make profitable. Each of these was a decision to do less, sooner, in order to do more, later. Timing also mattered enormously at the level of capital. The companies that raised large rounds at the 2021 peak and then spent as though the environment would persist, Owkin has been admirably candid about over-hiring, had to retrench painfully. Those that treated the downturn as a forcing function for profitability emerged stronger and, in Cera and Ada’s cases, were able to raise again from a position of strength. For founders, the practical implication is to raise when you can but spend as though you cannot, and to treat every expansion, new geography, new product line, new payer type, as a decision that must be earned by proof in the current one, not assumed by ambition. Focus, in this market, is not a constraint on growth; it is the mechanism of durable growth. The companies that endured were those willing to be smaller than their funding allowed until each step was proven, and the discipline to sequence carefully is perhaps the single most transferable lesson in this guide. Conclusion: a founder’s checklist for 2026 The ten companies in this guide are different in almost every respect, software and hardware, consumer and enterprise, profitable and pre-profit, AI-native and AI-enabling, yet they converge on a small set of principles that should shape any founder’s strategy in 2026. Build your business around a durable advantage, not a feature. In European health technology that advantage is almost always proprietary data, regulatory clearance, workflow entrenchment, deep-science IP or some stack of these. Ask continually how many years and how much capital a well-funded rival would need to copy what you have built. Be honest about what kind of company you are. If you are capital-intensive deep science or hardware, plan for a decade-long financing arc and choose patient, deep-pocketed investors. If you are software, the prize is scale and margin, but the AI layer alone will not protect you. Either way, get close to whoever actually pays for healthcare, in Europe that is usually a public payer or a clinician and prove the unit economics before you scale. Treat AI as a compounding layer, not an identity. The most defendable companies here use AI to amplify a moat they already own. A thin AI wrapper on someone else’s data or workflow is the most easily disrupted position in the market. Respect the asymmetry. The rewards in this market are extraordinary, but the failures, Babylon, Pear, Olive, were not small companies; they were well-funded, celebrated businesses that mistook a large valuation for a durable one. Discipline, evidence and proximity to the payer are what separated the survivors from the casualties. They will do so again in 2026. Looking ahead, the next wave of European health-technology value is likely to accrue to companies that combine a proprietary clinical-data asset with the new generation of AI, not as a thin application layer, but embedded in workflows and regulatory pathways that took years to earn. The maturation of generative AI lowers the cost of building a feature but raises the premium on the things AI cannot easily manufacture: trusted data, clinical evidence, regulatory clearance and entrenchment with the people who deliver and pay for care. The founders who understand that distinction, who use 2026’s cheap intelligence to compound an advantage rather than to substitute for one, will build the defendable companies of the coming decade. The ten companies in this guide have already shown how it is done. None had an easy path; several are still on theirs. But each, in its own way, made the hard, defensible, sometimes unfashionable choices that the European health-technology market rewards over time. For a founder setting out in 2026, that is the most valuable inheritance of all: not a formula, but a set of proven instincts about where durable value in this industry truly comes from. The Nelson Advisors founder checklist ▸ Name your moat(s) explicitly — data, regulation, workflow, IP — and quantify how long they take to replicate. ▸ Match your financing plan to your capital intensity; pursue non-dilutive grants early but never mistake them for a model. ▸ Get to the payer and prove unit economics before scaling; reimbursement is as important as regulatory clearance. ▸ Use AI to compound an existing advantage; avoid being a thin wrapper on someone else’s data. ▸ In a downturn, choose profitability and discipline over momentum — it is what kept the survivors alive. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Scaling Healthcare Innovation: Life Sciences, MedTech and HealthTech Success Stories from the Goldman Sachs 10,000 Small Businesses UK Programme The persistent productivity puzzle within the United Kingdom remains a major structural challenge for economists, academic institutions, and policymakers. While the British economy excels at spawning startups, transition rates from early-stage micro-enterprises to scaling, mid-market companies have historically been constrained by a pronounced management and leadership support gap. This barrier is particularly challenging in highly technical, regulated, and capital-intensive sectors such as life sciences, biotechnology, medtech, and healthtech, where long research and development cycles, complex clinical validation pathways, and talent acquisition hurdles compound the difficulties of scaling. To bridge this critical growth deficit, the Goldman Sachs 10,000 Small Businesses (10KSB) UK programme has acted as a vital educational and strategic intervention since its launch in 2010. Fully funded by the Goldman Sachs Foundation, the initiative provides high-growth small business leaders and social entrepreneurs with 100 hours of practical business and management education. Developed by leading experts, the curriculum is delivered in partnership with top-tier academic institutions, including Saïd Business School at the University of Oxford, the Aston Centre for Growth at Aston University, Leeds University Business School at the University of Leeds, and the Manchester Metropolitan University Business School. By targeting decision-makers of companies operating for at least three years with 5 to 50 employees and annual revenues exceeding £250,000, the programme provides the structural tools necessary to design and execute a robust, customized Business Growth Plan. An analysis of health-related business success stories within this framework shows how targeted business education helps scientific and clinical founders scale their companies, navigate market challenges, and create high-value employment. Longitudinal Economic Impact and the 10KSB Programme Effect The macroeconomic contribution of the 10KSB UK programme has expanded considerably over its fifteen-year history. Evaluations conducted by the Enterprise Research Centre (ERC) demonstrate that programme graduates achieve significantly higher rates of job creation, revenue generation, and productivity growth compared to matched control groups of similar size, age, and sector. The growth trajectory of the programme's aggregate economic footprint is detailed in the table below: Longitudinal Milestones (Year of Report) Total Scaling Graduates Combined Annual Revenue Estimated Combined Headcount Key Operational & Strategic Indicators Early Evaluation Phase (2015) 2,300+ (US & UK combined sites) N/A (Initial US/UK baseline collection) N/A (Baseline operational metrics) 66.8% of graduates reported revenue growth within 6 months; 76.0% grew revenues within 18 months. Middle Scaling Phase (2022) 1,900+ (UK graduates) £2.8 billion N/A (Focus on pandemic retention) 63% invested in R&D during the pandemic; 62% planned continued R&D investment over 2 years. Advanced Scaling Phase (2024) 2,300+ (UK graduates) £5.9 billion 53,000+ employees 47% expanded workforce during macro headwinds; 26% recorded annual turnover growth above 20%. 15-Year Milestone (2025) 2,500+ (UK graduates) £10.6 billion 82,000+ employees Combined 15-year net addition of £2.7 billion in revenue and 41,313 jobs directly attributable to the programme. This expansion is supported by deep behavioural changes. Following graduation, 94% of participants report higher confidence in managing scaling challenges, 84% systematically utilise financial data to drive strategic decisions, 97% feel more effective as business leaders, and 90% introduce new corporate processes or organisational systems. According to the Enterprise Research Centre, three years after completing the programme, 10KSB UK graduates outperform similar companies by increasing revenues by up to 43% more and growing their staff by over a third. The programme's impact also includes a 14% outperformance in productivity compared to equivalent companies, directly addressing the UK's broader productivity challenges. Pandemic Adaptation and Resilience Strategies The structural resilience of 10KSB UK alumni was tested during the COVID-19 pandemic. While SMEs generally faced severe disruptions, 10KSB graduates pivoted quickly by using the strategic frameworks of their business education. To support its network, the 10KSB UK programme launched the "Reimagining Business" initiative between March and May 2020, delivering targeted webinars, weekly coaching sessions, and faculty insights to over 450 small business leaders. This continuous support helped guide major pivots. Approximately 80% of programme participants revised their pre-pandemic business models, 68% adapted their operational structures, 69% successfully launched new products or services, and 88% accelerated their adoption of digital technologies. Within health-related sectors, many women-run and founder-led businesses exposed to healthcare, technology, or remote-capable operations reported revenue increases during the pandemic by adapting to meet shifting clinical and clinical-support needs. Sectoral Success Stories in the Life Sciences, Medtech and Healthtech The practical application of the 10KSB curriculum is best demonstrated through the growth of specific companies in the life sciences, medtech, and healthtech fields. These firms have successfully converted business training into scalable clinical and commercial operations. CatSci: Transitioning from Catalyst Screening to Global Drug Development CatSci Ltd, based in Cardiff, Wales, is a prominent life sciences success story that illustrates the journey from a specialised laboratory service to a globally recognised pharmaceutical innovation partner. Founded in 2011 by scientists following a spin-out from AstraZeneca, the business was initially established as a catalyst screening company. By 2019, CatSci operated with a turnover of £3 Million and employed 25 people. To scale further, Chief Executive Officer Dr. Ross Burn completed the 10KSB UK programme at Oxford Saïd Business School to build the commercial systems needed to expand the firm's global presence. Through the programme, Burn refined CatSci’s strategy and transitioned the company's focus to the broader, high-value field of process research and development for new medicines, with a particular focus on the development of scalable oligonucleotide therapeutics to support emerging RNA-based pipelines. This repositioning helped the firm grow past its initial targets. Between 2018 and 2022, CatSci grew its revenues by an average of 50% annually, expanded its headcount to 76, and grew its international trade footprint across 13 countries—including entry into the Japanese, European, and US markets. This growth in international trade earned CatSci the Queen’s Award for Enterprise in International Trade in 2022. By building solid financial and operational structures, CatSci successfully positioned itself to secure a major institutional investment from European private equity firm Keensight Capital, helping fund its continued laboratory expansion. https://catsci.com/about-us/our-history/ June Medical: Scaling Medtech Manufacturing through Operational Excellence June Medical, an award-winning medical device manufacturer founded by Angela Spång, shows how medtech scale-ups can use process innovation and structured workforce development to capture international market share. June Medical is best known for developing and manufacturing single-use, plastic injection molded surgical retraction systems made of advanced Terlux polymers, which improve surgical access and sterile control in urological procedures. Spång enrolled in the 10KSB UK programme, a curriculum she compared to a condensed Executive MBA, to build the management capacity required to scale her proprietary medical products globally. The programme challenged her to redefine her company's value proposition and transition from a localised distributor to an international IP-led manufacturer. This strategic development culminated in June Medical being named the "Most Innovative Business" winner across the entire 10KSB UK alumni community during the programme's 15th-anniversary milestone celebration at the Tate Modern in 2025. To support this rapid product growth, June Medical addressed the technical skills shortage in manufacturing by implementing a structured apprenticeship scheme. By standardising its training and operational processes, the company successfully integrated young apprentices into its commercial workflows, helping expand operations at its UK facilities and launch its US-focused export pipelines. https://junemedical.com Principle Healthcare: Internationalising Nutraceutical Manufacturing Principle Healthcare Group, based in Skipton, North Yorkshire, highlights how life sciences and consumer-health manufacturers can utilise regional business support to scale across Europe. Principle Healthcare is a major producer of vitamins, minerals and dietary supplements, with capabilities spanning formulation, advanced packaging, and large-scale manufacturing. Through its engagement with Leeds University Business School, one of the key 10KSB UK delivery partners, the firm integrated advanced marketing, supply-chain logistics, and export strategies into its core operations. These improvements allowed Principle Healthcare to expand its international trade footprint, leading to the company winning the UKTI Export Achievement Award at the Medilink Yorkshire and Humber Awards. The Medilink Awards celebrate the commercial achievements of healthcare technology and life sciences organisations in the region. By building structured commercial partnerships, Principle Healthcare scaled its international brand presence and secured a market-leading position. This successful trajectory made it an attractive strategic partner, culminating in its acquisition by the global healthcare group, helping cement its position in the European nutraceutical sector. https://www.principlehealthcare.com Concierge Medical: Systematising Rural Private Healthcare Delivery Concierge Medical, founded in 2013, operates a private, home-visiting general practice that provides continuous primary care across the Cotswolds and surrounding rural areas. The business model addresses a geographical challenge where access to traditional, physical primary care facilities can be difficult. Kat Carrick, representing Concierge Medical, completed the 10KSB UK curriculum to address operational constraints that were bottlenecking the company's growth. The clinical founders needed structured management frameworks to transition from a localised, hands-on medical practice into a scalable, membership-based healthcare business. The programme provided the tools necessary to analyse and resolve operational inefficiencies, leading to the design of a standardised, technology-enabled primary care platform. Following graduation, Concierge Medical recorded a 98% increase in its subscription membership base within six months. The confidence and operational discipline gained during the course helped the leadership set more ambitious growth targets, prompting the company to actively seek institutional external investment to scale its rural concierge model to other underserved regions across the UK. https://www.conciergemedical.co.uk/about-us/ Myonex: Rebranding and Scaling Global Clinical Trial Supply Channels Myonex, formerly known as Myoderm, shows how clinical trial support services can pivot their brand and operational footprint to capture global pharmaceutical demand. While the company had built a strong reputation in clinical trial supply within the United States, it initially struggled to scale its brand internationally. A major barrier was a widespread misconception among global audiences that the suffix "-derm" in the company's original name limited its services to dermatology clinical trials. To support its global expansion and clear up this market misconception, the company underwent a comprehensive rebranding process, officially launching as Myonex in 2020. This rebrand was supported by extensive market research, including interviews and surveys with life sciences professionals across Europe and North America. The strategic shift helped accelerate growth, with Myonex recording annual growth rates exceeding 20% for three consecutive years. During this scaling phase, the company tripled its global headcount, introduced new services tailored for decentralised clinical trials, opened a new 65,000-square-foot global headquarters in the US, and significantly expanded the clinical supply capacity of its UK-based facilities. https://www.myonex.com/ Ada Jabaru and Nistad Limited: Healthcare Compliance, Care Delivery and Community Advocacy Ada Jabaru, the founder and director of Nistad Limited, represents a unique 10KSB success story at the intersection of regulatory compliance, care delivery, and technology management. With over 17 years of experience in regulatory compliance, risk assessment, and financial audit, Jabaru initially built Nistad Limited to provide compliance solutions for financial institutions working with complex investment and asset management software. However, as a 10KSB UK alumna recognised within the healthcare and medical-related business categories, Jabaru leveraged her expertise in audit and compliance to expand into adult social care and community health systems. Her clinical and care-related portfolio included directing Flourish Adult Care Limited, alongside her leadership of the Nistad Empowerment Foundation. This foundation supports primary healthcare delivery and educational outreach in underserved communities, with a strong focus on training young people and women from disadvantaged backgrounds in AI and digital skills. By using the strategic insights gained from the 10KSB programme, Jabaru has become a prominent voice for SME leadership. She has participated in policy panels with senior Goldman Sachs executives at Mansion House, advocating for increased investment in technology education and digital skills to help solve the UK's skills crisis and improve healthcare access. https://nistadfs.com Scaling Healthcare Innovation: Life Sciences, MedTech and HealthTech Success Stories from the Goldman Sachs 10,000 Small Businesses UK Programme AI-Ready Transformation and Digital Telehealth Ecosystems The convergence of artificial intelligence, real-time analytics, and clinical operations represents the next major growth frontier for healthtech and medtech scale-ups. The 10KSB UK programme has continued to adapt its curriculum to help founders manage this technological transition, focusing on data governance, predictive modelling, and AI-driven clinical workflow automation. A key example of this focus is Data Inc, which was selected for the 10KSB UK programme in 2026. Data Inc specializes in helping scaling businesses transition toward value-assured, AI-ready operating models. For modern healthtech and clinical companies, data democratisation and predictive analytics are essential to maintain data reliability, comply with medical regulations, and protect patient information. By helping founders integrate machine learning and automated quality control, the 10KSB framework enables scaling healthcare companies to deploy predictive tools that improve patient diagnostics and operational agility. This systemic integration of AI within telehealth ecosystems is also illustrated by Ufonia, a healthtech venture supported by the Oxford Foundry, which is closely integrated with the Saïd Business School 10KSB partnership. During the pandemic, Ufonia pivoted its AI-telemedicine engine to address the clinical backlogs caused by cancelled procedures. By automating post-surgery clinical reviews and patient follow-ups via its AI-driven voice platform, Ufonia helped hospitals streamline post-operative workflows, demonstrate the efficacy of automated care, and reduce administrative burdens on frontline healthcare workers. Overcoming Structural Barriers to Scale in High-Growth Health Sectors An analysis of the success stories within the 10KSB UK alumni network reveals how specific scaling barriers in the healthcare and life sciences sectors can be systematically addressed through targeted business education: Distinct Scaling Challenge in Health Sectors Causal Impact on Business Growth 10KSB Educational & Strategic Solution Observed Operational Outcome The Technical Founder Dilemma Scientific or clinical founders often struggle with the transition from technical experts to strategic CEOs, leading to operational bottlenecks. Modules on Leadership & Culture focus on strategic delegation, process standardisation, and defining a clear corporate mission. Clinical and scientific founders successfully transition to strategic business development, enabling larger-scale operations. The Technical Skills & Talent Crisis 45% of fast-growth SMEs report an inability to access the technical, digital, and data talent needed to sustain their scaling plans. SME Talent Acquisition Strategy helps founders build internal training systems and structured apprenticeship pathways. June Medical implemented an apprenticeship model that brought in and trained young talent, supporting global export growth. Strict Regulatory Compliance & Auditing Medtech and life sciences products face strict regulatory approval and clinical compliance pathways before market entry. Modules on Strategic Operations & Metricsprovide frameworks to build audited socio-technical operating models. Data Inc and Nistad optimized their governance structures, helping de-risk their offerings for institutional partners. High R&D Capital Requirements Long clinical development cycles require significant upfront capital before generating sustainable commercial revenues. Cash & Funding Modulesteach business valuation, pitch readiness, and how to align with patient venture capital. CatSci secured growth funding from Keensight Capital; Concierge Medical positioned its model for institutional investment. Navigating the Founder-to-CEO Transition The transition from a technical founder to a strategic executive is a key tipping point for scaling healthcare businesses. Clinical and scientific founders are trained to focus heavily on scientific accuracy and patient care, which can sometimes lead to a highly centralised management style. The 10KSB curriculum addresses this by helping founders build a structured management team, delegate day-to-day operations, and focus on long-term corporate positioning. This shift is clear in the case of CatSci, where the transition from a localised laboratory provider to an international therapeutic development partner was enabled by establishing clear operational roles and institutional governance. Standardising Operations to Enable Scalable Care Subscription-based primary care and medical services are structurally limited by the physical capacity of their clinical providers. To scale, these models must standardize their administrative and clinical workflows. The 10KSB UK programme’s focus on strategic operations helps healthcare businesses utilise technology to automate scheduling, billing, and patient follow-ups. This process optimisation allowed Concierge Medical to grow its subscriber base by 98% in the months following graduation without needing to add proportional administrative staff, showing how standardising operations can help expand clinical access. Policy Advocacy, Generation Growth and Future Economic Trajectories Beyond direct business support, the 10KSB UK programme has become a significant advocate for small business growth, culminating in the launch of "Generation Growth: The Small Business Manifesto" and "The Growth Agenda: Growth Shots" in 2024 and 2025. These reports, based on detailed surveys of over 550 high-growth 10KSB UK alumni, outline the key policy measures necessary to unlock the full potential of scaling SMEs. The findings show that while access to capital remains a challenge, with 37% of surveyed small business owners reporting difficulties in obtaining the growth finance they need, the skills shortage is the single largest barrier to scaling. The Manifesto urges policymakers to prioritise the up-skilling of the UK workforce, ahead of traditional policy focuses like international trade support and business rate reform. Industry leaders, including ScaleUp Institute CEO Irene Graham OBE and British Business Bank Chair Stephen Welton CBE, have highlighted the importance of these recommendations, emphasising that supporting patient capital and vocational education is vital to unlocking the UK's broader innovation economy. The success stories of CatSci, June Medical, Principle Healthcare, Concierge Medical, Myonex, and Nistad demonstrate that when scientific and clinical expertise is paired with structured management education, high-growth healthcare companies can scale effectively. By standardising internal operations, adopting digital and AI-driven workflows, and building structured talent development pipelines, these businesses successfully navigate strict regulatory environments and create high-value employment. Expanding this educational support across the UK’s broader life sciences, medtech, and healthtech sectors will be key to addressing the nation’s persistent productivity puzzle and driving sustainable, innovation-led economic growth. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Beyond the Prescription Pad: The Strategic Convergence of Consumer Technology, Retail Infrastructure, and Preventive Healthcare The Macroeconomic Catalyst: The Crisis of Legacy Reactive Care and the Rise of Proactive Healthspan The global healthcare ecosystem is undergoing a profound structural transition. For decades, clinical medicine operated under a reactive, "one-size-fits-all" framework. Under this legacy model, clinical interventions were typically initiated only after the manifestation of symptomatic disease, overlooking the granular genetic, metabolic and physiological variations that define individual baselines. Today, a combination of macroeconomic pressures, demographic shifts and rapid technological acceleration is driving a transition toward active, human-centric health management. This evolution redefines the clinical focus from acute disease suppression to proactive healthspan extension. At the center of this transition is the integration of lifestyle medicine, digital health technologies, and functional diagnostics that look past the traditional prescription pad. Traditional clinical systems are increasingly burdened by aging populations, flat reimbursement rates, severe healthcare worker shortages, and rising operational overhead. These systemic vulnerabilities have compressed patient-provider interactions, leaving primary care physicians with insufficient time to address the root lifestyle behaviours such as nutrition, chronic stress, sleep architecture and metabolic fitness, that drive over 80% of chronic disease burdens. The scale of this primary care vacuum is significant; the Association of American Medical Colleges (AAMC) predicts a shortage of up to 55,000 primary care physicians in the United States over the next decade. This structural shortage has accelerated the growth of the global smart healthcare industry, which expanded from an estimated market size of $147.7 Billion in 2019 to $181.7 Billion in 2022, maintaining an average annual growth rate of 11.0%. As these platforms mature, healthcare delivery is shifting from episodic, product-centric transactions to integrated, platform-based solutions. This commercial evolution has created a bifurcated wellness and healthcare market. In the United States, fragmented insurance models and high operational friction have paved the way for a direct-access, cash-pay longevity ecosystem. Conversely, European markets view public healthcare as a social safety net, making European consumers less likely to pay directly for basic care. Startups operating in Europe must therefore package preventive health services with social capital, lifestyle experiences and identity markers to persuade consumers to pay out-of-pocket for services they expect to receive for free. Market Dimension Smart Healthcare Market (2019) Smart Healthcare Market (2022) Project CAGR Global Valuation $147.7 Billion $181.7 Billion 11.0% These regional market dynamics reflect broader socio-economic disparities. Sociological research indicates that health vulnerabilities scale with economic deprivation. For example, individuals in the most deprived deciles are twice as likely to live with five or more chronic conditions by late life compared to those in the least deprived deciles. Furthermore, individuals in high-resource areas are roughly 40% less likely to progress from a single chronic condition to multi-morbidity. To address these deep-seated disparities, frameworks such as the United Kingdom's "social prescribing" model connect older adults with non-pharmacological interventions like local walking groups, bereavement services, and community kitchens. This model addresses the social determinants of health directly, recognizing that loneliness and depression are primary drivers of clinical non-adherence. Proactive social connections have been shown to reverse cognitive and physiological decline, demonstrating that clinical outcomes are deeply connected to a patient's broader social environment. The integration of lifestyle medicine also extends to evidence-based complementary modalities funded by research bodies like the National Institutes of Health (NIH) National Center for Complementary and Integrative Health. Evidence-based therapies such as yoga and acupuncture, which utilises fine filiform needles across approximately 360 to 380 specific points in the human body, are increasingly used to manage chronic lower back pain, anxiety and depression while reducing dependency on prescription medications. Clinical observations indicate that incorporating weekly acupuncture sessions can enable chronic pain patients to reduce high-dose opioid and narcotic regimens by half within three months, and eliminate usage entirely by six months. By focusing on whole, plant-based foods rather than expensive synthetic supplements, functional medicine practitioners are demonstrating that dietary modifications can prevent clinical deterioration and reduce overall healthcare spending. Health Management Modality Target Biomarker / Symptom Clinical Evidence & Efficacy Weekly Acupuncture Chronic pain & opioid dependency. 50% dosage reduction at 3 months; complete cessation at 6 months. Yoga & Mindfulness Lower back pain, anxiety, & depression. Validated improvement in flexibility, balance, and mental health markers. "Food as Medicine" (FIM) Metabolic syndrome & diabetes risk. Whole-food, plant-based diets reduce cardiovascular risk by 80% and diabetes risk by 90%. Social Prescribing Geriatric multi-morbidity & isolation. Reverses cognitive decline and improves medication adherence. Passive Continuous Phenotyping and Remote Therapeutic Monitoring: The ŌURA Integration Framework The transition away from episodic clinical care requires a shift toward continuous passive digital phenotyping. While traditional medical records capture only static, point-in-time data during annual physicals, consumer wearables gather continuous physiological metrics in the user’s natural environment. This real-world evidence establishes highly personalised baselines, allowing algorithms to detect micro-deviations before they manifest as acute clinical events. Within this wearable landscape, the ŌURA Ring has transitioned from a consumer wellness tracker into a clinically validated, research-grade remote monitoring platform. The form factor of a smart ring offers distinct advantages over wrist-worn alternatives. By measuring biometrics from the digital arteries of the finger, where the pulse signal is 50 to 100 times stronger than on top of the wrist, the smart ring achieves superior signal-to-noise ratios. This sensor stability translates into excellent data fidelity, particularly for sleep stage classification, heart rate variability (HRV), and resting heart rate (RHR). Independent clinical validation has established the device's accuracy compared to laboratory polysomnography (PSG), the gold standard for sleep evaluation. Research shows that the ŌURA Ring Generation 3 demonstrates approximately 94.4% sensitivity and 91.7% overall sleep accuracy, achieving 79% agreement with PSG in four-stage sleep classification. This level of agreement is remarkably close to the 83% consensus rate typically observed between trained sleep technicians scoring the same recording manually. Furthermore, a 2025 independent study found that the ring exhibited the strongest agreement among consumer wearables for both HRV and RHR measurements. To integrate these capabilities into traditional clinical workflows, ŌURA has moved aggressively to establish direct APIs with electronic health record (EHR) systems and clinical platforms. These integrations allow consumer-generated data to flow passively into platforms like Epic via consumer portals such as MyChart, eliminating patient data entry burdens. Rather than presenting physicians with raw, uncontextualized metrics, integration software normalises the data, organising it into trends displayed alongside standard clinical charts. Wearable Performance Metric Clinical Validation vs. Polysomnography (PSG) Source Validation Study Sleep Detection Sensitivity 94.4% Sensitivity Svensson et al. 2024 Overall Sleep Accuracy 91.7% Accuracy Svensson et al. 2024 Four-Stage Sleep Classification 79.0% Agreement (PSG scoring baseline is 83.0%) Robbins et al. 2025 Device Wear Adherence 95.0% compliance (24-hour wear time over 8 weeks) Independent Wearable Compliance Study These continuous physiological metrics are particularly valuable for Remote Therapeutic Monitoring (RTM) programs. Under US Medicare guidelines, clinicians can use CPT codes 98975 through 98981 to bill for monitoring non-physiological data such as therapy adherence and musculoskeletal or respiratory response. By combining continuous, passive wearable data with subjective patient-reported outcomes, clinicians can build comprehensive, longitudinal datasets while avoiding the survey fatigue that often undermines traditional remote patient monitoring. Furthermore, because ŌURA’s finger-worn form factor maintains a 95% compliance rate over an eight-week period, outperforming wrist-worn devices that suffer from frequent drop-offs, clinicians can capture more ecologically valid biometric data during everyday routines. This continuous data pipeline has enabled a series of strategic integrations across clinical and research fields: Medicare Advantage Programs: In June 2026, Essence Healthcare integrated ŌURA Ring data into its physician-led clinical care workflows, allowing providers to monitor sleep patterns, recovery metrics, and early markers of illness in Medicare Advantage populations. Digital Women's Health: In May 2026, Twentyeight Health integrated the ring's high-fidelity skin temperature sensors to track reproductive cycles. This integration builds upon the ring's compatibility with FDA-cleared birth control platforms like Natural Cycles, which analyzes temperature trends to determine fertile windows. Academic Research Collaborations: The ring is used in major research initiatives, including the University of California, San Francisco (UCSF) TemPredict project, which tracks early infection patterns, and a University of Vermont study focused on tracking objective sleep and physical recovery metrics to evaluate student mental health. The Retail Retreat and Re-alignment: Deconstructing Walmart's Pivot to Decentralised Health Operations The physical footprint of major retailers has long been viewed as a potential solution to the accessibility and affordability issues of the American healthcare system. However, the operational realities of brick-and-mortar primary care delivery have forced a major strategic re-evaluation. In 2024, retail health faced significant disruption. Industry giants like Walgreens closed approximately half of their VillageMD clinics, CVS Health realigned its leadership amid cost pressures within its Aetna Medicare Advantage segment, and Walmart announced the complete closure of all 51 in-store health centres and the termination of its Walmart Health Virtual Care platform (formerly MeMD). The closure of Walmart Health centers after a five-year effort highlights the difficulties of operating physical clinics under traditional fee-for-service reimbursement models. Positioned to serve low-income and medically underserved communities, Walmart’s clinics struggled with flat insurance reimbursement rates, rising labor costs, and a nationwide shortage of healthcare workers. Unlike selling consumer goods, clinical healthcare delivery requires specialised, highly compensated personnel, complex billing infrastructures, and extensive liability management, factors that clashed with Walmart's high-volume, low-margin retail business model. Retail Health Entity 2024–2026 Operational Realignment Details Associated Labour & Footprint Reductions Walmart Health Closed all 51 physical health centers and terminated its virtual care platform. 90 days of transition pay for clinical associates and providers. Walgreens (VillageMD) Closed 160 VillageMD clinics, shifting away from an exclusive reliance on a single-provider model. Shuttering 1,200 retail locations (14% of footprint) over three years. CVS Health (Aetna) Replaced CEO Karen Lynch with David Joyner; faced Medicare Advantage margin pressures. Laid off 2,900 employees, closed 29 retail pharmacies, and cut Coram infusion services. Amazon Health Services Repositioned digital assets to focus on virtual care and Amazon Pharmacy. Eliminated several hundred roles across One Medical and Amazon Pharmacy. This retail retreat has shifted the competitive landscape. While CVS has maintained its commitment to physical clinics by operating over 200 stand-alone Oak Street Health centers across 25 states, other retailers are shifting to asset-light, digital-first models. Rather than managing clinical clinics directly, Walmart is leveraging its core strengths: its retail data, its fresh food supply chain, and its network of 4,600 physical pharmacies. Because over 4,000 of Walmart's stores are located in federally designated medical provider shortage areas, its in-store pharmacies and 3,000 Vision Centers often serve as the primary entry point for local healthcare. This infrastructure allows Walmart to offer essential services like immunisations, point-of-care testing, and medication therapy management without the overhead of operating dedicated physical clinics. A key component of this post-clinic strategy is the Walmart Healthcare Research Institute (WHRI), launched in 2022 to connect retail reach with clinical trials. In January 2026, Walmart announced a partnership with clinical research company Care Access to open four clinical research sites in spring 2026, situated at former clinic locations and a rural retail store. This model allows Walmart to offer health screenings and clinical study access to diverse, rural, and underserved populations without the burden of maintaining full-service primary care facilities. Simultaneously, Walmart is positioning its stores to capture the trend of Food as Medicine (FIM), particularly in response to the rise of GLP-1 receptor agonists (such as Ozempic and Wegovy). While some food retailers worry about GLP-1s reducing overall caloric intake, Walmart is using its pharmacy infrastructure as a gateway to drive healthy, nutrient-dense food sales. Because GLP-1 therapy requires long-term lifestyle modification, specifically maintaining lean muscle mass through high-protein diets and nutrient-dense foods, the pharmacy can connect prescriptions directly to targeted retail grocery programs. By combining its retail transaction data with digital wallets and filtered-spend technology (e.g., directing SNAP benefits or employer wellness funds toward medically tailored groceries), Walmart is turning its stores into community wellness centres. Integrated FIM & GLP-1 Retail Models Key Platform Capabilities Target Clinical Population Walmart Pharmacy & SNAP Link Connects GLP-1 prescriptions with filtered-spend grocery and "Great for You" tracking. Medically underserved and rural populations. Instacart Health & Dispatch Health Offers seniors aging in place targeted nutrition programs using virtual storefronts and Care Carts. Geriatric populations with multi-morbidity. Season Health & Employer Plans Integrates digital wallets with medically tailored groceries and customised nutrition coaching. Employees utilising GLP-1s for weight loss. H-E-B Wellness Integration Integrates physical retail grocery stores with registered dieticians and curated menu planning. Regionally concentrated families and chronic disease patients. Beyond the Prescription Pad: The Strategic Convergence of Consumer Technology, Retail Infrastructure, and Preventive Healthcare Virtual Clinics as Holistic Benefit Solutions: The Maven Clinic Case Study While retail giants adjust their physical footprints, virtual clinics are proving that digital-first care can drive clinical outcomes and reduce employer costs. Historically, digital health benefits were highly fragmented, with employers adopting isolated point solutions for fertility, maternity, postpartum depression and menopause. This fragmentation created administrative inefficiencies, low user engagement, and disjointed care experiences. This fragmentation is particularly costly given the high financial and operational impact of reproductive health challenges on employers: High Intervention Costs: An average round of IVF in the United States costs approximately $23,000, and more than a third of patients spend over $50,000 over the course of their fertility journeys. Maternity Care Deserts: More than 50% of counties in the United States lack a single practicing OB-GYN, making geographical access a major barrier. Mental Health Losses: Untreated perinatal mood and anxiety disorders result in an average presenteeism cost of $2,871 per affected employee per year, contributing to an estimated $40,478 in economic losses per person due to associated unemployment. Surgical Delivery Rates: The standard C-section rate in the United States stands at 32%, significantly higher than the World Health Organization’s recommended baseline of 10%. This disparity drives clinical costs, with each surgical delivery costing employers an average of $26,000. Maven Clinic, founded in 2014, pioneered a comprehensive, unified family health benefits platform spanning fertility, maternity, pediatrics and menopause. Maven operates as an integrated virtual clinic and benefits administrator, coordinating care through a network of over 30 provider specialties, including reproductive endocrinologists, OB-GYNs, doulas, midwives, lactation consultants, and mental health professionals. This virtual-first architecture provides 24/7 coverage, which is particularly beneficial for remote and hybrid workers or those living in maternity care deserts; in fact, 60% of Maven appointments occur outside standard office hours. Maven's continuous support model has demonstrated clear, peer-reviewed clinical and financial outcomes, establishing a strong business case for corporate benefits integration: NICU Admission Reductions: Maven’s proactive monitoring and educational interventions contribute to an up to 28% reduction in Neonatal Intensive Care Unit (NICU) admissions. C-Section Rate Reductions: By connecting mothers with doulas and personalised birth planning resources, Maven helps lower C-section rates by up to 15%. Alternative Paths to Conception: Among fertility members, 30% achieve pregnancy naturally without requiring expensive assisted reproductive technologies (ART) like in vitro fertilisation (IVF) or intrauterine irritation (IUI). Retention and Return-to-Work: Over 90% (and up to 94% in certain cohorts) of Maven members return to work post-parental leave, compared to a national average of just 57%, saving employers significant recruiting and onboarding costs. Financial ROI: These clinical improvements generate average direct savings of up to $5,000 per member, translating to a validated 2x to 4x return on investment (ROI) for employer clients. Clinical & Financial Outcome Metric Traditional Legacy Healthcare Baseline Maven Integrated Platform Performance NICU Admission Rate Standard industry benchmarks. Up to 28.0% Relative Reduction C-Section Delivery Rate 32.0% US National Average. Up to 15.0% Relative Reduction Post-Leave Return-to-Work Rate 57.0% US National Average. 90.0% to 94.0% Return Adherence Pregnancy Without Assisted Tech Requires IVF/IUI initiation. 30.0% natural conception rate among fertility members Employer Return on Investment (ROI) Uncoordinated point-solution loss. 2x to 4x validated return ratio This integrated approach contrasts with traditional benefit models like Progyny. While Progyny operates primarily as a fertility benefits manager focused on structured insurance coverage and clinical partnerships, Maven functions as a continuous virtual clinic. By combining digital tools like Maven Wallet for expense reimbursement with clinical resources like Maven Milk, the platform coordinates care across the entire parenting journey. Supported by over $425 Million in venture funding from investors such as General Catalyst, Sequoia, and Dragoneer, Maven has expanded its model into direct-to-consumer (DTC) services. This expansion includes dedicated programs for GLP-1 prescribing, hormone replacement therapies and midlife health, demonstrating how platforms built on employer benefits can expand into consumer-driven markets. Direct-to-Consumer Biomarker Ecosystems: Deciphering the Cash-Pay Longevity and Preventive Space The shift beyond traditional prescriptions has fuelled a growing direct-to-consumer health diagnostic market. Increasingly, health conscious consumers are seeking direct access to advanced medical testing without waiting for symptoms to appear or navigating insurance constraints. Startups like Function Health, Levels, and January Health are building cash-pay models that treat deep diagnostic tracking as a personal wellness investment. Function Health, co-founded by Dr. Mark Hyman in 2023, has emerged as a key player in this direct-to-consumer market. Operating entirely outside the traditional insurance system, Function charges an annual subscription fee (typically $499 billed upfront) to provide members with extensive, regular biomarker testing. To complete this extensive panel, members must follow a strict preparation protocol designed to prevent interference with sensitive biomarker assays: 72 Hours Prior: Stop all vitamins and nutritional supplements, as ingredients like biotin can skew hormone and thyroid assays, though prescribed medications must be continued. 48 Hours Prior: Avoid eating seafood to prevent temporary spikes in mercury measurements. 8 Hours Prior: Fast completely from food and drinks, including black coffee, with the sole exception of water. Morning of Visit: Drink at least 1 litre of water to ensure proper hydration for faster blood draw flow, and avoid physical exercise until the blood draws are complete. Once collected, the raw biomarker data is normalised and uploaded to a HIPAA-compliant digital dashboard. The platform organises results into logical groupings (eg., advanced lipid panels measuring ApoB, hs-CRP, and Lp(a); metabolic markers; thyroid profiles; and hormone levels) and visually maps them against optimal, rather than merely conventional, clinical ranges. Approximately 28 days after testing, members receive a clinical summary from a licensed provider. This report synthesises their biomarker data with their intake goals to deliver personalised diet, lifestyle, and supplement protocols (such as customised list cards detailing top foods to enjoy and avoid). Subscription Component Associated Financial Costs Included Biomarker & Imaging Services Annual Function Membership $499 billed upfront annually. 160+ biomarkers tracked over two semi-annual testing rounds. Out-of-Pocket Lab Fees Approx. $200 per draw visit ($400 total). Paid directly to lab networks for drawing and processing blood. Extended Autoimmunity $249 optional add-on panel. Targeted biomarkers for autoimmune disease detection. Lyme Disease Panel $549 optional add-on panel. Advanced Lyme antibody screening. Celiac Screening $69 optional add-on panel. Immunological markers for gluten sensitivity. Advanced Imaging (MRI/CT) $200 member credit (regularly $999). Whole-body cancer, stroke, and aneurysm imaging. The operational logistics of direct-to-consumer diagnostics require close integration with national laboratory networks. Function Health partners with Quest Diagnostics to process its extensive panel, which requires drawing approximately 35 milliliters of blood. To make this volume manageable for patients, the initial draw is split across two appointments scheduled within a 10-day window. Each visit requires drawing 10 vials of blood, and the second visit includes a urine sample collection. To protect the discounted rates negotiated with its lab partners, Function blocks members from syncing their results with standard laboratory patient portals, hosting all longitudinal trends directly within its own proprietary application. This direct-access testing model is supported by significant venture capital. Function Health has raised over $50 Million from major investors including Andreessen Horowitz (a16z), while its direct competitor Superpower secured a $30 Million Series A round led by Forerunner. These platforms are also integrating emerging diagnostic technologies, such as Verséa Health’s mescreen™, which evaluates cellular energetics and mitochondrial function to track metabolic health at a cellular level. However, this rapid growth has sparked debate within the clinical community. Traditional primary care physicians often argue that testing over 100 biomarkers in asymptomatic individuals inevitably flags minor, clinically insignificant out-of-range values. This "over-testing" can cause patient anxiety, drive unnecessary follow-up evaluations and lead to self-prescribed, unmonitored supplement regimens. Furthermore, critics note that automated clinician notes and generic dietary recommendations can feel formulaic, sometimes lacking the clinical depth of a comprehensive in-person medical assessment. However, proponents maintain that the primary value of these platforms lies in tracking longitudinal biomarker trends over time. By identifying subtle changes within an individual's unique historical baseline, users can make proactive, data-backed lifestyle changes to prevent metabolic and cardiovascular decline before chronic diseases develop. The Regulatory Frontier: Evolving Compliance Requirements and Legal Safeguards As direct-to-consumer wellness devices, health software, and direct-access lab services proliferate, they are navigating a rapidly shifting regulatory landscape. In early 2026, the U.S. Food and Drug Administration (FDA) released updated guidance documents designed to clarify the boundaries between regulated medical devices and low-risk general wellness tools. The 2026 General Wellness Policy Released on January 6th, 2026, the final guidance clarifies how the FDA regulates wearable products that estimate physiological measures. Under this framework, software functions and wearable products intended solely for maintaining, encouraging, or tracking healthy lifestyles, without diagnosing or treating specific conditions are generally exempt from medical device regulation. However, if a device makes specific disease claims (such as diagnosing hypertension or sleep apnea), it crosses the threshold into regulated software or medical hardware, triggering strict review processes. This policy encourages wellness innovation while maintaining oversight for products making diagnostic claims. Clinical Decision Support (CDS) Software Guidance Updated on January 29, 2026, the CDS Final Guidance clarifies which software functions are classified as regulated medical tools. Under this update, software that provides clinicians or consumers with health recommendations must be transparent. If the software operates as a "black box", where the user cannot independently review the underlying data, clinical evidence, or logic behind a recommendation, it is regulated as a medical device. This forces digital platforms (including ŌURA’s diagnostic algorithms and Function Health’s clinical summaries) to clearly explain their data sources and scientific rationale, protecting consumers from unregulated, automated medical advice. AI Predetermined Change Control Plans (PCCP) and Security Protocols The regulatory framework also addresses artificial intelligence integrations and cybersecurity requirements: PCCP Final Guidance (August 2025): Establishes guidelines for Predetermined Change Control Plans (PCCP) in AI-enabled device software. This framework allows developers to implement pre-approved machine learning updates and algorithm modifications without requiring a new 510(k) submission, provided the modifications do not alter the device’s core diagnostic intent. FDA Cyber-Security Requirements (February 2026): Mandates that all connected medical devices and wellness platforms processing patient-generated health data (PGHD) must implement end-to-end data encryption and strict access controls to protect user privacy. Enforcement Actions: The FDA has demonstrated a willingness to enforce these standards, issuing warning letters to wearable manufacturers that make diagnostic disease claims without clinical evidence or regulatory clearance. These evolving rules show that while the FDA is relaxing regulations for low-risk wellness software and consumer devices, it continues to enforce strict oversight on clinical diagnostics and automated decision-making platforms. Wellness startups must design their products within these clear boundaries to ensure consumer safety, maintain clinical credibility and avoid regulatory compliance issues. Nuanced Conclusions and Strategic Outlook The shift from reactive "sick-care" to proactive healthspan management represents a major reorganization of the healthcare market. Traditional healthcare systems are struggling with physician shortages and rising operational costs, leaving consumer technology platforms, virtual clinics and retail pharmacies to build a new model of continuous, daily health support. This structural evolution is driven by consumer demand for diagnostic access and personalised health insights, combined with employer efforts to manage rising healthcare benefit costs. However, the rapid growth of this cash-pay wellness market highlights a deepening division within the healthcare system. While high-income consumers use continuous tracking, advanced biomarkers, and personalised coaching to optimise their health, lower-income and rural populations remain vulnerable to a declining primary care infrastructure. To address these challenges, the healthcare industry must focus on building cohesive, integrated solutions: Standardised API Interoperability: Connecting consumer-generated health data from wearables directly to electronic health records (EHRs) to give primary care providers a continuous, longitudinal view of patient health. Transparent Clinical Support: Developing clear, validated decision support software that translates continuous biometric trends into actionable insights, helping clinicians provide targeted care. Asset-Light Community Access: Repurposing retail spaces to support clinical research, health screenings, and preventive services, ensuring diverse populations can access clinical innovations. Integrated Metabolic Care: Linking physical pharmacy dispensing with food-as-medicine programs, helping patients successfully navigate long-term lifestyle changes. Ultimately, moving "beyond the prescription" requires integrating consumer-driven technology with traditional clinical workflows. By connecting continuous biometric data, accessible diagnostic platforms, and personalised behaviour modification, the healthcare ecosystem can transition from a reactive model of symptom suppression to a proactive, integrated framework focused on extending human healthspan. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Passive Continuous Phenotyping and Remote Therapeutic Monitoring: The ŌURA Integration Framework Clinical Philosophy of Passive Continuous Phenotyping Passive continuous phenotyping represents a paradigm shift in modern clinical medicine, transitioning diagnostic and therapeutic monitoring from reactive, episodic clinical visits to continuous, proactive and ecologically valid tracking of individual physiological baselines. Traditional medical models rely on static, sparse measurements that are highly vulnerable to clinical artifacts, such as "white-coat" hypertension or retrospective recall bias and fail to capture the dynamic, circadian fluctuations of chronic pathologies. By deploying low-profile consumer biosensors, clinical systems can acquire highly dense, longitudinal physiological data streams directly from a patient’s daily environment without imposing a cognitive or behavioral burden. This continuous acquisition is vital because early physiological decompensation often manifests as sub-clinical deviations in resting metrics, autonomic tone and thermal regulation. Continuous multi-parametric tracking allows for the construction of highly individualised homeostatic baselines. Rather than evaluating an individual against broad, heterogeneous population level norms, clinical algorithms can model intra individual variability to detect micro-deviations that precede acute symptomatic expression. The mathematical modelling of these baseline shifts serves as a predictive early-warning system across multiple domains, including infectious disease onset, cardiovascular degradation and neuropsychiatric status changes. When integrated into clinical care networks, these continuous biometrics enable a proactive care model where therapeutic adjustments are driven by real-world physiological signatures. Biosensing Architecture and Multi-Parametric Clinical Validation The physical ring platform utilises a highly optimised multi-sensor array designed to continuously capture biometrics from the digital arteries on the palmar surface of the finger. This sensing suite comprises three primary components: Dual-Wavelength Infrared Photoplethysmography (PPG): Emits light into the digital arteries to monitor arterial volume changes, tracking pulse waveforms, heart rate, inter-beat intervals (IBI) and pulse transit times. Negative Temperature Coefficient (NTC) Thermistors: Measures skin temperature directly from the finger, capturing continuous peripheral thermoregulatory fluctuations. Tri-Axial Accelerometer: Registers physical movement across three axes to determine sleep-wake cycles, physical activity metrics, and resting periods. To establish clinical utility, these continuous sensor streams have undergone extensive validation against gold-standard clinical measures. This validation spans sleep architecture, autonomic balance, cardiovascular aging, thermal regulation and respiratory disorders. Clinical Outcome Area Reference Standard Ring Performance Metrics Clinical Relevance Source Sleep Staging (Legacy Algorithm) In-lab Polysomnography (PSG) TST underestimated by 32.8\47.3 min; N3 sleep overestimated by 31.5\46.8 min; REM sleep underestimated by 12.8\19.5 min Broadly comparable to research-grade actigraphy (Actiwatch 2). various Sleep Staging (Deep Learning Algorithm) Polysomnography (PSG) 84 overall staging accuracy; REM sleep sensitivity at 90.6 % Light sleep sensitivity at 75.5% High-resolution tracking of longitudinal sleep architecture. various Autonomic Control (HRV/RMSSD) Shimmer3 Electrocardiogram (ECG) Low mean bias in overnight average test; high Pearson correlations for RMSSD and SDNN. Real-world tracking of chronic stress and cardiovascular strain. various Vascular Age (NUS Pipeline) Clinical Fingertip PPG Sensor Mean estimation error of 6\7 years; strong correlation with baseline clinical blood pressure. Scalable, home-based cardiovascular aging assessment. various Hypertension Screening Self-reported status / Cuff measurements 62% sensitivity; 91% specificity; trained on $300,000+$ active study participants. Non-invasive population-level screening for cardiovascular risk. various Nocturnal Dipping Behavior 48-Hour Ambulatory Blood Pressure 84% sensitivity; 69% specificity; Area under the Curve (AUC) of $0.87 Identification of cardiovascular dipping vs. non-dipping risks. various Moderate-to-Severe Sleep Apnea Type 1 In-lab Polysomnography 76% sensitivity; 89% specificity; evaluated on 339 active clinical subjects. Continuous home-based triage of suspected sleep-disordered breathing. various Infectious Fever Monitoring Self-reported Symptom Onset (TemPredict) Changes in daily min temp visible 2\3 days prior to symptom onset in 76\% of COVID-19 cases. Early detection and self-isolation guidance in health systems. various In sleep medicine, early ring models exhibited systematic deviations compared to polysomnography, including an underestimation of total sleep time (TST) and light sleep, alongside an overestimation of deep slow-wave sleep (N3). The deployment of a deep-learning sleep-staging algorithm addressed these gaps, achieving an 84% overall agreement with PSG, with particularly high sensitivity for REM sleep (90.6%). This validation supports its clinical use as an alternative to actigraphy for tracking longitudinal sleep architecture, sleep onset latency (SOL), and wake after sleep onset (WASO). In home-based clinical validation trials against continuous Shimmer3 ECG monitors, the ring demonstrated highly accurate tracking of both nocturnal resting heart rate and RMSSD. Moderate-to-high correlations were also observed for the standard deviation of NN intervals (SDNN) and the percentage of successive normal beat-to-beat intervals differing by more than 50 Milliseconds (pNN50), validating the platform for tracking chronic stress, cardiorespiratory fitness, and autonomic neuropathy. To assess cardiovascular health, researchers from the Centre for Sleep and Cognition at NUS Medicine developed an independent analytical pipeline using overnight peripheral PPG waveforms. By extracting pulse features passively during sleep, their deep-learning model estimated vascular age with a mean error of six to seven years, showing a strong correlation with baseline blood pressure. Continuous skin temperature tracking provides further clinical insight into thermoregulatory homeostasis. Under the TemPredict initiative, co-led by Ashley Mason at the UCSF Weill Institute for Neurosciences and Benjamin Smarr at UCSD, investigators analysed data from over $65,000 international participants. Supported by funding from #startsmall and the Department of Defense (including $800K and $5.1M contract awards), the study demonstrated that the ring's temperature sensor detected early illness patterns in 76% of COVID-19 cases up to 2 to 3 days prior to symptom onset. This predictive capability relied on identifying disruptions in the user's typical circadian temperature minimums and maximums. Additionally, the study revealed a significant correlation between elevated average dermal temperatures, compressed 24-hour temperature fluctuations (reduced circadian amplitude), and the severity of depressive symptoms. This thermal signature indicates that disruptions in peripheral heat dissipation and circadian amplitude may serve as objective biomarkers for major depressive phases, supporting heat-based clinical interventions designed to trigger biological self-cooling mechanisms. Building on these findings, the Oura Science Team released clinical validation data in June 2026 across three key diagnostic domains. First, utilising data from the Blood Pressure Profile Study (which enrolled over 300,000 consenting participants in Oura Labs starting in December 2025), a software-based hypertension screening algorithm demonstrated 62% sensitivity and 91% specificity in identifying self-reported hypertension without a physical cuff. Second, an algorithm designed to classify nocturnal blood pressure dipping behaviours against 48-hour ambulatory references demonstrated 84% sensitivity and 69% specificity, achieving an Area under the Curve (AUC) of 0.87. Third, an algorithm trained to screen for moderate-to-severe sleep apnea against Type 1 attended in-lab polysomnography in 339 subjects demonstrated 76% sensitivity and 89% specificity. This component-based regulatory strategy, following the precedent set by the ring's integration with the FDA-cleared Natural Cycles application for fertility tracking, aims to establish clinical-grade diagnostic pathways on consumer hardware. Remote Therapeutic Monitoring and the Regulatory Reimbursement Landscape Remote Therapeutic Monitoring (RTM) was established by the Centers for Medicare & Medicaid Services (CMS) to reimburse healthcare providers for the systematic tracking of non-physiological data related to treatment adherence, therapy response, and behavioural health outcomes. This model is distinct from Remote Patient Monitoring (RPM), which is restricted to the collection of physiological data (such as blood pressure or blood glucose) using medical devices. RTM explicitly allows for the tracking of subjective, patient-reported outcomes alongside device-derived, non-physiological metrics, including therapeutic exercise adherence, medication compliance, and cognitive behavioural therapy (CBT) engagement. Crucially, while RPM billing is restricted to physicians and non-physician practitioners (such as Nurse Practitioners and Physician Assistants), RTM billing is also open to physical therapists (PTs), occupational therapists (OTs), speech-language pathologists (SLPs), and clinical psychologists. Integrating the ring into an RTM workflow allows providers to monitor therapy adherence and physiologic responses dynamically. For example, in behavioural health and CBT-I (Cognitive Behavioural Therapy for Insomnia) protocols, patients utilise the ring to passively track sleep efficiency, latency, and fragmentation alongside mobile application logs tracking mood and sleep hygiene compliance. The clinical team reviews these consolidated data streams remotely. Cumulative data review time and subsequent tele-support consultations are billed under CPT codes 98980 and 98981, requiring a minimum of 20 minutes of treatment management and at least one synchronous interactive communication per calendar month. This creates a sustainable, reimbursable clinical workflow that supports therapeutic adjustments and patient compliance between standard clinical visits. In addition, RTM billing codes allow for multi-provider clinical coordination. Unlike RPM programs where only a single medical provider can bill for monthly device monitoring, the RTM framework allows multiple specialised clinicians to concurrently track different therapeutic domains. For example, a sleep medicine specialist can monitor a patient's CPAP device and subjective sleep metrics under CPT code 98976, while the patient’s primary care physician manages chronic musculoskeletal pain or metabolic factors using the ring under CPT code 98977. This multi-provider model increases practice revenue and coordinates care across specialties without causing reimbursement conflicts. Enterprise Architecture and Developer Integration Frameworks Building continuous pheno typing pipelines requires a secure, performant and scalable technical architecture to handle high-throughput, time-series data. The integration framework must process raw metrics while ensuring strict data privacy and compliance with global health regulations. The REST API V2 operates at the base URL https://api.ouraring.com/v2. Accessing these data streams requires transition from deprecated Personal Access Tokens (fully deprecated in December 2025) to the standard OAuth 2.0 Authorisation Code flow. The OAuth process redirects users to the consent portal at https://cloud.ouraring.com/oauth/authorize with requested scopes, returning a temporary authorisation code that the backend exchanges at /oauth/token for a 30-day access token and refresh token. Users grant permissions across granular scopes: email, personal, daily (for sleep, readiness, and activity summaries), heartrate (5-minute interval resting and active streams), workout (workout sessions), tag (user annotations), session (guided breathing/meditation), and spo2Daily (average sleep oxygen saturation). If a user's subscription expires, the API returns a 403 Forbidden error, prompting the application to manage account status flows gracefully. For integration testing, developers can call the sandbox endpoint at /v2/sandbox/usercollection/sleep to retrieve mock payloads without connecting live physical rings. Rather than relying on periodic REST polling, which can trigger rate limits (capped aggregate limit of 5,000 requests per 5 minutes), developers can deploy a real-time webhook architecture. When a user opens their mobile application and syncs their ring, raw physiological metrics are pushed to the cloud. Approximately 30 seconds later, the webhook triggers, posting a payload containing the updated resource indicators to the registered callback URL. Webhooks are configured via POST /v2/webhook/subscription. During registration, the endpoint must resolve a GET verification challenge within 10 seconds to activate. The receiving backend should verify the cryptographic HMAC-SHA256 signature transmitted in the x-oura-signature header using its client secret to prevent spoofing. Local testing setups often route these webhooks through tools like ngrok, although developers frequently encounter 504 Gateway Timeout errors during portal registration due to misconfigured challenge-response handlers. To simplify development, teams can utilise pre-built low-code automation tools, data integration toolkits, and unified healthcare APIs. n8n Workflow Nodes: Provides visual integration triggers to retrieve activity, readiness, and sleep summaries, bypassing custom API clients and using HTTP Request nodes for direct REST calls. Tiny Command Recipes: Supports visual workflow recipes to map actions like Get Profile or Get Activity Summary directly into communication channels (such as Slack alerts) or clinical logging targets (Google Sheets, Notion databases). Terra API: Standardises and pushes normalised payloads (Activity, Body, Daily, and Sleep) containing hypnograms and 5-minute heart rate samples to destinations including MongoDB, SQL, Webhooks, Google Cloud Storage, or Firestore. Open Wearables Framework: Standardizes biometrics from multiple providers into a unified schema, managing the token lifecycle and generating auditable metrics like the Resilience Score (which combines HRV and resting heart rate). The Open Wearables framework also supports standard Model Context Protocol (MCP) servers, enabling Large Language Models (such as Claude or ChatGPT) to query clinical data. Rather than analysing raw time-series numbers directly, the MCP server provides pre-computed health scores and anomalies, allowing clinical chatbots and virtual clinics to interpret patient trends against their baseline. Finally, these normalised biometric streams can be routed to electronic health record systems through SMART-on-FHIR pipelines, such as Validic’s Epic App Orchard integration. This middleware enables custom clinical exception rules. Clinicians do not have to review raw sleep data; instead, the system triggers an alert in their Epic InBasket only when physiological metrics (such as sleep fragmentation or resting heart rate) deviate from established safety thresholds over a set period, optimising clinical attention. Passive Continuous Phenotyping and Remote Therapeutic Monitoring: The ŌURA Integration Framework Strategic Deployment Models in Payer and Corporate Systems To drive enrolment and reduce clinical costs, healthcare insurers, employers, and benefits managers are integrating these wearable frameworks into their wellness and chronic care benefits programs. In the payer sector, Medicare Advantage plans (covering over 31 million Americans) leverage wearable metrics to improve Star Ratings and lower acute care claims costs. For instance, Essence Healthcare began a large-scale deployment in 2025, distributing free rings to its Medicare Advantage members. This program aligns patient incentives (free hardware) with provider revenue (RTM billing codes) and payer cost containment (fewer preventable acute hospitalisations). Similarly, private health management programs, such as Discovery Vitality, offer members up to 25% premium discounts when they share verified sleep and physical activity metrics. These continuous biometrics allow insurers to run targeted wellness programs for diabetes, chronic pain, and hypertension, using baseline shifts to prompt clinical outreach. Corporate employers also leverage these platforms to manage group health insurance premiums and reduce absenteeism. Oura for Business provides aggregated wellness and recovery dashboards that correlate sleep deficits with organizational safety risks. Enterprises often offer $200 to $300 hardware credits through integrations with wellness platforms like Virgin Pulse or Wellable to reduce program friction. To navigate regulatory boundaries, these programs must comply with Equal Employment Opportunity Commission (EEOC) guidelines. Updated guidance dictates that all corporate wellness programs must be strictly voluntary; while wellness incentives remain permissible, employers cannot penalise, isolate, or raise premiums for employees who choose not to share their personal biometric data. Systemic Vulnerabilities and Future Engineering Horizons While continuous phenotyping offers substantial clinical utility, developers and systems engineers must address structural vulnerabilities to ensure patient safety and data integrity. The sync latency and "night gap" vulnerability To optimise its small battery and protect user sleep, the ring's Bluetooth transmitter is largely deactivated during sleep. Physiological data does not sync continuously throughout the night; instead, it is cached locally on the ring's onboard memory and transmitted only when the user wakes up and opens the companion mobile application. This creates a systemic "night gap" that limits the device's utility for real-time clinical monitoring. Consequently, the platform cannot support active, real-time emergency alerting (e.g., immediate nocturnal cardiac arrest, sleep apnea, or fall detection). If a life-threatening physiological event occurs, the clinical backend will not receive the data until a manual sync is performed the following morning.\ The clinical ambiguity of missing data A key challenge for clinical tracking is the handling of missing data. Biometric data gaps stem from both physiological and behavioural sources: Motion Artifacts: Optical PPG signals are sensitive to motion noise during sleep, which can disrupt continuous heart rate and HRV recording. Compliance Drops: Users may forget to wear the device or fail to recharge the battery. Zero-Value Ambiguity: Unlike clinical-grade equipment that logs explicit error codes, consumer wearables typically handle missing data by omitting the time-series entry entirely rather than recording a zero value. For automated decision-support systems, distinguishing between a disconnected ring, a dead battery, and actual patient distress is highly complex. If a patient's data stream halts abruptly, clinical algorithms cannot determine if the user has removed the device or experienced a cardiac event. This ambiguity requires developers to implement sophisticated statistical imputation methods to handle sparse records without generating false-positive clinical alerts. Future engineering plans must focus on low-power background sync APIs to reduce sync latency while protecting battery life. Standardising data schemas and error logging will also help clinical backends distinguish technical dropouts from physiological emergencies. As consumer wearables secure further regulatory approvals and integrate with clinical workflows, addressing these structural vulnerabilities will be essential to establishing them as safe, reliable tools for continuous patient monitoring. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Strategic Reconfiguration of Global Healthcare: Analysing Prosus’s €400 Million Investment in Alan and the Broader Naspers AI Ecosystem Moat The global technology investment landscape experienced a significant consolidation in June 2026 when the Netherlands-listed technology investor Prosus finalised a €400 Million (US$460 million) direct investment into the French digital health and insurtech platform, Alan. This transaction was executed as the leading component of a larger €480 Million (US$550 Million) Series G funding round. It valued the Paris-based digital insurer at €5.5 Billion (US$6.3 Billion). The investment architecture utilised a structured combination of newly issued primary equity and the acquisition of secondary shares, allowing early liquidity for select historical stakeholders while injecting substantial fresh balance-sheet capital to drive international expansion. This transaction represents an extraordinary valuation step-up within a remarkably compressed operational timeframe. Only three months prior, in March 2026, Alan completed an initial Series G primary capital raise of €100 Million (US$116 Million) at a post-money valuation of €5.0 Billion. The subsequent June financing round, led by Prosus, elevated Alan's market capitalisation by €500 Million in less than 90 days. This trajectory highlights strong investor demand and highlights a fundamental re-rating of Alan’s underlying operating model. The broader investment syndicate for this round involved both elite venture capital and sovereign-scale allocations. Prosus was joined by existing institutional backers Teachers' Venture Growth (TVG) and Index Ventures, alongside a new equity commitment from Dara Holdings. Operationally, the final closing of the round remains subject to standard regulatory clearances, primarily from the French Prudential Supervision and Resolution Authority (ACPR), which serves as Alan’s direct insurance supervisor. Financial and Transactional Milestones Transaction Details Strategic and Market Implications Series G (Primary Phase) March 2026; €100 million raised at a €5.0 billion post-money valuation Established the baseline valuation and provided initial capital for international market entry. Series G (Consolidated Phase) June 2026; €480 million total round size led by a €400 million commitment from Prosus Valued the company at €5.5 billion ($6.3 billion); introduced secondary liquidity and primary capital. Cumulative Funding to Date Approximately $1.3 billion across nine structured funding rounds Positions Alan among the most capitalized digital health platforms globally. Q1 2026 ARR Performance €800 million (US$909 million), representing 53% year-on-year growth Demonstrates the rapid transition of the business from a local startup to an institutional scale. This funding round occurred amid a broader shift in the European digital health and insurance technology sectors. The total European private health insurance market was valued at approximately $517 Billion in 2025 and is projected to expand to $772 Billion by 2034. Private capital has responded to this market size: European digital health companies raised $1.2 Billion in venture funding in the first quarter of 2026 alone, with digital health insurance platforms capturing $116 Million of that total. This trend is further illustrated by the rapid close of dedicated institutional vehicles, such as Lauxera Capital’s €520 Million healthtech fund, which closed in under 18 months, indicating strong investor confidence in late-stage European healthcare platforms. Alan’s capital strategy is designed to establish "prevention insurance" as a global category. Part of the Series G capital will fund expansion beyond France into Spain, Belgium, and Canada. To build brand equity as it enters these highly regulated markets, Alan secured a partnership with international football star Kylian Mbappé, who invested in the company and signed on as a global brand ambassador. Additionally, the company is targeting new demographics to sustain its growth. It plans to launch "Alan Campus" in January 2027, a digital-first health insurance product designed for students aged 18 to 28. This offering aims to capture users early in their healthcare journeys and transition them into long-term enterprise contracts as they enter the workforce. The Operational and AI Architecture of Alan: Unlocking Extreme Operating Leverage The strategic logic of Prosus’s investment lies in Alan’s capacity to decouple policyholder growth from administrative headcount. Traditional health insurance operations scale linearly: as policyholder numbers grow, insurers must expand their back-office teams to handle claims, underwriting, and customer support. In contrast, Alan serves more than 1.1 Million members and 37,000 corporate clients with a lean workforce of only 850 employees. This structural efficiency is enabled by its AI-native platform, which automates core operational workflows. This automated operational architecture has a significant impact on unit economics. By deploying large language models to automate claims processing, fraud detection, and customer support triage, Alan reduced its per-member administrative costs by 28% in 2023. Because its infrastructure is digital-first, most standard reimbursements are processed, verified, and disbursed to policyholders within 24 hours. A key factor in Alan's technical positioning is its relationship with Paris-based Mistral AI. Both of Alan's co-founders, Jean-Charles Samuelian-Werve (CEO) and Charles Gorintin (CTO), serve as co-founding advisors and board members of Mistral AI, which was established in 2023. This relationship provides Alan with direct access to advanced open-source large language models. It allows the company to integrate specialized, highly secure clinical and administrative language models directly into its insurance platform while maintaining strict compliance with European data sovereignty regulations. This integration of AI into a regulated business model creates an interesting valuation dynamic. While Alan uses AI to power much of its platform, the vast majority of its revenue still comes from traditional insurance premiums on collective corporate contracts. This shows that while Alan is structurally a regulated insurance business, its AI-driven efficiencies allow it to achieve the high operating leverage and margin profiles typically associated with pure-play software companies. This operational profile is what justifies its premium, AI-like valuation multiples in private markets. The NasperscProsus Portfolio Strategy: Transitioning to an Integrated Platform Play The investment in Alan is part of a broader strategic shift by Prosus and its parent company, Naspers. In 2019, Naspers spun off and listed its international internet assets as Prosus on the Euronext Amsterdam. This move was designed to unlock shareholder value and address the persistent valuation discount of Naspers shares relative to its underlying 2001 investment in Chinese technology giant Tencent. Historically, Naspers focused on early-stage, region-specific venture investing through vehicles like Naspers Foundry. This initiative deployed R1.4 Billion (approximately $300 Million) into South African startups, backing businesses such as home services platform SweepSouth, agritech platform Aerobotics, and early insurtech players Ctrl and Naked Insurance. Under current CEO Fabricio Bloisi, however, the group has shifted toward a more integrated global platform strategy. Prosus is actively working to transition its portfolio of consumer internet businesses into an interconnected "life assistant" platform. This strategy aims to integrate food delivery, payments, fintech, travel, and classifieds into a single consumer ecosystem. To support this unified ecosystem, Prosus entered a global partnership agreement with Amazon Web Services (AWS) in early 2026. This agreement standardises artificial intelligence infrastructure across Prosus's global operations, allowing portfolio businesses, including iFood, OLX, PayU, Despegar, eMag, and Just Eat Takeaway, to build on shared technical frameworks. By investing in Alan, Prosus adds a highly scalable, digital health and preventative care layer to this ecosystem. This healthcare integration allows Prosus to connect its transactional platforms, such as food delivery and wellness commerce, with a regulated medical and insurance network. Investment Platform or Vehicle Core Mandate & Geographic Focus Historical / Current Operational Scaling AI Integration & Ecosystem Role Naspers Foundry Early-stage, South Africa-focused venture capital Deployed over R200 million across key initial holdings like SweepSouth and Aerobotics. Addressed local socioeconomic needs via localized technology applications. Prosus Ventures Global early-stage and growth technology investments Active globally; committed over $400 million across 40+ deals in FY25. Backs early-stage AI startups that optimize logistics, commerce, and healthcare workflows. AWS Global Partnership [ Enterprise cloud and AI standardization framework Standardised cloud operations across major international business units Leverages AWS advanced machine learning to build secure, compliant consumer experiences. Technical Analysis of the Prosus AI Engine: Large Commerce Models and Agentic Infrastructure At the core of Prosus’s technology strategy is its proprietary Large Commerce Model (LCM). The LCM is a specialized, agentic AI model trained on Prosus's global database of commercial transactions. This database comprises over 10 Trillion tokens of commercial data, reflecting real-world interactions from 500 Million users and 5 Million merchant partners. Unlike general-purpose large language models, the LCM is built to understand, reason about and anticipate consumer transactional intent. It can interpret complex, multi-variable requests and execute actions across different transactional platforms. The operational efficiency of the LCM is a major differentiator. In benchmarking tests, the model proved to be 60 times cheaper to run than leading general-purpose frontier models while delivering higher conversion accuracy on commercial and transactional tasks. Prosus has demonstrated the model's commercial impact through its food delivery business, iFood, in Brazil. The platform has deployed the LCM across more than 40 distinct use cases, resulting in a 19% increase in home-screen conversions, a 51% reduction in advertising acquisition costs, and a 75% increase in push-notification engagement. To bring this agentic capability to its broader partner network, Prosus launched ToqanClaw and Zapia. ToqanClaw is a secure, no-code development platform integrated with Prosus's internal AI engine, Toqan. The system allows businesses—such as restaurants, merchants, and logistics partners—to build custom automations and analytic dashboards using natural language prompts. To optimize performance and minimise costs, ToqanClaw dynamically routes tasks across more than 20 open-source and proprietary language models. This strategy has reduced operational token costs for participating small businesses by up to 90%. Platform / Tool Core Technical Architecture Performance & Cost Benchmarks Consumer / Enterprise Deployment Large Commerce Model (LCM) Proprietary agentic AI model trained on 10 trillion commercial tokens 60 times cheaper to run than leading general-purpose frontier models Deployed across iFood, OLX, Just Eat Takeaway, and eMag. Toqan / ToqanClaw Secure, multi-model no-code development platform Reduces token execution costs by up to 90% via dynamic routing Deployed to over 5 million merchant partners and small businesses. Zapia Consumer-facing, autonomous agentic AI assistant Executes multi-step, real-world tasks across messaging APIs Reached 7 million monthly active users, primarily in Latin America. Zapia is the consumer-facing interface for this agentic ecosystem. Rather than acting as a standard conversational chatbot, Zapia is an autonomous assistant designed to execute multi-step tasks across different apps. For example, a user can instruct Zapia to find a restaurant with specific dietary options, coordinate a booking with friends over WhatsApp, gather their preferences, and confirm the reservation. Currently serving over 7 Million users, Zapia’s growth has been driven by its integration with WhatsApp in Latin America. By connecting Alan’s clinical navigation tools with the LCM, ToqanClaw, and Zapia, Prosus can provide Alan's members with highly automated, conversational healthcare navigation. This allows users to manage wellness tracking, schedule medical appointments, and coordinate insurance approvals within a single, unified interface. Strategic Reconfiguration of Global Healthcare: Analysing Prosus’s €400 Million Investment in Alan and the Broader Naspers AI Ecosystem Moat Mapping Prosus’s Global Healthtech Assets: From Infrastructure Layers to AI Diagnostics The investment in Alan is part of a broader, multi-region healthcare technology portfolio managed by Prosus. The group’s healthcare strategy focuses on platforms that integrate clinical workflows, automate documentation, and streamline healthcare distribution. Mevo (Brazil) In March 2026, Prosus led an $18 Million (R$95 Million) funding round for Mevo, Brazil's leading e-prescription platform. Historically, Brazil's healthcare system processed over one billion handwritten prescriptions annually, leading to high administrative friction and risk of errors. Mevo addresses this by connecting doctors, clinical institutions, patients, and retail pharmacies through a unified digital prescription network. The company operates a transactional monetization model. Its digital prescription system is provided to clinical institutions and physicians at no upfront cost to capture distribution. Monetisation occurs downstream through Mevo Shop, an integrated consumer portal that facilitates exam scheduling, patient support program integration, and direct medicine fulfilment through a network of 11 major pharmacy chains across 1,600 retail locations. Mevo has integrated its platform into more than 1,100 healthcare institutions and seven major health insurance providers, covering approximately 30% of Brazil's private healthcare market. The company projects that it will process digital prescriptions for over 20 Million patients in 2026. Corti (Denmark) Co-led by Prosus Ventures and Atomico, Copenhagen-based Corti secured a $60 Million Series B in September 2023 to scale its clinical AI co-pilot. Corti’s software processes speech and text in real time during clinical consultations and public safety emergency calls. The AI provides diagnostic suggestions, flags critical symptoms (such as cardiac arrest during emergency calls), and automates post-encounter administrative workloads, including clinical coding, documentation, and quality assurance. Corti currently supports clinical workflows over 150,000 times a day, covering approximately 100 million patients annually across Europe and the United States. VOA Health (Brazil) In March 2025, Prosus backed Belo Horizonte-based VOA Health with a $3 Million Seed investment. VOA Health develops generative AI tools designed to streamline clinical documentation for healthcare providers. By automating the creation of medical records, patient histories, and prescriptions, the platform aims to reduce administrative workloads and allow doctors to focus more on direct patient care. PharmEasy (India) Prosus’s investment history in India’s PharmEasy (API Holdings) highlights the financial complexities of scaling digital health platforms in emerging markets. In April 2021, Prosus Ventures and TPG co-led a $350 Million Series E round that established PharmEasy as a unicorn at a valuation of approximately $1.5 Billion, which subsequently climbed to a peak private valuation of $5.6 Billion in late 2021 following the acquisition of listed diagnostics provider Thyrocare. However, post-pandemic macroeconomic tightening and the postponement of its planned public offering forced PharmEasy to undergo severe corporate restructuring. By 2023, the company faced substantial valuation markdowns and debt-servicing challenges. To stabilise its balance sheet, PharmEasy completed a highly dilutive rights issue in late 2023 / early 2024, raising approximately $417 Million (including direct participation from Prosus and Temasek), followed by a $216 Million capital round in April 2024 led by Ranjan Pai (MEMG Family Office) at a restructured valuation of approximately $710 Million. This restructuring was concluded in September 2025, with PharmEasy securing $193 Million (INR 1,700 crore) in debt financing led by 360 ONE Asset to refinance high-cost debt and focus strictly on positive EBITDA generation. Operationally, the company successfully pivoted from a capital-intensive inventory model to a highly profitable, asset-light aggregator network. This transition was achieved by utilizing machine learning models to reduce partner pharmacy stock-outs by 40%, expanding high-margin diagnostic services via Thyrocare's 3,000+ collection centers, and scaling higher-margin private-label wellness products. Portfolio Company Regional Focus & Scope Key Financial Event AI & Automation Drivers Strategic Integration / Status Mevo Brazil; covers 30% of the private healthcare market. Led by Prosus in March 2026; $18 million Series B extension. Digital e-prescription engine and integrated marketplace. Connected to 1,100+ medical centers and 1,600+ pharmacies. Corti Europe & US; processes 150,000 daily patient consultations. Co-led by Prosus Ventures and Atomico; $60 million Series B. Real-time speech and text analysis for emergency triage. Optimizes clinical workflows and automates billing codes. VOA Health [ Brazil; operates in clinical documentation space. Funded by Prosus in March 2025; $3 million Seed round. Generative AI to automate patient histories and clinical records. Focuses on reducing administrative overhead for clinicians. PharmEasy India; serves over 20 million registered users across 1,200+ cities. Series E co-led by Prosus Ventures; secured $193M debt in Sept 2025. ML models for inventory demand forecasting to cut stock-outs. Transitioned to an asset-light aggregator with positive EBITDA. Clarity Global; operates in highly regulated customer support. Early-stage venture investment backed by Prosus Ventures. Secure AI customer experience platform for healthcare/finance. Enhances enterprise data security and compliance. Dognosis Global; focuses on early-stage non-invasive diagnostics. Early-stage funding round in March 2026. Canine olfaction, robotics, and AI to identify cancers from breath. Expands preventative diagnostic capabilities in oncology. Strategic Implications for the Global Managed Care and Insurtech Landscapes The convergence of global capital and specialised AI models across Prosus’s healthcare portfolio suggest several key structural shifts in the healthcare and insurance markets. The Decoupling of Margin Profiles in Managed Care Traditional insurance carriers have historically operated with high administrative loss ratios and low operating margins due to the intensive manual labor required to manage claims processing, clinical reviews, and member support. By using specialized open-source LLMs like Mistral for claim auditing and customer interactions, digital platforms can scale their membership base exponentially while keeping headcount flat. This shifts the financial profile of an insurtech platform from a traditional financial-services multiple to a high-margin software multiple, driving the valuation premium seen in Alan’s €5.5 Billion valuation. Regulatory Protectionism as a Structural Barrier to Entry Unlike standard consumer software, healthcare operates within a highly regulated environment. Insurtech platforms must maintain significant capital reserves and secure approvals from national supervisors like the ACPR in France. This regulatory complexity acts as a powerful barrier to entry for big-tech competitors. Consequently, global technology investors like Prosus must deploy capital into vertically integrated, pre-regulated players (such as Alan) rather than attempting to build alternative consumer-facing digital health layers from scratch. The Evolution from Transactional E-Commerce to Ambient Life Assistants The integration of specialised AI tools like Prosus’s Large Commerce Model with clinical assets like Mevo and Alan indicates a shift in how consumers access healthcare. Instead of navigating multiple disjointed apps for health insurance, doctor consultations, prescriptions, and lifestyle-related purchases, consumer interaction is consolidating around singular, agentic conversational hubs. This agentic orchestration can autonomously manage the entire care loop: tracking a user's preventative wellness goals, flagging clinical risks, booking consultations, authorising insurance claims, and delivering prescriptions directly to the home. This continuous loop optimizes health outcomes while creating a highly defensible, data-rich ecosystem moat around the underwriting platform. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada

The Scaleup Europe Fund: Navigating Late-Stage Growth Capital Opportunities for European HealthTech and MedTech Companies Strategic Genesis: Combatting the European Tech Exodus in Life Sciences Despite Europe's thriving startup ecosystem, which consistently produces world-class scientific discoveries and breakthrough technologies, innovative enterprises face severe challenges when attempting to scale within the continent. As tech and life science companies transition from early-stage validation to the capital-intensive scaleup phase, they routinely encounter an underdeveloped late-stage venture capital sector. This domestic funding gap, particularly acute in growth rounds approaching or exceeding nine figures, has historically forced many of Europe's most promising innovators to seek capital from foreign institutional investors, often relocating their headquarters, executive talent, and intellectual property to the United States or Asia. This capital flight represents a systemic drain on European economic value and technological sovereignty. The vulnerability of European innovation is underscored by high-profile foreign acquisitions of pioneering technology firms. Notable examples include Advanced Micro Devices acquiring the Finnish artificial intelligence company Silo AI for $665 Million in 2024, and IonQ's purchase of the UK-based quantum computing firm Oxford Ionics for more than $1 Billion in 2025. To curb this trend and foster domestic alternatives, European policymakers have designed the Scaleup Europe Fund as a concrete deliverable of the European Commission's Competitiveness Compass and a direct response to the Draghi Report's urgent call to close Europe's deep-tech financing gap. Operating as a key pillar of the EU Startup and Scaleup Strategy, the Scaleup Europe Fund is designed to serve as a strategic autonomy tool. Implemented with the support of the European Investment Bank, the fund acts as a catalyst to mobilise private and public institutional capital, ensuring that the critical technologies of the next decade remain anchored in Europe. For healthtech, medtech and biotechnology companies, sectors characterised by highly capital-intensive development timelines, prolonged clinical trials, and stringent regulatory processes, this fund represents a transformative shift in the European funding landscape. Core Architecture: Fund Size, Structure and Private Governance The Scaleup Europe Fund is positioned to become Europe's largest technology growth fund, targeting €5 Billion in total commitments. To achieve global parity and effectively compete with the massive venture funds of the US and China, the European Commission has signaled intentions to scale the fund's total capacity to €25 Billion over time. The core capital structure is a public-private hybrid. The European Commission has committed €1 Billion to the fund, sourced directly from Horizon Europe, the EU's flagship research and innovation programme. The remaining €4 Billion is being raised from private and sovereign institutional investors, with private partners having already committed €1.5 Billion by the end of 2025. Following a highly competitive public call for expressions of interest launched between December 2025 and February 2026, the European Innovation Council Fund Board shortlisted elite management firms from Sweden, the UK, and France to oversee the vehicle. This shortlist included EQT and Northzone from Sweden, Eurazeo from France, and Atomico and Vitruvian Partners from the United Kingdom. In May 2026, Swedish investment firm EQT was appointed as the preferred adviser and fund manager. EQT operates as an independent, market-based manager, ensuring that investment decisions are commercially driven and free from political influence. Furthermore, EQT commits a significant portion of its own capital to the fund, establishing a profit-making framework that aligns public policy objectives with private sector returns. Structurally, the Scaleup Europe Fund will operate as a separate compartment within the existing EIC Fund umbrella. This architecture allows the fund to deploy significantly larger investment tickets than previous European funding mechanisms. While the EIC Fund historically capped its equity investments at €30 Million, the Scaleup Europe Fund will focus on direct equity investments in the range of €100 Million and above. This capability is designed to lead or co-lead major financing rounds, helping European innovators scale into "unicorns" without relinquishing operational control to foreign buyers. Strategic Alignment: Positioning Healthtech, Medtech and Biotech for Scale For healthtech, medtech, and biotechnology scaleups, the launch of the fund, scheduled to execute its first investments in autumn 2026, addresses the financial mismatch inherent in scaling life science technologies. Healthcare innovation requires patient, long-term growth capital to finance multi-centre Phase II/III clinical trials, secure global regulatory approvals (such as CE-MDR and FDA clearances) and construct advanced, compliant manufacturing facilities. The availability of €100 Million+ investment tickets provides the financial runway required to navigate these hurdles. The composition of the fund’s founding investors provides portfolio companies with strategic benefits that extend far beyond capital injection. Founding Investor Group Institutional Members Strategic Value to Healthtech & Medtech Scaleups Life Sciences Specialists Novo Holdings Brings unmatched clinical, commercial, and industrial expertise, with a deep understanding of biotechnology development and global drug distribution networks. Sovereign & Promotional Banks EIFO (Denmark), Wallenberg Investments (Sweden), BGK (Poland) Provides stable, long-term backing linked to national and European industrial strategies, facilitating local regulatory navigation and commercial procurement within regional health systems. Pension & Asset Managers APG Asset Management (representing Dutch pension fund ABP), Allianz (German Insurer) Represents vast pools of non-dilutive, patient capital capable of supporting successive growth rounds and stabilizing long-term corporate valuation. Commercial Banking Networks Santander/Mouro Capital, Intesa Sanpaolo Offers access to cross-border financial services, debt facilities, corporate banking, and established corporate healthcare networks across Europe. Philanthropic Foundations Fondazione Compagnia di San Paolo, Fondazione Cariplo Bridges the gap to clinical research institutions, university hospital networks, and public health initiatives aligned with broader societal and UN development goals. The management of the fund will actively leverage EQT's specialised internal divisions, particularly its dedicated Life Sciences, Ventures, and Growth teams. This cross-disciplinary expertise is essential for modern healthtech companies, which frequently operate at the intersection of biology, software, and advanced engineering. By connecting scaleups with EQT's global network of clinical advisors, hospital executives, and industrial partners, the fund helps portfolio companies accelerate commercialisation, optimise supply chains and secure market entry across multiple European jurisdictions. Comparative Framework: Navigating the Multi-Tiered European Growth Capital Ecosystem To navigate the expanding European funding landscape, healthcare executives must understand the distinct operational roles of the EIC Accelerator, the EIC STEP Scale Up call, and the Scaleup Europe Fund. Each mechanism represents a different level of maturity, funding capacity, and qualification requirements. Feature / Metric EIC Accelerator EIC STEP Scale Up Call Scaleup Europe Fund (SEF) Target Technology Maturity TRL 6 to 8 (Technology demonstrated in relevant environments) Late-stage development & rapid scaling of strategic tech Series B & C commercial scaling, global deployment, and market expansion Primary Financial Instruments Blended finance: up to €2.5M in grants and €0.5M to €10M (or up to €15M) in equity Equity-only investments Direct equity and quasi-equity growth capital Funding Amount (Ticket Size) Max €2.5M grant; equity capped typically at €10M–€15M €10 million to €30 million €100 million and above Institutional Scale Under the main EIC Fund umbrella Part of the EIC STEP call within the 2026 Work Programme Independent, privately managed compartment under EQT Evaluation Framework Standard EIC multi-stage process with quarterly cutoff dates Quarterly batching system for rigorous strategic and financial proposals Direct application to the fund manager (EQT) utilizing commercial private market due diligence Co-investment Requirements Evaluates risk; crowding in private capital is desired but not rigidly benchmarked at entry Strictly enforces the "20% Rule" pre-commitment from a qualified lead investor Market-driven, leading or co-leading major, syndicated European investment rounds To ensure application readiness, corporate planning must align with the specific batching and evaluation timelines established under the EIC 2026 Work Programme. The cut-off dates for both early-stage Accelerator proposals and the mid-tier STEP Scale-Up program are highly structured, requiring significant lead times for preparation. Evaluation Cycle (2026) EIC Accelerator Step 2 Cut-off Dates EIC STEP Scale-Up Cut-off Dates First Batch / Q1 January 7, 2026 February 11, 2026 Second Batch / Q2 March 4, 2026 May 6, 2026 Third Batch / Q3 May 6, 2026 September 9, 2026 Fourth Batch / Q4 July 8, 2026 November 25, 2026 Fifth Batch / Q5 September 2, 2026 No corresponding cut-off in Q5 Sixth Batch / Q6 November 4, 2026 No corresponding cut-off in Q6 The Scaleup Europe Fund: Navigating Late-Stage Growth Capital Opportunities for European HealthTech and MedTech Companies Geographic Compliance, UK Exclusion and Swiss Bilateral Frameworks As a concrete delivery of European strategic autonomy, the Scaleup Europe Fund mandates that funded companies retain the majority of their value creation, including intellectual property, manufacturing capabilities and headquarter functions, within the European Union or Horizon Europe associated countries. This geopolitical positioning has significant strategic and operational implications for healthtech and medtech companies located in non-EU-27 jurisdictions, specifically within the United Kingdom and Switzerland. The United Kingdom: Complete Equity Exclusion and Corporate Redomiciling The post-Brexit relationship between the United Kingdom and the European Union creates a restrictive operational environment for British healthtech and medtech enterprises. While the UK’s formal association with Horizon Europe allows British SMEs and research consortiums to participate in research centric grants, such as the EIC Pathfinder and EIC Transition initiatives, it explicitly excludes them from accessing any equity or investment components. Consequently, UK-domiciled startups are eligible to apply for the grant portion of the EIC Accelerator (up to €2.5 Million for TRL 6-8 development), but they are completely ineligible for the EIC STEP Scale-Up call and the Scaleup Europe Fund. For high-growth British healthtech scaleups seeking to access these multi-million-euro equity pools, the only viable pathway is to execute a corporate restructure, effectively establishing a primary operating headquarters and transferring key intellectual property to an eligible EU Member State or Associated Country prior to submitting a full application. Switzerland: Bilateral Pathways and Strict Compliance Audits In contrast to the UK, Switzerland's active participation as an Associated Country to Horizon Europe allows Swiss-domiciled startups and "small mid-caps" (up to 499 employees) to qualify for late-stage equity initiatives, including the Scaleup Europe Fund. However, Swiss healthtech scaleups must navigate a rigorous, multi-layered compliance audit to demonstrate their strategic alignment with the broader European ecosystem. Swiss companies cannot pitch their solutions solely within the context of their domestic market. Instead, they must explicitly show how their technologies, manufacturing pipelines, and clinical data structures strengthen European industrial sovereignty and security of supply, particularly for products on the Union list of critical medicines. Furthermore, Swiss applicants must present a funded, executable plan detailing how they will establish or scale physical operations, clinical testing sites, or commercial distribution centres within EU Member States within 12 months of receiving the investment. Executive Playbook: Qualification Benchmarks and Pre-Commitment Rules For healthtech and medtech executives preparing to apply for the Scaleup Europe Fund or the mid-tier EIC STEP program, operational planning must begin six to twelve months in advance. Because the fund is overseen by EQT alongside highly analytical institutional investors, the diligence process focuses heavily on financial discipline, commercial scalability, and regulatory compliance. Operational and Financial Benchmarks To qualify for these late-stage growth vehicles, a healthtech company must demonstrate robust commercial traction. While early-stage grants focus primarily on scientific novelty, the Scaleup Europe Fund and its precursors target scaleups with established product-market fit. The fund typically targets enterprises with annual revenues ranging between €2 Million and €15 Million, with a proven, audited year-over-year growth rate exceeding 25% for at least two consecutive fiscal years. For the EIC STEP Scale-Up program, the commercial benchmarks are even higher, requiring an Annual Recurring Revenue (ARR) of over €10 Million and gross margins exceeding 40%. Although current profitability is not a strict requirement, the application must include an investor-grade, five-year financial model outlining a credible path to EBITDA breakeven within three to four years post-investment. The Pre-Commitment Mandate and the "20% Rule" A critical hurdle for healthtech scaleups is the "20% Rule" pre-commitment requirement mandated under the EIC STEP Scale-Up framework. Companies cannot apply for these public-private growth equity tickets in a vacuum. To secure a €10 Million to €30 Million ticket, the applicant must have already obtained a formal, legally backed commitment from a qualified private lead investor. This lead investor must commit to funding at least 20% of the total target round. Furthermore, the total funding round must be three to five times the size of the requested EU equity ticket. For example, if a medical device scaleup requests a €20 Million equity ticket from the EIC, it must target a total funding round of €60 Million to €100 Million, with a private lead investor committing at least €12 Million to €20 Million. This mechanism ensures that public capital acts as a cornerstone to catalyze larger private co-investments, de-risking the round and accelerating market deployment. Data Sovereignty and Regulatory Auditing Because the fund serves as a strategic autonomy tool, healthtech scaleups must ensure that their technical and regulatory frameworks align with European standards. This is particularly critical for digital health and artificial intelligence companies, where compliance with the EU AI Act and GDPR must be integrated directly into the product design. Investee companies are expected to host their infrastructure on European servers, minimise dependencies on non-EU cloud hyperscalers to mitigate vendor lock-in, and maintain absolute, unencumbered ownership of their core software codebase, patented clinical algorithms, and proprietary medical data. Conclusions and Strategic Recommendations for Board-Level Decision-Makers The establishment of the Scaleup Europe Fund represents a significant evolution in the European Union’s approach to venture capital and industrial planning. By partnering with an experienced global manager like EQT and securing anchor commitments from major institutional investors like Novo Holdings and Allianz, the European Commission is shifting from grant-based, fragmented funding toward a market-driven growth equity model. This structural change provides healthtech, medtech, and biotech scaleups with the large-scale, long-term capital required to build global healthcare leaders without having to leave the European ecosystem. For healthtech and medtech boards of directors, the emergence of this multi-billion-euro funding architecture requires immediate, proactive adjustments to corporate finance and operational strategies: Sovereignty-by-Design in Corporate Structuring: Healthtech scaleups, particularly those based in the UK, must evaluate their long-term corporate geography. If late-stage capital requirements exceed €50 million, boards should consider establishing an operational headquarters, transferring intellectual property, or redomiciling to an eligible EU Member State or Associated Country. Similarly, Swiss entities must structure their growth plans to include rapid, measurable expansion of operations, manufacturing, or clinical sites inside the EU-27 borders. Alignment with Life Science Anchor Backers: Healthcare scaleups should tailor their business models to align with the strategic goals of the fund's founding partners. Positioning technologies to align with the investment criteria of life science specialists like Novo Holdings, or ensuring compatibility with the long-term pension goals of APG/ABP, can significantly improve a company's prospects during the due diligence process. Accelerating Investor Readiness: Scaleup executives should initiate comprehensive pre-audit processes to ensure their financial reporting, beneficial ownership records, and data architectures meet institutional standards. Preparing five-year financial models that demonstrate a clear, audited path to EBITDA breakeven within three to four years is essential to withstand the rigorous due diligence of independent managers like EQT. Securing Qualified Lead Investors: Because the EIC STEP Scale-Up program and the broader fund rely on co-investment structures, companies must build relationships with qualified private lead investors well ahead of application deadlines. Securing a firm commitment for at least 20% of the target round from a private lead investor is a necessary first step to unlock public matching equity. By implementing these strategic preparations, healthtech and medtech enterprises can position themselves to successfully leverage the Scaleup Europe Fund, turning Europe's boldest venture capital initiative into a launchpad for global healthcare leadership. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Venture to Venture M&A: Strategic Consolidation in European HealthTech and MedTech Strategic Consolidation in European Healthtech and Medtech: An Analytical Assessment of Venture-to-Venture Tuck In Trends The European healthcare technology and services landscape has entered a structurally distinct phase of maturation, transitioning from the speculative, growth-at-all-costs venture capital paradigms of the post-pandemic era into an era defined by profitable efficiency, clinical validation and platform scale. Following several years of valuation corrections and capital constraints, mergers and acquisitions have become the dominant, necessary exit route for maturing enterprises, consistently and overwhelmingly outperforming initial public offerings by volume. Within this overarching consolidation wave, venture-to-venture "tuck-in" transactions, where late-stage, well capitalised digital health scale-ups acquire early-stage, highly specialised startups, have experienced a marked acceleration. This shift represents a strategic pivot away from funding isolated, single-purpose point solutions and toward the integration of robust, multi-product enterprise platforms capable of delivering quantifiable clinical and operational returns to overstretched health systems. The Industrialisation of Healthcare: Macroeconomic and Regulatory Drivers The acceleration of tuck-in transactions across Europe is driven by a convergence of severe macroeconomic pressures, evolving regulatory frameworks, and shifting capital-market dynamics. These forces have combined to create a unique pressure cooker for consolidation, which industry analysts have termed the industrialisation of care. The Regulatory Sandbox and Compliance Barriers The implementation of rigorous European regulatory frameworks has acted as an artificial clearing mechanism in the healthtech sector. Evolving compliance mandates, such as the full implementation of the EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR), have created capital intensive barriers to entry. The substantial costs associated with obtaining Notified Body certification and generating continuous clinical data act as a strategic barrier for undercapitalised Small and Medium-sized Enterprises (SMEs), driving them into the arms of larger platforms with scaled regulatory departments. Simultaneously, the introduction of the new EU AI Act and the Digital Omnibus package, which outlines the "Data Unlock" concept to streamline the interaction between AI governance, MDR and GDPR, places complex compliance requirements on high-risk artificial intelligence systems. Smaller startups, unable to absorb these compliance overheads, increasingly seek integration with larger strategic entities. Private Equity Liquidity Dynamics and Arbitrage While regulatory barriers constrain early-stage independent survival, the massive capital overhang within the private equity and venture capital ecosystems provides the necessary liquidity to execute consolidations. Sponsors are under immense pressure to return capital to Limited Partners. With the public IPO window remaining selective, sponsors are increasingly utilising continuation funds and secondary buyouts to extend their holding periods over high-performing platform assets. These platforms act as consolidation engines, executing "buy-and-build" strategies that capitalise on multiple arbitrage. By acquiring smaller competitors at lower multiples, typically x6 to x8 EBITDA and integrating them into a larger platform valued at a premium of x12 to x15 EBITDA, sponsors can drive significant non-organic value creation. Quantitative Assessment of Market Activity The transition from fragmented growth to structured scale is reflected in global and regional transaction volumes, average deal sizes, and capital allocation trends. Financial Metrics and Exit Ratios The primary quantitative metrics of the healthtech and medtech sectors demonstrate a clear consolidation trajectory. Metric Historical Value Current/Observed Value Strategic Significance Sources Global Digital Health Exits 113 Total (H1 2025) 107 M&A vs. 6 IPOs Outlines the unassailable dominance of M&A (94.7% of exits) over public listings Various Average Healthtech Deal Size $13.6 Million (Q1 2022) $46.6 Million (Q1 2026) Demonstrates a shift away from early-stage testing to late-stage platform scale Various European Digital Health Funding ~$1.1 Billion (Q1 2024) ~$2.0 Billion (Q1 2025) Reflects a major rebound (82% YoY) focused on platform scale and integration Various Global Venture Capital Funding $12.1 Billion (Historical) $15.3 Billion (Recent YoY) Indicates a market recovery (26% YoY increase) driven by larger, AI-powered rounds Various Private Equity Dry Powder $2.0 Trillion (Historical) $2.5 Trillion (Current Overhang) Underpins massive capital availability for programmatic buy-and-build strategies Various Platform Valuation Multiples 6x - 8x EBITDA (Target) 12x–15x EBITDA (Platform) Illustrates the multiple arbitrage driving private equity-backed consolidation Various Regional M&A Architecture and Geographic Bifurcation Consolidation maturity varies across European geographies. In highly integrated markets, such as the Netherlands and the United Kingdom, consolidation is advanced. The strategic focus in these regions has shifted toward secondary buyouts, the creation of pan-European "super-platforms," and operational optimisation. Conversely, in Southern and Eastern Europe, the market remains highly fragmented, offering attractive entry multiples relative to the saturated Northern and Nordic markets. Spain has emerged as a key gateway for cross-border transactions, bucking broader European downturns with a robust healthcare M&A market. Geographic Region Market Maturity & Strategic Focus Notable Subsector Allocation Transaction Dynamics Sources United Kingdom & Netherlands Advanced maturity; focus on secondary buyouts and super-platform creation Integrated care, primary care booking SaaS, telecare High concentration of corporate clinical groups Various Spain (Southern Europe) Highly active gateway; dynamic domestic and cross-border consolidation Hospitals & Clinics (36.4%), Elderly Care (18.2%), Medtech (13.7%) Balance of 52% strategic and 48% financial buyers Various Nordic Region (Sweden/Finland) Mature innovation hub; focus on outbound strategic acquisitions and wearables Digital therapeutics, mental health platforms, biometric hardware Programmatic cross-border acquisitions Various Rather than deploying entirely cash on balance sheet models, acquirers rely on structured transaction components. Performance-contingent earn outs, representing approximately twenty to thirty percent of total deal value, are increasingly standard in digital health acquisitions where steep revenue trajectories remain unproven or tied to complex public reimbursement pathways. Additionally, minority equity rollovers require founders of acquired startups to roll over thirty to forty percent of their equity into the parent platform, thereby limiting initial cash expenditures for the acquirer while maintaining strategic alignment during subsequent integration phases. Finally, vendor financing is utilised in specialised private equity and strategic consolidator scenarios, where sellers extend credit to the buyer to facilitate the completion of the transaction under tight debt-market conditions. Strategic Anatomy of the Ten Key Transactions The venture-to-venture consolidations executed in the European digital health and medical technology ecosystems reveal distinct strategic pathways. The table below outlines ten prominent examples of European healthtech platforms acquiring peer startups to establish scale, expand functionality, and secure market dominance. Platform Acquirer Target Venture Transaction Date Primary Specialisation Key Operational Metrics & Financials Sources Huma eConsult October 2, 2024 Primary & urgent care digital triage Est. valuation $29M–$43M; based on 50M consultations Various Huma Alcedis January 9, 2023 Data-driven clinical trial technology Combined 1,000 studies across 60+ countries Various Huma iPLATO January 2022 Patient engagement & myGP scheduling Undisclosed value; £3.5M central NHS contract Various Mindler ieso Digital Health UK August 20, 2025 Telecare & typed CBT clinical platform Est. £20M deal; 145,000 patients served Various Mindler Medified Prior to 2025 Mental health outcome tracking SaaS Integrated outcome analytics architecture Various Doctolib Siilo March 2, 2023 Secure healthcare provider messaging Largest European professional chat app Various Doctolib Tanker January 2022 Cryptographic end-to-end encryption Secure communications infrastructure Various Unmind Frankie Health February 2023 B2B personal mental resilience software $1.25M target funding; 1,000+ therapist network Various ŌURA Veri September 11, 2024 Metabolic health & continuous CGM tracking Share exchange; ŌURA $11B corporate valuation Various Mediktor Sensely June 5, 2024 Conversational AI & medical virtual avatars Combined global diagnostic avatar network Various The Huma Ecosystem: Consolidating Patient Monitoring, Engagement and Research Huma has systematically executed a platform consolidation strategy, acquiring three highly complementary UK and German healthcare ventures to build a comprehensive, end to end technology platform for proactive care and clinical research. This programmatic acquisition strategy was supported by Huma's $80 Million Series D funding round, which brought its total funding to over $300 Million. The acquisition of primary care digital triage platform eConsult allowed Huma to integrate automated triage capabilities into its "Huma Workspace" platform. eConsult, which serves more than 1,800 GP practices and has delivered over 50 million digital consultations, provides a critical entry point for patient care. By integrating eConsult's clinical triage technology, Huma created an integrated patient pathway that guides individuals from initial triage to automated remote patient monitoring and virtual ward environments. This integrated system is embedded directly into the NHS App, providing a unified access point for patients and healthcare providers. This primary care strategy was further reinforced by Huma's earlier acquisition of patient engagement specialist iPLATO. iPLATO's myGP platform, which holds key NHS primary care contracts, brought deep patient engagement and communication capabilities to the Huma group. The transaction allowed Huma to combine its acute-care remote monitoring services with iPLATO's scheduling and clinical communication tools, expanding its reach across primary care networks. Simultaneously, Huma expanded its pharmaceutical services through the acquisition of Frankfurt-based Alcedis. Alcedis brought over 25 years of experience in data-driven clinical research and hybrid trial technology. By combining Huma's remote monitoring technology with Alcedis's operational expertise, Huma established a dedicated clinical trials division. The combined entity has managed nearly 1,000 studies across 60 countries, demonstrating how a unified healthtech platform can collect real-world clinical data and manage complex trials at scale. Mental Health Integration: Mindler and Unmind's Platform Strategies The digital mental health sector is consolidating rapidly as platforms move away from simple wellness applications and toward clinically validated, integrated care models. Stockholm-headquartered digital therapy provider Mindler demonstrated this trend by acquiring the UK telecare business of ieso Digital Health. ieso's UK business had supported over 145,000 patients and delivered more than 640,000 hours of cognitive behavioral therapy (CBT) across one third of England's Integrated Care Systems (ICSs). The acquisition, estimated at £20 Million, allowed Mindler to combine its video-based digital therapy platform with ieso’s typed CBT interface and clinical AI tools. This integrated model helps address capacity constraints in the UK, where 11.3% of mental health roles remain vacant and patients face long waiting lists. To support these clinical pathways, Mindler also acquired Finnish outcome-analytics startup Medified, embedding objective, patient-reported tracking software directly into its therapeutic platform. This clinical integration strategy is mirrored in the employer-sponsored wellness sector. Workplace mental health platform Unmind, which has raised $109 Million in funding, acquired Dublin-based Frankie Health to launch its "Unmind Talk" service. Frankie Health brought a personalized mental health platform, a network of over 1,000 licensed therapists, and clinical scheduling technology to Unmind. The integration allowed Unmind to expand its offering beyond preventative wellness tools, providing employees with direct access to clinical therapy and crisis support. Peer-reviewed trials of the integrated platform indicate that these personalized interventions can improve employee productivity by an average of 12%. Secure Communications and Cryptography: The Doctolib Playbook Doctolib, a leading European e-health platform, has utilized acquisitions to expand its core scheduling platform into secure clinical communications and data protection. Doctolib acquired Amsterdam-based secure messaging startup Siilo, the largest professional medical messaging application in Europe. Siilo's platform enables secure, HIPAA- and GDPR-compliant communication among healthcare professionals. By integrating Siilo’s secure messaging tools, Doctolib launched "Doctolib Teams," enabling clinical collaboration, case discussion, and care coordination within its broader booking ecosystem. This secure communication network is supported by Doctolib’s earlier acquisition of French cryptographic startup Tanker. Tanker developed end-to-end data encryption protocols designed to secure sensitive health records. Integrating Tanker’s encryption technology allowed Doctolib to establish high medical confidentiality and data privacy standards across its entire platform, helping the company meet strict European healthcare data requirements as it expanded into new geographies. Biometric Wearables and AI Diagnostics: Oura and Mediktor In the biometric wearables and clinical diagnostics sectors, tuck-in transactions are being used to integrate hardware and software capabilities. Finnish smart-ring pioneer ŌURA, which reached an $11 Billion valuation following a $900 Million Series E funding round, acquired continuous glucose monitoring (CGM) analytics developer Veri. Veri developed software that pairs with CGM sensors to help users analyze how diet and lifestyle choice impact metabolic health. The acquisition allowed ŌURA to integrate Veri’s metabolic tracking software with the Oura Ring's passive biometric monitoring. This software integration supported the launch of the "Meals" feature within the Oura App, enabling users to track meal timing and understand how diet affects sleep, stress, and recovery. This transaction fits into ŌURA’s broader programmatic acquisition strategy, which includes digital identity startup Proxy, performance analytics platform Sparta Science, and gesture recognition pioneer Doublepoint. In clinical diagnostics, Barcelona-based Mediktor acquired San Francisco-based Sensely, a pioneer in empathy-driven conversational AI. Mediktor developed a highly accurate, clinically validated AI symptom-checker engine. Sensely's platform uses virtual avatars to support patient triage and navigate individuals through healthcare systems. The combination of Mediktor’s diagnostic accuracy with Sensely’s conversational interface enables health systems and insurers to deploy virtual assistants that direct patients to the appropriate level of care, helping to optimise resources and reduce clinical workloads. Venture to Venture M&A: Strategic Consolidation in European HealthTech and MedTech Strategic Implications for the Digital Health Value Chain The shift from independent point solutions to integrated platform models is reshaping value creation and competitive dynamics across the European healthcare ecosystem. Shifting from Fragmented Point Solutions to Platforms For enterprise buyers, managing multiple independent digital health applications has become commercially and technically challenging. Employers, commercial insurers and public health systems are increasingly prioritising integrated platforms over single purpose apps. Consolidating multiple clinical pathways under a single platform offers several strategic advantages: Interoperability and Data Architecture: Integrated platforms connect diagnostic, remote monitoring and triage tools under a unified data framework, reducing data silos. Regulatory Compliance and Security: Platforms with established regulatory infrastructures can absorb the high compliance overhead of GDPR, the EU AI Act and clinical device standards. Demonstrable Return on Investment: Unified platforms with integrated clinical dashboards allow enterprise buyers to measure patient outcomes and financial returns through a single vendor. Automated Administration and Margin Expansion Tuck-in acquisitions are also targeting automated provider operations and administrative workflows, which have become a significant focus for venture capital and private equity investment. This sub-sector captured approximately 44% of total healthtech funding, driven by the immediate returns of administrative automation. By integrating generative AI and large language models (LLMs) into billing, coding, and prior authorisation workflows, consolidators can automate routine clinical claims and documentation. This automation helps expand operational margins, in some cases shifting service heavy business models toward high-multiple, recurring software-as-a-service (SaaS) frameworks. This transition supports the broader maturation of the European healthtech and medtech sectors, helping to build sustainable, clinically validated platforms capable of addressing the rising costs and capacity constraints facing European health systems. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Digital Health IPO Landscape in 2026 and Exit Backlog Paradox Structural Re-engineering of the Healthtech Exit: The 2026–2027 Digital Health IPO Landscape and Valuation Reset The public equity market for digital health entered a period of pronounced stagnation in 2026, creating a stark paradox for the venture capital ecosystem. While broader healthcare sectors, biotechnology platforms and emergency service providers successfully accessed public capital, not a single core digital health platform completed an initial public offering (IPO) during the first half of the year. This freeze stands in sharp contrast to the momentum of Mid 2025, when a brief opening of the public window allowed five pioneering healthtech companies, Hinge Health, Omada Health, HeartFlow, Carlsmed, and Profusa to break a multi-year listing drought. The completed listings of 2025 proved that public markets would support scaled, operationally disciplined healthtech companies. For example, Hinge Health (NYSE: HNGE) priced its IPO at the top of its range at $32 per share, raising $437 Million at an implied valuation of $2.6 Billion. Omada Health (NASDAQ: OMDA) followed shortly after, completing its listing to raise $150 Million at a valuation of $1.1 Billion. Meanwhile, the precision oncology and clinical diagnostics developer Caris Life Sciences priced its IPO to list on NASDAQ as well. The year closed with the massive $6.26 Billion listing of medical supply giant Medline, confirming deep institutional demand for healthcare assets with predictable margins and immense scale. This momentum did not translate into active digital health IPOs in 2026. While early 2026 saw non-digital healthcare sectors thrive, evidenced by biotechnology companies pulling in over $1 Billion in a single week and emergency transport provider GMR Solutions raising $479 Million in its NYSE listing, the core digital health window remained closed. This ongoing stagnation has created a major backlog. Dozens of late stage digital health platforms that raised billions in venture funding at peak valuations must go public, as few strategic corporate buyers can afford to acquire them at their current scales. The resulting buildup of pre-IPO companies is forcing a structural revaluation across the private market. Quantitative Trends in Healthtech Private Capital Allocation The stagnation of the 2026 public exit window is directly impacting private market financing. Rather than a collapse in aggregate funding, the sector is experiencing a concentrated consolidation of capital. Private equity and late stage venture funds are executing fewer, larger transactions, focusing on enterprise grade software and platforms with defensible intellectual property. Metric 2021 2022 2023 2024 2025 Total U.S. Venture Capital Funding $29.3Bn $15.3Bn $10.7Bn $10.5Bn $14.2Bn Total Global Venture Capital Funding $52.7Bn $25.5Bn $13.2Bn $17.2Bn (US) $28.8Bn Deal Count (U.S.) 729 572 509 509 482 Average Deal Size (U.S.) $40.2M $26.8M $21.0M $20.7M $29.3M Concentration into Mega-Deals ($100M+) — — — — 42% of total AI Share of Sector Funding — 29% 33% ~45% 54% The funding patterns illustrate a transition from speculative, consumer directed models to enterprise platforms. While total deal counts in 2025 reached a five-year low of 482, the average deal size rebounded by 42% to $29.3 Million, driven by the concentration of capital into market-dominant platforms. This concentration of capital is highly focused on clinical AI, which captured 54% of all digital health funding in 2025. This trend is driven by clear return-on-investment parameters, with healthcare AI tools yielding an average payback period of 14 months and returning $3.20 for every $1.00 invested. As the 2026 public window remains closed, late-stage crossover investors, including Fidelity, T. Rowe Price, Coatue, and Wellington Management, are shifting their focus toward capital-preservation strategies, funding highly selective late-stage bridge rounds to sustain balance sheets until a viable public window opens in 2027. The Shift in Valuation Metrics: 2021 Peak vs. Modern Realities The public and private market valuation framework has undergone a major correction since the 2021 peak. The speculative multiples of the pandemic era, which frequently reached 15x to 20x forward revenues for growth-at-all-costs platforms, have been replaced by strict fundamentals. In the 2026 market, core digital health companies are valued within a normalised range of 4x to 6x revenue. Premium platforms that present proprietary AI, deep integration into medical clinical workflows and validated data moats command multiples of 6x to 8x+. Conversely, sub-scale or unprofitable companies without clinical evidence are compressed to multiples of 3x to 4x revenue. Public & Private Health Tech Cohort Enterprise Value to Revenue Multiple Annualized Revenue Growth Rate Free Cash Flow (FCF) Margin Rule of 40 Score (Growth + FCF) HeartFlow 13.8x 49% -36% 13% Tempus AI 9.3x 85% -22% 63% Caris Life Sciences 8.9x 117% -7% 110% Waystar 6.9x 12% 27% 39% Hinge Health 5.7x 72% 26% 98% Omada Health 2.5x 65% -1% 64% Healthtech Cohort Average 7.2x 67% -2% 65% The financial data of this cohort shows that the public markets continue to apply a discount to platforms that lack positive cash generation. Although modern healthtech companies exhibit growth and free cash flow margins that match or exceed those of top-tier cloud software companies, they trade at a 10% to 20% discount relative to their enterprise SaaS counterparts. This valuation discount is expected to close as AI-native digital health companies prove their structural leverage. Traditional medical services generate an average of $100,000 to $200,000 in revenue per full-time equivalent (FTE), and legacy healthcare SaaS generates $200,000 to $400,000 per FTE. However, AI-native platforms are achieving $500,000 to over $1 Million in revenue per FTE. This performance is driving a transition in investor evaluation from revenue-based screening to EBITDA-based metrics, with profitable mid-market digital health platforms commanding 10x to 14x EV/EBITDA. Digital Health IPO Landscape in 2026 and Exit Backlog Paradox Profile Analysis of the Private Backlog Waiting in the Wings The pool of digital health companies awaiting a public listing represents a diverse mix of technologies, scale, and operational focus. These companies can be categorised by their core technology engines and market strategies. Clinical Artificial Intelligence and Data Platforms Abridge has positioned itself as a leading clinical generative AI platform, focused on reducing clinician burnout by automating medical documentation and clinical conversation summaries. Now deployed across more than 150 health systems and analyzing over 50 million medical conversations annually, Abridge has demonstrated strong clinical workflow integration with enterprise partners like Johns Hopkins, Kaiser Permanente and the Mayo Clinic. Supported by a $300 million Series E round in mid-2025 that increased its valuation to $5.3 Billion, Abridge presents a highly predictable, SaaS-like recurring revenue model that is well-suited for a targeted public listing. Innovaccer, known as the "Healthcare Intelligence Cloud," provides a critical data integration layer that unifies fragmented patient records for large health systems. By maintaining a 50% year-over-year revenue growth rate for five consecutive years while generating positive cash flow, Innovaccer has established a stable financial foundation. A $75 Million secondary ESOP buyback in January 2026 provided liquidity to early employees and signalled structured financial preparation for an IPO. The company was valued at $3.45 Billion in its January 2025 funding round. Commure focuses on automated administrative workflows to reduce clinical and administrative overhead. Backed by a Series D-3 funding round of $70 Million in May 2026, led by General Catalyst and Sequoia Capital, Commure achieved a $7.0 Billion valuation, establishing a strong capital position for an eventually receptive public market. Wearables, Devices and Early Diagnostics Oura Health is transitioning from consumer wellness to clinical diagnostics. The company sold over 5.5 million smart rings by late 2025 and is projected to generate between $1.5 Billion and $2.0 Billion in revenue in 2026, up from $1.0 Billion in 2025. Supported by a late 2025 Series E round that valued the company at $11 Billion, Oura confidentially filed for an IPO in mid-2026, leveraging its high recurring subscription revenue and a cash-rich balance sheet. Freenome develops blood-based tests for early-stage cancer detection, utilising its multiomics platform to analyse cell-free biomarkers via machine learning. Freenome announced a definitive business combination with Perceptive Capital Solutions Corp, which is expected to yield $330 Million in gross proceeds and establish a post-merger equity value of approximately $1.1 Billion under the NASDAQ ticker "FRNM". Speciality Virtual Care and Metabolic Reversal Platforms Ro has transitioned from a direct-to-consumer telemedicine provider into a vertically integrated telehealth infrastructure platform. Sources indicate that Ro's revenue run rate grew from $185.3 Million in 2023 to $598 Million in 2024, with growth accelerating into 2026. By establishing direct-to-consumer integrations with pharmaceutical manufacturers like Novo Nordisk for GLP-1 weight loss therapies, Ro is positioning itself for a 2027 public listing. Ro was last valued in the private markets at $7.0 Billion in 2022. Noom has navigated the competitive GLP-1 prescribing market with its "Microdose" clinical program, which pairs low-dose compounded semaglutide with digital behavioural coaching. This combination accounts for 60% of Noom's revenue. Noom possesses zero debt, positive EBITDA, and positive free cash flow, and is re-evaluating the public markets after postponing its initial IPO plans in 2022. The company was valued at $3.7 Billion in its 2021 funding round. Virta Health utilises a specialised clinical model to reverse Type 2 diabetes and provide clinical oversight for patients tapering off GLP-1 medications. Surpassing $160 Million in annualised revenue in late 2025 with an 80% year-over-year growth rate, Virta Health is positioned as a key partner for payers seeking to manage metabolic drug spend. CEO Sami Inkinen has stated that the company expects to be IPO-ready in 2026. The company was valued at $2.0 Billion in 2021. Workforce Mental Health and Enterprise Benefits Navigation Lyra Health represents a major enterprise platform in employer-sponsored mental health care, covering 17 million lives and commanding approximately 18% to 22% of the premium U.S. workforce market. Lyra Health's annualised revenue run rate reached $235 Million in late 2024, up from $111.3 Million in 2023. The company is valued at $5.58 Billion to $5.9 Billion. Its proprietary network of over 10,000 clinicians allows Lyra Health to guarantee care access in 2.2 days, compared to the 25-day national average, supporting a strong enterprise ROI model. The company secured a $57 Million Series G funding round in June 2026 to fund its clinical AI integrations. Spring Health, another major employer-focused mental health platform, expanded its coverage to over 20 million lives. Spring Health has raised approximately $509 Million in venture capital, with its latest valuation at $3.3 Billion. The company explicitly signalled its public intentions following a $100 Million Series E round, designed to strengthen its balance sheet for an IPO. Maven Clinic is a large virtual provider of women's and family health services, serving over 2,000 employers and health plans. In 2025, Maven Clinic expanded its client base by 170%, covering 23 Million individuals globally. Valued at $1.7 Billion in its 2024 Series F round, the company appointed senior executives with public market experience in 2025, signalling deliberate preparations for an IPO. Devoted Health combines a Medicare Advantage plan with a virtual-first clinical group. Devoted Health has raised $2.3 Billion in capital, with its last valuation at $12.6 Billion. The company's technology enabled administrative model yields higher margins than traditional insurers, making it a strong value based candidate for 2026. Regional Regimes and Cross-Border Listing Venue Dynamics The structural environment of the 2026–2027 IPO market is heavily influenced by regulatory updates and listing platform dynamics across the United States and Europe. High-growth European digital health companies are increasingly restructuring via the "Delaware Flip" to list directly on the NASDAQ or NYSE, seeking to access deeper public capital pools and achieve valuation parity with U.S. competitors. In response to capital flight, European financial authorities have implemented regulatory updates to retain home grown healthcare champions: The UK Financial Conduct Authority (FCA): The FCA removed the historical requirement for shareholder votes on certain transaction classes and relaxed dual-class share restrictions to make the London Stock Exchange (LSE) more appealing to founder-led companies. This supports LSE candidates like Huma, which is positioned as "the AWS of digital health" with its clinically cleared hospital-at-home platform. Deutsche Boerse: The German exchange reduced post-IPO capital listing fees, while Germany’s Future Financing Act relaxed listing requirements and expanded opportunities for Special Purpose Acquisition Companies (SPACs). Euronext: Standardised cross-border listings using English documentation via the European Common Prospectus initiative, which was fully enacted in late 2024 to simplify listings for companies like France’s Doctolib. This regulatory environment is further shaped by strict compliance frameworks. The EU AI Act, enforced in March 2026, imposes strict data governance, transparency, and validation standards on medical AI algorithms designated as "high-risk". This has shifted venture capital away from "black box" machine learning models toward explainable AI solutions that can pass clinical audits, creating a compliance moat for established platforms. Additionally, the European Health Data Space (EHDS) mandates that clinical networks make electronic health data available for secondary research, turning secure clinical databases into valuable assets that support the valuations of platforms like Owkin and Huma. Systematic Implications of the Stagnant Exit Window on Healthcare Operations The lack of digital health IPO exits in 2026 has direct, practical consequences for telehealth buyers and healthcare practices. Because many late-stage virtual care and clinical platform vendors are unable to access public markets for liquidity, they are under pressure to extend their cash runways. This financial strain creates several operational risks for healthcare organisations evaluating multi-year technology contracts: Roadmap Stagnation: To conserve capital, late-stage vendors are frequently forced to implement hiring freezes, reduce staff, or suspend research and development budgets. This means the technology platform a medical practice selects in 2026 is highly likely to see its development roadmap frozen for 12 to 18 months, leaving the buyer anchored to a stagnant platform. Vendor Insolvency and Reinsurance Exposure: Rising interest rates and changes to Medicaid and Affordable Care Act (ACA) reimbursement structures are putting pressure on vendor balance sheets. If a critical virtual care or remote patient monitoring vendor experiences insolvency, it can disrupt patient care workflows and expose health systems to compliance risks. Defensive Consolidation: To survive, smaller virtual care providers are merging with larger, more stable platforms, often at compressed valuations (e.g., Swoop acquiring Nimble). While consolidation can bring stability, it often leads to product sunsetting, forced data migrations, and integration challenges for the clinical practices using those systems. Consequently, healthcare procurement offices in 2026 are shifting their evaluation criteria from purely technical features to balance sheet durability. Organisations must require prospective vendors to provide clear disclosure regarding their cash reserves, burn rates, and historical funding cycles before committing to long-term enterprise agreements. Strategic Imperatives for Late-Stage Exit Readiness To successfully list in the late 2026 or 2027 window, candidates in the digital health backlog must transition from venture-backed growth strategies to public-market discipline. This operational transition requires focusing on three key areas: SaaS-Equivalent Unit Economics: Candidates must show that their platform models can generate stable gross margins of 60% to 80%. This requires automating clinical documentation, improving automated routing, and utilising AI assistants to increase the revenue generated per clinician and administrative employee. Rule of 40 Validation: Public markets are applying a discount to digital health platforms that exhibit high growth but significant losses. Listing candidates must show a clear path to positive EBITDA, ensuring their growth rate combined with their free cash flow margin satisfies the "Rule of 40" threshold. Clinical Evidence and Regulatory Compliance: As regulatory guardrails like the EU AI Act and MDR/IVDR become fully enforced, public market investors are demanding clinical validation. Candidates must back their platforms with randomized controlled trials (RCTs), peer-reviewed real-world outcomes, and payer-grade cost-effectiveness data to justify premium valuations. By focusing on these operational fundamentals, the digital health candidates currently waiting in the wings can build the financial durability needed to navigate a selective public listing window and secure long-term public market support. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Structural Convergence of Care Management and Remote Monitoring: A Strategic Valuation of ChartSpan’s Acquisition of Validic On June 22nd, 2026, ChartSpan Medical Technologies finalised its strategic acquisition of Validic, a prominent personal health data and healthcare Internet of Things (IoT) platform. Operating as a consolidated entity under the ChartSpan banner, the transaction establishes a unified clinical delivery layer that merges full-service virtual care teams with a scaled device-logistics and data normalisation ecosystem. The transaction bridges a historically fragmented healthcare data gap by combining traditional Chronic Care Management (CCM) and Advanced Primary Care Management (APCM) with continuous, home-based Remote Patient Monitoring (RPM). Transaction Overview and Financial Underpinnings While the transaction’s absolute dollar valuation was not publicly disclosed, the acquisition was supported by structured institutional financing led by BIP Capital. The investment firm’s efforts were directed by Managing Partner and CEO Mark Buffington alongside Principal RT Wyatt. Securities and Exchange Commission (SEC) filings reveal that a specialised Delaware-incorporated entity named BIP Ventures ChartSpan Equity I-QP, LLC (CIK: 0002126958) was registered in 2026 to facilitate the capitalisation. The entity initiated a pooled investment offering of $15,100,000 on June 2, 2026, with $6,890,000 in equity sold as of mid-June 2026. To execute the transaction, Validic retained Oppenheimer & Co. Inc. as its exclusive financial advisor. Prior to the acquisition, both organisations maintained independent, highly capitalised trajectories. ChartSpan had accumulated $37.1 million across six funding rounds, notably anchored by a $15 million Series A round in June 2019 led by BIP Capital, which led to the appointment of BIP Capital's Sarath Degala to ChartSpan’s Board of Directors. Validic had secured $31.6 million across eight investment rounds, backed by institutional investors including Kaiser Permanente Ventures, SJF Ventures, and Greycroft. Capitalisation and Financial Parameters ChartSpan Medical Technologies Validic, Inc. Consolidated Organization Total Venture Funding Raised $37.1 Million $31.6 Million Structured consolidated debt & equity capital Primary Institutional Backers BIP Capital, Blue Heron Capital, Cypress Growth Capital Kaiser Permanente Ventures, SJF Ventures, Greycroft BIP Capital, BIP Ventures, and historic investors Lead Investment Advisors Croft & Bender (historic) Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. and BIP Capital Transaction Structure Corporate Acquirer Acquired Subsidiary Merged operating unit under ChartSpan brand Historical Trajectories and Strategic Positioning ChartSpan was co-founded in 2012 by Jon-Michial Carter, his brother, and a third unnamed co-founder in Greenville, South Carolina. The startup emerged from The Iron Yard accelerator, initially focusing on a patient-facing mobile application designed to digitize paper-based medical charts through mobile optical character recognition. Recognizing structural shifts in federal reimbursement, ChartSpan pivoted to become the largest provider of managed Chronic Care Management services in the United States. Under the executive leadership of Chief Executive Officer Christine Hawkins, the company deployed specialised clinical software and an expansive, 24/7 virtual nursing workforce to manage high-risk Medicare populations. ChartSpan achieved strong performance metrics, including average patient enrollment rates of 45% in primary care practices and 35% in specialty practices, supported by complimentary Merit-based Incentive Payment System (MIPS) and quality improvement services for its clients. Validic was founded in 2010 by Drew Schiller and Ryan Beckland in Durham, North Carolina, as a pioneer in patient-generated health data aggregation. Operating as a platform-as-a-service (PaaS) model, Validic’s core database normalized and integrated biomedical telemetry from hundreds of disparate clinical and consumer devices. By 2026, the company’s platform reached over 223 million lives across 52 countries. A major turning point in Validic's operational history occurred on May 15th, 2023, when the company acquired the assets of Trapollo LLC, a connected health and device logistics provider, from its parent company, Cox Communications. This acquisition integrated Trapollo's fulfillment center in Sterling, Virginia, directly into Validic's operations. Steve Nester, the former General Manager of Trapollo, transitioned to Senior Vice President and General Manager of Validic’s logistics division. The integration of Trapollo enabled Validic to manage the entire device lifecycle, including inventory management, configuration, delivery of pre-paired medical kits, and patient technical onboarding. This operational capability was demonstrated in its joint program with Kaiser Permanente on the West Coast, which supported over 300,000 enrolled patients. This scale of clinical and device logistics integration yielded documented, high-precision clinical outcomes across large populations. Clinical & Operational Metrics Kaiser Permanente & Joint Program Baseline Outcomes Enrolled Population (West Coast) 300,000+ patients since program inception Glycated Hemoglobin (A1C) Control 1.2 point absolute reduction within a 90-day period for diabetic patients Systolic Blood Pressure (SBP) Control 12% drop in SBP in 45 days, transitioning stage 2 hypertension to normal Clinical Efficiency Rate 88% of participating clinicians reported saved administrative and active clinical time Clinician-Patient Communication 63% reduction in phone call times, from an average of 15 minutes to 5.5 minutes Patient Adherence and Engagement 76% of enrolled patients maintained biometric readings at least twice daily after 90 days Patient Care Satisfaction Score 75% of active participants reported feeling they were receiving superior, highly personal care Technical Integration and Product Infrastructure The combined platform combines Validic's two primary product categories, Validic Inform and Validic Impact, directly with ChartSpan’s care orchestration workflows. Validic Inform acts as a persistent, standardised data infrastructure layer. Rather than requiring hospital IT teams to build separate API integrations for different medical hardware brands, the Inform platform normalises streams from over 700 consumer and clinical-grade devices into a unified, developer-friendly interface. The system operates across a wide array of technical interfaces, providing developers with REST APIs, real-time streaming services, native iOS and Android SDKs, and push notification architectures. Validic Impact builds upon this normalization engine to deliver a turnkey, clinical-facing application integrated directly into electronic health records (EHRs) such as Epic and Oracle Health (Cerner). By writing biometric data directly to EHR flowsheets, clinical charts, and in-basket routing systems, the platform minimizes the administrative burden on clinical staff. When combined with ChartSpan’s human capital, this integration changes the delivery of remote care. Instead of practicing blind, periodic monthly outreach, ChartSpan’s care managers can review continuous physiological data and respond to automatic alerts triggered by patient devices. This continuous clinical triage allows care teams to address physiological decompensation in real time, preventing conditions from worsening into emergencies. Regulatory Compliance and Reimbursement Economics under CMS Guideline Revisions The financial and operational rationale for combining CCM, APCM, and RPM services is reinforced by updates in the Medicare Physician Fee Schedule (PFS). Historically, primary care groups struggled with the administrative burden of tracking staff minutes for Chronic Care Management billing. To address this friction, CMS introduced Advanced Primary Care Management (APCM) on January 1st, 2025, as an activity-based monthly bundle comprising 13 structural service elements. APCM consolidates the care coordination goals of CCM, Principal Care Management (PCM), and Transitional Care Management (TCM) into a single, non-time-based billing structure. In the CY 2026 Physician Fee Schedule, CMS increased reimbursement rates by approximately 10% across the three base APCM G-codes (G0556, G0557, G0558). In addition, CMS finalised three new behavioral health integration (BHI) add-on codes, G0568, G0569, and G0570, designed to support the Psychiatric Collaborative Care Model (CoCM) and general BHI within primary care workflows without requiring time-based documentation. Rural Health Clinics (RHCs) and Federally Qualified Health Centers (FQHCs) have also transitioned to these codes, billing individual APCM codes at national non-facility PFS rates. HCPCS Billing Code Risk & Complexity Level Qualifying Patient Profile 2025 National Rate 2026 National Rate Key Reimbursement Guidelines G0556 Level 1 APCM Patients diagnosed with 0 to 1 chronic condition. $15.00 ~$16.00 Requires verbal/written patient consent; primary care provider only. G0557 Level 2 APCM Patients diagnosed with $\ge 2$ complex chronic conditions. $49.00 ~$54.00 Conditions must last $\ge 12$ months, posing significant risk of acute decline. G0558 Level 3 APCM Level 2 clinical criteria + Qualified Medicare Beneficiary (QMB) status. $107.00 ~$117.00 Intended for dual-eligible populations with state-covered copays. G0568 CoCM Add-on Initial month of Collaborative Care Model services. N/A ~$162.00 Billed alongside base APCM codes; mirrors CPT 99492 but without time tracking. G0569 CoCM Add-on Subsequent months of Collaborative Care Model services. N/A ~$146.00 Billed alongside base APCM codes; mirrors CPT 99493 but without time tracking. G0570 General BHI Add-on Continuous general Behavioral Health Integration. N/A ~$57.00 Billed alongside base APCM codes; mirrors CPT 99484 but without time tracking. Under CMS regulations, APCM and traditional CCM codes are mutually exclusive for the same patient in the same billing month. However, providers are explicitly permitted to bill either APCM or CCM concurrently with Remote Patient Monitoring (RPM). To bill both services concurrently and maintain compliance during audits, clinical teams must adhere to strict guidelines. First, both programs must independently satisfy their respective CMS criteria. No clinical activity minutes may be double-counted; the time a care team spends coordinating chronic care (CCM) cannot be counted toward the time a clinician spends reviewing physiological data (RPM). For new patients, an initiating face-to-face visit, such as an Annual Wellness Visit (AWV) or standard Evaluation and Management (E/M) service, is required to discuss and obtain separate consent for each program. The RPM component requires the patient to use an FDA-defined medical device that automatically transmits physiological measurements, recording a minimum of 16 days of readings in a 30-day period (CPT 99454). Additionally, the care team must spend a distinct 20 minutes per month performing clinical data review and interactive communication (CPT 99457). The Structural Convergence of Care Management and Remote Monitoring: A Strategic Valuation of ChartSpan’s Acquisition of Validic Market Expansion and Enterprise Commercial Strategy The acquisition of Validic transforms ChartSpan’s commercial model from a clinic-focused care provider into a multi-sided enterprise digital health platform. Traditionally, ChartSpan’s client footprint was concentrated in independent primary care practices. By integrating Validic’s assets, the combined organisation can expand its commercial target footprint to serve health systems, commercial payers, digital health innovators and life sciences companies. For health systems and Accountable Care Organizations (ACOs), the consolidated platform addresses the operational fragmentation caused by managing multiple digital health point-solutions. Instead of using separate vendors for care management, remote patient monitoring devices, patient onboarding and EHR software integration, health systems can deploy ChartSpan as a single, unified clinical and technological partner. This approach simplifies procurement, aligns clinical care teams, and lowers administrative overhead for hospital staff. For payers and managed care organisations, the combined offering supports proactive risk management. By using home-based biometric telemetry, payers can identify physiological decompensation early and intervene before conditions worsen, helping to reduce expensive emergency room visits and hospital readmissions. For digital health innovators and life sciences companies, the platform provides a scalable data infrastructure. Access to normalised real-world data (RWD) from over 20 Million connected lives can help life sciences organisations track long-term treatment efficacy, monitor medication adherence, and streamline decentralised clinical trial designs. Strategic Implications and Future Outlook The consolidation of ChartSpan and Validic represents a significant maturity milestone for the remote care industry. For over a decade, the health IT market operated in silos, with software vendors providing data connectivity and clinical organizations operating in isolation. This transaction directly addresses that fragmentation by combining a scaled health IoT platform and device logistics system with a dedicated clinical care workforce. As CMS continues to transition toward value-based reimbursement models, such as Advanced Primary Care Management, the demand for integrated, continuous remote care is expected to rise. By leveraging its in-house device logistics, real-time data normalization, and 24/7 virtual care teams, the combined entity is well-positioned to lead this shift. This unified approach helps healthcare organizations move beyond periodic, episodic patient observations to establish a model of continuous clinical understanding. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The MedTech and HealthTech Corporate Divestiture landscape over the next 12 months The global medical technology and healthcare technology sectors are undergoing a profound structural realignment, shifting from post-pandemic volume driven consolidation toward highly disciplined portfolio design. Corporate divestitures, spin-offs and carve-outs have become primary mechanisms for multinational healthtech organisations seeking to optimise operating margins, reduce debt and redeploy capital toward high-growth, high-margin clinical categories. Driven by macroeconomic volatility, persistent inflation, supply chain pressures and localised market headwinds, corporate boards are abandoning broad diversification in favour of absolute category leadership. This corporate rationalisation is further accelerated by operational challenges in key markets such as China, alongside shifts in clinical care delivery, particularly the rapid migration of procedures to ambulatory surgical centres (ASCs) and home-care environments. Consequently, corporate assets that fail to align with a parent company's core operating model, clinical sales channels, or capital expenditure requirements are actively being carved out. Over the next 12 months, this structural pivot will produce a deep pipeline of high-value carve-out opportunities for both strategic acquirers and private equity investors. The New Paradigm of Portfolio Discipline and Strategic Consolidation The broader medtech mergers and acquisitions landscape demonstrates a clear rebound in aggregate transaction values, contrasted by a decline in overall deal participation. This divergence indicates a highly selective environment where capital is concentrated in fewer, larger, and more strategic transactions. Aggregate announced medtech deal values surged to approximately $61 Billion in 2025, up from $45 Billion in 2024 and $26 Billion in 2023. This momentum has carried into 2026, with the first half of the year generating $36.5 Billion in transaction value, including a robust Q1 that recorded approximately $27 Billion across 38 deals. This consolidation is characterised by massive strategic platforms, illustrated by Boston Scientific's $14.5 Billion acquisition of thrombectomy leader Penumbra in January 2026 and Danaher Corporation's $9.9 Billion acquisition of Masimo Corporation in February 2026. Together, these two transactions represented approximately 94% of total Q1 2026 deal value, highlighting a market that heavily favours established, operationally mature targets with proven scalability. Concurrently, spin-offs and divestitures accounted for approximately 34% of total medtech deal value in 2025, a noticeable increase from the five-year historical average of 29%. This acceleration reflects a fundamental shift in corporate strategy. Large multinationals are actively pruning non-core operations to unlock shareholder value and defend operating margins. Recent landmark divestitures, such as Solventum's $4.1 Billion sale of its Purification & Filtration business to Thermo Fisher Scientific and Baxter International's $3.8 Billion sale of its Vantive kidney care unit to the Carlyle Group, demonstrate how corporate spin-offs are rapidly followed by secondary portfolio rationalisation. Major Medtech Divisional Divestitures and Structural Separations (2025–2026) Divesting Parent Target Business Unit / Division Transaction Value & Structure Buyer / Transaction Partner Operational Status / Close Date Becton Dickinson Biosciences & Diagnostic Solutions $17.5 Billion; Reverse Morris Trust Waters Corporation Completed February 9, 2026 Solventum Purification & Filtration $4.1 Billion; Direct Asset Sale Thermo Fisher Scientific Completed Baxter International Vantive Kidney Care $3.8 Billion; Direct Asset Sale Carlyle Group & Atmas Health Completed January 2025 Royal Philips Emergency Care Undisclosed Value; Brand Licensing Bridgefield Capital Completed January 8, 2026 Medtronic Patient Monitoring & Recovery (Partial) $6.1 Billion; Cash Asset Sale Cardinal Health Completed This ongoing rationalisation suggests that corporate diversification is being systematically deprioritised in favor of market-specific depth. Companies are increasingly evaluating where they possess a differentiated "right to win," shedding auxiliary businesses to concentrate financial and human capital on high-margin, clinically urgent spaces. Active Divisional Carve-Outs and Structured Separations The corporate carve-out pipeline for the next 12 months is anchored by several multi-billion-dollar divisions currently undergoing active financial and operational separation. These assets are transitioning from integrated corporate units into independent, market-ready targets. Siemens Healthineers: The Diagnostics Carve-Out The most significant structural separation in the active pipeline is the formal carve-out of the Diagnostics business unit by Siemens Healthineers. In May 2026, corporate management officially transitioned the Diagnostics separation from an exploratory assessment to an active, group-wide operational carve-out project. This decision was driven by sharp operational divergence between the company's high-performing imaging and advanced therapies segments and its underperforming diagnostics division. The Diagnostics business has faced severe headwind in the Chinese market, which accounts for approximately 10% of total Siemens Healthineers revenue, due to the domestic implementation of volume-based procurement policies and centralised reimbursement cuts. This pricing pressure led to a 6.5% year-over-year decline in Diagnostics revenue, dragging down consolidated corporate performance and prompting management to lower its fiscal 2026 revenue growth guidance to 4.5%–5.0% and compress its adjusted basic earnings per share outlook to €2.20–€2.30. The Diagnostics carve-out is structured to establish absolute strategic optionality. By decoupling the Diagnostics business from the highly profitable Imaging and Precision Therapy divisions, Siemens Healthineers creates a clean asset prepared for a potential trade sale, a joint venture, or a private equity buyout. This operational separation runs parallel to a broader corporate event: parent company Siemens AG is preparing to deconsolidate its remaining 67% controlling stake in Siemens Healthineers. Siemens AG plans to execute a direct spin-off of a 30% stake in Siemens Healthineers to its own shareholders in early 2027, with formal shareholder votes scheduled for February 2027. Carving out the volatile Diagnostics segment maximises the market value and financial profile of the core Siemens Healthineers imaging business prior to this parent-level unwind. Johnson & Johnson: The DePuy Synthes Strategic Unwind Johnson & Johnson is actively preparing for a major portfolio rationalization through the potential sale or structured carve-out of its orthopedics subsidiary, DePuy Synthes, in a transaction estimated to exceed $20 billion. DePuy Synthes is a major force in the global orthopaedic market, producing hip, knee, trauma, and spine implants that generated approximately $9.3 billion in revenue in 2025 and maintained a 6.3% growth rate in the first quarter of 2026. Despite its scale, the orthopedics division represents a mature, capital-intensive segment characterized by heavy clinical sales overhead and pricing compression. Johnson & Johnson's overarching strategy is to shift capital and operational focus entirely toward its highest-growth, highest-margin segments, specifically Innovative Medicine and its advanced interventional MedTech solutions in surgery, vision, and cardiovascular care. While J&J originally evaluated a tax-free public spin-off as the primary separation path, the company has pivoted to compile comprehensive carve-out financials to facilitate a direct sale. Large-cap private equity consortiums have emerged as the most likely buyers, though interest from rival medtech strategics remains possible. To prepare the asset for separation, DePuy Synthes has continued to execute localized acquisitions, such as its May 2026 purchase of the Gemtrack miniature radiofrequency tracking technology from MinMaxMedical. This technology integrates real-time tracking directly into DePuy's Velys digital surgery platform without relying on invasive pins or infrared line-of-sight cameras. By embedding high-value digital navigation capabilities directly into the joints portfolio, J&J is enhancing the clinical differentiation and valuation of the DePuy asset ahead of a finalised transaction. Becton Dickinson: The Biosciences & Diagnostics Separation The corporate separation of Becton Dickinson's (BD) Biosciences & Diagnostic Solutions business represents a completed blueprint for high-value structured carve-outs. Structured as a tax-free Reverse Morris Trust, the unit was spun off to BD shareholders and simultaneously combined with Waters Corporation in a transaction valued at $17.5 Billion. The transaction closed on February 9, 2026, following a record date set for February 5, 2026. Under the terms of the transaction, BD received a tax-free cash distribution of $4 Billion, which the company has committed to deploying toward debt reduction and share repurchases. BD shareholders received common stock in Waters Corporation, representing a 39.2% ownership stake in the combined entity. The resulting business combined Waters' expertise in liquid chromatography-mass spectrometry (LC-MS) and chemistry consumables with BD's diagnostic reagents, flow cytometry platforms and clinical regulatory footprint. The transaction was underpinned by highly complementary operational synergies, with the combined entity projected to realise $200 Million in annual cost synergies by year three and $290 Million in annual revenue synergies by year five. This separation allowed BD to focus on its medical and interventional segments while capturing significant equity upside in a pure-play life sciences and diagnostics leader. The Next Wave of 12-Month Strategic Divestitures (H2 2026–H1 2027) A secondary wave of corporate carve-outs is poised to enter the market over the next 12 months, driven by active parent restructuring, integration cleanup from recent mega-mergers, and regional risk mitigation strategies. Medtronic: The Complete Diabetes Spin-Off and Acute Care Focus Medtronic is actively pursuing a long-term strategy to streamline its diversified portfolio and concentrate capital on high-growth, high-margin opportunities. The primary target for complete separation in the next 12 months is its global Diabetes business unit. The Diabetes division, while commercially scaled, has faced intense competitive pressure in the continuous glucose monitoring (CGM) and insulin pump markets, which has limited its market share expansion. In fiscal year 2025, the Diabetes segment accounted for 8% of Medtronic's consolidated revenues, but contributed only 4% of total operating profits. To optimise its consolidated margin profile, Medtronic executed a carve-out IPO of its diabetes business under the MiniMed Group brand in Q1 2026, raising approximately $560 Million at a market capitalisation of $5.6 Billion. Medtronic plans to execute a complete split and divestiture of the remaining business by the end of 2026. This separation follows a historical precedent of portfolio pruning at Medtronic, including the prior $6.1 billion cash sale of a portion of its Patient Monitoring & Recovery division to Cardinal Health and its renal care joint venture with DaVita. Furthermore, Medtronic has restructured its remaining Patient Monitoring and Respiratory Interventions divisions. After canceling a planned standalone spin-off of these units in early 2024 due to shifting capital market conditions, the company combined them into a new Acute Care & Monitoring (ACM) segment. As part of this consolidation, Medtronic initiated a phase-out of its unprofitable ventilator product lines. Sub-acute patient monitoring lines within the ACM division remain highly susceptible to secondary private equity-backed carve-outs over the next 12 months as Medtronic focuses capital on its core cardiovascular, robotic surgery, and neurovascular segments. This is demonstrated by its $550 million acquisition of Scientia Vascular to expand its neurovascular footprint. Danaher Corporation: The Post-Acquisition Masimo Consumer Carve-Out Danaher completed its $9.9 Billion acquisition of Masimo Corporation on June 10, 2026, integrating Masimo’s clinical pulse oximetry, brain monitoring, and acute-care automation solutions into its Diagnostics segment. The acquisition was highly strategic, expanding Danaher's diagnostics franchise alongside established operating companies such as Beckman Coulter, Radiometer, Leica Biosystems and Cepheid. However, the final terms of the transaction required Danaher to absorb Masimo’s consumer audio and consumer health divisions, which were previously under review for a potential spin-off. Historically, Masimo’s acquisition of consumer audio parent Sound United for $1 Billion in 2022 triggered intense shareholder opposition and a proxy battle led by Politan Capital. While Masimo successfully sold Sound United to Samsung’s Harman division for $350 Million in May 2025, the remaining consumer health wearables and retail monitoring operations do not align with Danaher's business-to-business clinical model. Danaher operates with a strict focus on highly regulated, high-margin diagnostic platforms characterised by recurring consumable revenue streams. Consequently, Masimo’s non-clinical consumer health and retail-oriented pulse oximetry watch divisions are prime candidates for a strategic carve-out or private equity divestiture in late 2026 or early 2027 to pay down the commercial paper issued to fund the acquisition. GE HealthCare: Targeted Localisation and Regional Carve-Outs Since its independent spin-off from General Electric in 2023, GE HealthCare has focused on a software-enabled precision care model. In April 2026, the company executed a major segment restructuring, combining its two largest imaging divisions into a unified imaging and clinical visualization segment. This operational reorganization is designed to support its cloud-first enterprise imaging strategy, which was accelerated by the $2.3 Billion acquisition of Intelerad in March 2026. To protect global operating margins from regional macroeconomic pressures and domestic procurement policies, GE HealthCare is pursuing highly targeted localization strategies. In January 2026, the company commenced pre-marketing activities for a carve-out sale of its localized China imaging business. By selling a majority stake in this regional operation to domestic Chinese entities or localized joint ventures, GE HealthCare can insulate its global corporate margins from volume-based pricing compression in China. This structure allows the company to retain key manufacturing partnerships and licensing agreements while transferring capital-intensive local commercial operations off its consolidated balance sheet. Royal Philips: Refining the Connected Care Portfolio Royal Philips continues to execute its multi-year strategy to simplify its operational structure and concentrate resources on clinical imaging, ultrasound, and image-guided therapy. Following the completion of the sale of its Emergency Care business to Bridgefield Capital on January 8th, 2026, a transaction that included a 15 year brand licensing agreement, the company is evaluating further separations. The company's Connected Care segment, which includes patient monitoring and sleep and respiratory care products under the Respironics brand, has faced persistent regulatory and operational headwinds. Over the next 12 months, selective carve-outs of specific sub-acute respiratory care and home-use sleep therapy product lines are highly likely. This rationalisation will enable Philips to focus capital on high-margin hospital enterprise informatics, clinical AI integrations, and coronary intravascular imaging platforms, such as its recent acquisition of SpectraWAVE. The MedTech and HealthTech Corporate Divestiture landscape over the next 12 months Market Dynamics, Clinical Shifts and Valuation Adjustments The surge in medtech carve-out activity is fundamentally linked to shifts in clinical care delivery, technological requirements, and capital market valuation resets. Forward-Looking Pipeline of High-Probability Carve-Outs and Divestitures (H2 2026–H1 2027) Parent Corporation Target Divestiture / Carve-Out Unit Estimated Valuation Range Primary Structural Pathway Target Market / Clinical Category Strategic Rationale Siemens Healthineers Clinical Diagnostics Business $8.0 Billion – $12.0 Billion Group-wide formal carve-out; Trade sale or PE JV In-Vitro Diagnostics & Core Lab Testing Mitigate China procurement headwinds; optimize imaging core Johnson & Johnson DePuy Synthes $20.0 Billion+ Direct trade sale or Private Equity buyout Hip, Knee, Spine, and Trauma Orthopedics Capital reallocation to innovative oncology and immunology Medtronic Diabetes Division (MiniMed) $5.0 Billion – $6.0 Billion Complete corporate split and share distribution Insulin Pumps & CGM Systems Enhance margins; improve agility against pure-play competitors Danaher Corporation Masimo Consumer Health $400 Million – $600 Million Secondary carve-out; Private trade sale Wearable sensors & consumer monitoring Focus on B2B clinical diagnostics; debt reduction GE HealthCare Localized China Imaging Business TBD Pre-marketing regional carve-out Regional CT, MRI, and Ultrasound Insulate global margins from local pricing pressures Royal Philips Connected Care / Sleep Therapy lines $800 Million – $1.2 Billion Selective carve-out or private asset sale Home CPAP and Respiratory Consumables Portfolio simplification; focus on enterprise informatics The migration of high-acuity surgical procedures from traditional acute-care hospital settings to lower-cost, high-throughput ambulatory surgery centers (ASCs) is a primary operational catalyst. The Centers for Medicare and Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System and ASC Payment System final rule added more than 500 procedures to the ASC Covered Procedures List, including AFib-treating cardiac catheter ablations, advanced spine procedures, and complex cardiology interventions. This regulatory shift has altered the commercial landscape. Heavy, capital-intensive hardware platforms designed exclusively for stationary hospital operating rooms are experiencing declining commercial demand, making them key targets for corporate divestiture. Conversely, procedural platforms that are mobile, digitally integrated, and optimised for rapid clinical throughput are commanding high valuation premiums. Furthermore, the rise of GLP-1 receptor agonist therapies is reshaping strategic planning across the medtech sector. These metabolic therapies have the potential to reduce long-term device utilisation across obesity-linked therapeutic segments, including sleep apnea, diabetes management, joint reconstruction, and cardiovascular support. In response, strategic buyers are focusing their acquisition pipelines on clinical assets that remain insulated from or complementary to GLP-1 treatment pathways. This is illustrated by Stryker's acquisition of Inari Medical, which anchors portfolio growth in late-stage thromboembolic disease that persists downstream of metabolic dysfunction. Consequently, legacy device lines that are highly vulnerable to GLP-1-driven demand declines are being systematically deprioritized and prepared for divestiture. To bridge valuation gaps in an environment characterized by elevated capital costs and selective buyers, deal structures have evolved. Upfront cash considerations are frequently supplemented by earnouts, structured equity components, and performance-based milestone payments. These milestone payments are tied to specific clinical, regulatory, or commercial achievements, allowing sellers to capture fair value while mitigating integration risks for strategic and private equity buyers. Strategic Conclusions - MedTech and HealthTech Corporate Divestiture in the next 12 months The medtech and healthtech corporate divestiture landscape over the next 12 months is defined by a rigorous focus on core business optimisation and structural efficiency. Corporate leaders are increasingly utilising carve-outs to simplify governance, reduce operational complexity and insulate corporate balance sheets from inflationary and geopolitical headwinds. The active separation of Siemens Healthineers' diagnostics division, the potential sale of Johnson & Johnson's DePuy Synthes unit, and the ongoing spin-off of Medtronic's diabetes segment highlight a clear industry trend. These transactions demonstrate a shift away from the diversified healthcare conglomerate model in favour of agile, pure-play market leaders. For private equity sponsors and strategic buyers, these corporate separations provide a valuable pipeline of scaled, operationally mature assets with stable cash flows and established commercial channels. Acquirers who can successfully navigate the complexities of transitional services agreements (TSAs) and implement targeted operational improvements will be well-positioned to drive substantial value creation in a reorganising global healthcare market. Concurrently, divesting parent corporations will emerge as more focused, agile, and high-margin entities, with the capital flexibility required to invest in next-generation digital, robotic, and precision care platforms. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Engineering Sovereign AI in Healthcare: Architecture, Compliance, and National Strategies for On-Premises Clinical Deployment The Paradigm of Sovereign Infrastructure in Clinical Environments Clinical enterprises are undergoing a fundamental transformation in how they deploy, orchestrate and manage artificial intelligence workloads. The rapid integration of high-performance models into core workflows, ranging from real-time diagnostic imaging to predictive patient risk modelling and automated clinical documentation, has exposed the limits of traditional public cloud architectures. In response, healthcare systems are increasingly adopting sovereign artificial intelligence architectures. Sovereign AI represents a model-hosting paradigm in which a healthcare system runs its own AI platform on its own infrastructure, on-premises or in a dedicated single-tenant environment, ensuring that protected health information (PHI) never leaves its perimeter. This approach represents a shift from data residency to true technological and jurisdictional autonomy. While traditional AI deployments prioritise rapid scaling, convenience, and low initial infrastructure costs by utilising shared external cloud resources, sovereign AI focuses on complete control, systemic resilience and alignment with strict legal perimeters. It is critical to distinguish sovereign AI from simple data sovereignty. Data sovereignty focuses narrowly on the geographic location where raw data is stored and the legal framework governing that storage. Sovereign AI encompasses a broader ecosystem, asserting verifiable ownership over the entire AI technology stack. This includes the physical graphics processing units (GPUs) and server nodes, the model weights and training methodologies, the data processing pipelines, the execution runtime and the operational governance policies. AI sovereignty describes an organisation's high-level capability to control its artificial intelligence ecosystem, whereas sovereign AI provides the concrete technical infrastructure and computational foundation required to realise that control. Architectural Domain Traditional Cloud AI Deployment On-Premises Sovereign AI Architecture Physical Infrastructure Multi-tenant public cloud datacenters operated by foreign hyperscalers On-premises data centers or isolated single-tenant virtual datacenters Data Perimeter Controls Cryptographic transit across external network boundaries to third-party endpoints Zero-egress local perimeters; raw protected health information remains within the local network Legal & Jurisdictional Scope Subject to foreign extraterritorial laws and parent company disclosures Exclusive governance by regional legislation and local health authorities Execution Architecture Shared, multi-tenant container runtimes and remote API-based endpoints Isolated physical clusters, private containers, and local hardware enclaves Operational Autonomy Vulnerable to external internet outages, API deprecation, and remote shutdowns Air-gapped capable; continuous operations independent of public internet access Compliance Proofs Contractual agreements, standard security certificates, and third-party DPAs Hardware-enforced cryptographic attestations and local audit ledgers This architectural transition is driven by the reality that clinical datasets represent highly sensitive corporate intellectual property and high-value targets for cyberattacks. By bringing the model directly to the data rather than exporting data to external models, clinical enterprises can eliminate the risk of data leakage during transit, prevent the unauthorised use of clinical data for model training and protect their workflows against external operational disruptions. Regulatory and Jurisdictional Drivers: The Extraterritoriality Threat The regulatory environment governing healthcare operations globally has made the use of traditional multi-tenant cloud services increasingly complex and risky. In the United States, HIPAA mandates strict administrative, physical, and technical safeguards to protect patient health information, with clinical data breaches reaching an average cost of $9.77 Million dollars in 2024. In the European Union, GDPR Article 9 imposes a strict prohibition on processing "Special Category Data," which includes genetic, biometric, and health-specific information, unless explicit consent is obtained or a specific legal basis is established. Standard cloud service agreements and general Data Processing Agreements (DPAs) frequently fail to satisfy these Article 9 requirements, leaving healthcare institutions exposed to regulatory penalties that can reach up to 4% of global annual revenue. A major operational challenge for health systems is the legal reach of non-European extraterritorial laws over global cloud providers. Under the United States Clarifying Lawful Overseas Use of Data (CLOUD) Act and Section 702 of the Foreign Intelligence Surveillance Act (FISA), U.S. law enforcement and intelligence agencies can legally compel technology providers subject to U.S. jurisdiction to surrender data under their control, regardless of whether that data is physically stored in Europe, Dublin, or Frankfurt. This jurisdictional conflict was highlighted by the Court of Justice of the European Union in the landmark Schrems II ruling, which invalidated the EU-U.S. Privacy Shield framework. The court determined that standard contractual clauses and data residency promises cannot guarantee protection against foreign intelligence collection, even when data is hosted on European soil by subsidiaries of U.S. firms. This vulnerability was confirmed under oath during a French Senate inquiry, where Microsoft's legal director acknowledged that the company could not refuse a U.S. legal order seeking access to European citizens' data. To address these vulnerabilities, national cybersecurity authorities have developed rigorous certification standards to isolate sensitive operations from foreign legal jurisdictions. In France, the National Agency for Information Systems Security (ANSSI) developed the SecNumCloud qualification. Now in version 3.2, SecNumCloud enforces strict operational, legal, and organizational requirements. To achieve SecNumCloud qualification, a cloud offering must be hosted on physical infrastructure located exclusively within the European Union, administered by EU-based personnel, and operated by an entity whose capital structure and governance prevent any non-European parent organisation or shareholder from exercising direct or indirect control. By establishing a legal barrier against extraterritorial warrants, these qualified platforms ensure that sensitive databases are subject only to local judicial authorisation. National System Realignment: Case Studies in Clinical Autonomy France: The Health Data Hub Transition France’s shift toward digital sovereignty is illustrated by the decision to migrate its Plateforme des Données de Santé, commonly known as the Health Data Hub, off Microsoft Azure. The Health Data Hub was created to centralise and standardise health records across the French medical system, including the extensive Système National des Données de Santé (SNDS) database, to accelerate public health research, epidemiology and clinical AI development. Despite operating under strict security protocols, the platform faced continuous legal challenges and criticism from the CNIL, which refused to approve the permanent hosting of the full national dataset on Microsoft's cloud infrastructure due to potential exposure to U.S. intelligence laws. To resolve this issue, the French government launched a public procurement process tied to the UGAP framework, requiring that the future host be SecNumCloud-qualified. Following a competitive evaluation based on over 350 technical criteria, domestic cloud provider Scaleway was selected to replace Microsoft Azure. The transition is scheduled for completion between late 2026 and early 2027. This move highlights how digital sovereignty has transitioned from a theoretical policy goal into a mandatory procurement requirement for clinical workloads. United Kingdom: NHS Cyber Resilience and the Maturity Paradox In the United Kingdom, the operational vulnerability of clinical networks was highlighted in June 2024 by a ransomware attack on pathology supplier Synnovis. The attack disrupted services across multiple London hospitals, leading to the cancellation of thousands of operations, the postponement of critical appointments, and at least one patient death alongside over 120 documented cases of patient harm. This incident exposed the vulnerability of a highly connected digital network where a security compromise at a single node can disrupt services across multiple regional trusts. Digital health leaders, such as Humber Teaching NHS Foundation Trust CIO Lee Rickles, have emphasised that failing to manage infrastructure sovereignty presents a severe strategic risk. Clinical organisations face a "maturity paradox" where rapid digital adoption creates operational dependencies without a corresponding maturity in cybersecurity and system recovery capabilities. Furthermore, the Tony Blair Institute for Global Change and government advisory bodies have outlined a three-tiered AI infrastructure strategy designed to protect sensitive datasets while supporting local control. National Initiative Lead Agency / Sponsor Primary Objective Key Technical Architecture French Health Data Hub Migration Ministry of Health, ANSSI, CNIL Protect national clinical databases (SNDS) from foreign extraterritorial access SecNumCloud-qualified, HDS-certified Scaleway infrastructure UK AI Growth Zones (AIGZs) Department for Science, Innovation and Technology Cluster domestic compute power, streamline planning, and coordinate energy assets Corridor deployments (e.g., Slough to Cardiff) utilising experimental silicon UK Sovereign Venture Fund British State Venture Fund Capitalize and scale domestic AI startups in clinical and scientific sectors Direct equity funding paired with access to 1 million sovereign GPU hours Alliance Santé IA Programme Montpellier University Hospital & Adlin Science Build and deploy localized clinical research AI models across French hospitals Scaleway cloud hosting integrated with local university hospital data lakes The UK's AI Opportunities Action Plan highlights that operational continuity requires local control over compute resources. If AI models become deeply integrated into critical diagnostic pipelines, a loss of access to foreign-hosted models during a global crisis or diplomatic dispute could disrupt clinical operations. To mitigate this risk, the UK is establishing designated AI Growth Zones (AIGZs). These zones are designed to support computational clustering along high-impact geographic corridors, such as Slough to Cardiff or the West Midlands to South Wales. By coordinating planning consents, simplifying environmental reviews and integrating data centers directly into energy-system planning, these growth zones aim to secure the power and infrastructure required to run high-density clinical AI workloads locally. Engineering Sovereign AI in Healthcare: Architecture, Compliance, and National Strategies for On-Premises Clinical Deployment On-Premises Hardware Engineering and Compute Infrastructure Deploying a sovereign clinical AI platform on-premises requires high-density computing infrastructure capable of hosting and training models without relying on public cloud connections. Hardware manufacturers and system integrators have developed pre-validated, turnkey infrastructure platforms designed specifically for local enterprise deployments. HPE Private Cloud AI Developed in partnership with NVIDIA, HPE Private Cloud AI provides a fully integrated, turnkey computational platform. The platform ranges from entry-level installations featuring ProLiant Compute servers with NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs to high-density clusters utilizing the ProLiant Compute XD685. The XD685 incorporates direct-liquid cooling loops and supports NVIDIA Blackwell Ultra processors and the GB300 NVL72 platform. The compute cluster is integrated with high-performance GreenLake file storage to run a local data lake house. While the data plane runs entirely on-premises, the control plane is managed via HPE GreenLake. This hybrid orchestration allows clinical IT administrators to deploy models and manage resources through a unified dashboard while ensuring that protected health information remains within the local network perimeter. Dell AI Factory Dell's high-density computational portfolio is built around its PowerEdge XE server lineup. The PowerEdge XE8712 supports up to 144 NVIDIA Blackwell GPUs per rack and utilises direct-liquid cooling to manage thermal limits under heavy training loads. For air-cooled data centres, Dell offers the PowerEdge XE9780 and XE9785, which feature NVIDIA HGX B300 GPUs connected via 800 gigabits-per-second ConnectX-8 networking. These compute nodes are supported by the Dell APEX hybrid cloud management portfolio, providing a framework to scale on-premises hardware adjacent to active clinical storage systems. Cisco Nexus HyperFabric AI Cluster Cisco's approach to local sovereign AI emphasises network orchestration and automated fabrics. The HyperFabric platform pairs Cisco’s Silicon One architecture and Nexus 6000 series high-end Ethernet switches (operating at 400 and 800 Gb/s) with NVIDIA Tensor Core GPUs, BlueField-3 Data Processing Units (DPUs), and VAST Data storage solutions. This pre-validated design functions as a plug-and-play AI datacenter. The platform uses automated deployment tools to manage network pathways, minimize latency, and provide end-to-end visibility across the physical compute fabric. Palantir & NVIDIA Sovereign AI Reference Architecture This reference architecture provides an enterprise-ready operating system designed to run on-premises. The platform integrates Palantir’s Foundry services with local NVIDIA Blackwell Ultra GPU clusters and Spectrum-X Ethernet networking. Running on hardened Kubernetes container systems, this architecture is designed for healthcare systems that require low-latency inference and data sovereignty. It allows clinical organizations to deploy and manage AI systems locally, ensuring that patient data never crosses the hospital network boundary. Google Distributed Cloud (GDC) To support sovereign workloads, Google offers Google Distributed Cloud, which brings its public cloud software stack directly to on-premises hardware. Operating on commercial off-the-shelf hardware and managed via Kubernetes, GDC can run in either connected or fully air-gapped modes. The air-gapped configuration isolates the physical deployment from the public internet. It runs independently and cannot be remotely shut down by Google, satisfying national security and high-risk regulatory requirements. In Europe, Google collaborates with local operating partners like S3NS in France to deliver these isolated environments, aligning their operational resilience with SecNumCloud and European sovereignty standards. Technical Security Mechanics: Confidential Computing and Attestation To prevent privileged system administrators or compromised hypervisors from inspecting sensitive patient data, sovereign AI architectures utilise hardware-enforced confidential computing. This approach relies on Trusted Execution Environments (TEEs), which are hardware-isolated enclaves in system memory managed directly by the CPU. Technology Paradigm Isolation Granularity Encryption Mechanism Remote Attestation Basis Key Target Use Cases Intel SGX (Software Guard Extensions) Application-level; creates encrypted user-space enclaves in memory Hardware-enforced memory encryption engine inside the CPU Code measurements (MRENCLAVE) and signer identity (MRSIGNER) Modular application components and cryptographic key vaults Intel TDX (Trust Domain Extensions) Virtual Machine-level; isolates guest VMs in secure Trust Domains Secure Arbitration Mode (SEAM) shielding guest memory Intel SGX/DCAP cryptographic quotes checked via root CA Turnkey container runtimes and VM-based model training AMD SEV-SNP (Secure Encrypted Virtualization-Secure Nested Paging) Virtual Machine-level; isolates guest VMs with memory integrity Independent hardware AES keys managed by AMD Secure Processor Hardware-signed report containing hypervisor mapping logs GPU-accelerated workloads, data lakes, and private cloud nodes By utilising these TEEs, a clinical AI platform can encrypt patient data in memory during active processing, protecting it from host-level threats. In a clinical context, this prevents unauthorized access by privileged insiders, such as system administrators, who might otherwise inspect decrypted payloads or model weights. This attestation sequence ensures that sensitive clinical data is only processed by verified, unmodified hardware enclaves. This framework is illustrated by Rapha’s clinical AI edge appliances, which utilise Intel SGX and TDX paired with TPM 2.0 to verify platform integrity. The system verifies code measurements (MRENCLAVE), signer identity (MRSIGNER), and platform configurations against Intel's root certificate authority. Only after verifying this cryptographic evidence does the platform release the necessary decryption keys, allowing clinical training and transaction settlement on the Polygon mainnet via RaphaClearingVault. By isolating workloads at the hardware layer, confidential computing enables secure collaboration across clinical boundaries. For example, multiple healthcare institutions can participate in federated learning studies to train models without centralising their patient datasets. Each hospital trains the model locally within its own confidential enclave. The resulting model updates are encrypted and sent to a central server, where they are aggregated inside a secure TEE, protecting both patient privacy and model weights from unauthorized inspection. Architectural Implementation Patterns and Local Operations Deploying a sovereign AI platform requires a modular software architecture to manage model lifecycles and enforce security boundaries. A key reference design is the MAGS-SLH Sovereign pattern, which coordinates specialized AI agents while maintaining human control. The central Core Engine coordinates tasks and delegates execution to the Crew Agent Manager. The Crew Agent Manager instantiates specialized, ephemeral AI agents inside isolated runtimes to perform specific tasks, such as parsing an incoming diagnostic report, and terminates them immediately upon completion. By destroying these containers after use, the platform minimises the persistent attack surface and reduces the risk of lateral compromise. To integrate human oversight into automated workflows, the architecture features a Human-in-the-Loop Arbitrated Cognitive Interface (HACI). HACI provides operators with visibility into model decisions, allowing clinical staff to inspect, modify, or reject sensitive recommendations before they are finalised. Additionally, every step, data access event, and model output is logged to an immutable, eIDAS-compliant ledger, providing signed, timestamped records to support clinical audits. Turnkey Conversational Interfaces and Privacy Grounding Within a sovereign network, a private conversational interface can serve as a primary portal to access local infrastructure. Clinicians and administrators can interact with the system using natural language queries—for example, directing the orchestrator to deploy a new LLM container or allocate specific GPU nodes to an imaging pipeline. Because the interface and underlying models run entirely on-premises, users can input complete patient histories and detailed clinical notes without risking data exposure. This enables the system to generate more accurate, context-aware summaries and recommendations. To minimise the risk of model hallucinations, which present compliance and clinical safety risks, sovereign architectures utilise retrieval-grounded systems with built-in validation layers. These systems use local vector databases to retrieve verified context from approved clinical guidelines, medical textbooks, or institutional knowledge bases. The model relies on this retrieved context to formulate its response, rather than generating answers from its training data. A validation layer then evaluates the output against safety metrics and confidence thresholds, escalating low-confidence results to human specialists. Local Clinical Workflows and Medical Imaging Integration Sovereign AI architectures integrate directly with existing hospital infrastructure, such as picture archiving and communication systems (PACS). For example, a local medical imaging pipeline can use containerized models to segment anatomical structures in real time: In this localised workflow, DICOM format medical images are stored on secure local disks and imported to the containerised environment. The NVIDIA VISTA-3D NIM container segments over 120 organs and anatomical structures on a local GPU cluster, using Triton Inference Server to optimise throughput and reduce latency. The resulting segmentation masks are audited by a local validation layer before being returned to the PACS viewer for clinician review, keeping all patient data inside the hospital network. This local execution model is supported by offline productivity tools like Meetily, which run transcription and clinical summarisation models directly on end-user devices. By processing audio locally, these applications eliminate the need for external data transit or vendor Data Processing Agreements (DPAs), satisfying privacy-by-design requirements under GDPR Article 25. To support on-premises data protection, organizations deploy automated backup tools like Velero, configured to write to local, immutable storage targets. These configurations are restricted to prevent cross-region replication or data transfer to unauthorised locations. Every backup run, secret access event, and service account operation is cryptographically logged, providing audit trails to verify compliance. Operational Resilience, Recovery and the Human Factor Maintaining operational continuity is a critical requirement for sovereign clinical AI deployments. When high-performance models are integrated into daily clinical workflows, system outages can directly impact patient care and safety. Therefore, healthcare organisations must shift from a purely preventive security posture to a recovery-oriented resilience model. To manage operational risks and eliminate single points of failure across the local hardware stack, clinical IT teams utilise Failure Mode and Effects Analysis (FEMA). FEMA processes evaluate how hardware dependencies or network disconnects affect clinical services, establishing automated failovers to maintain system availability. For example, if a local GPU node experiences a hardware fault during a real-time diagnostic scan, the cluster controller automatically migrates the containerised workload to a healthy node, ensuring continuous operation. To defend against cyberattacks, sovereign architectures utilize Isolated Recovery Environments (IREs). An IRE is an air-gapped, distinct computational vault isolated from the primary network. It contains verified immutable backups, clean deployment images for all core models and operational systems, and offline copies of recovery playbooks and license keys. If a ransomware attack compromises the active network, the IRE allows the healthcare system to reconstruct its primary clinical AI pipelines without relying on external connections. Furthermore, managing the human factor is critical to maintaining operational resilience. During network outages, clinical personnel must be trained on validated fallback processes to prevent operational disruption. If clinical systems are unavailable, staff should not resort to unsanctioned consumer apps like personal WhatsApp or Gmail accounts to coordinate care, as this can lead to data exposure and regulatory non-compliance. By combining hardware-enforced isolation, offline recovery environments, and structured operational training, clinical enterprises can protect patient privacy while ensuring continuous access to critical AI capabilities. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Valuation Architectures in Healthtech and Medtech: Discounted Cash Flow and Terminal Value Frameworks Valuation Architectures in Healthtech and Medtech: Discounted Cash Flow and Terminal Value Frameworks The valuation of healthtech and medtech entities represents one of the most complex exercises in corporate finance, requiring analysts to bridge the gap between long-term scientific development, binary regulatory approvals, capital intensive commercialisation and rapid technological obsolescence. Within a discounted cash flow (DCF) model, the terminal value is the single most critical and sensitive component of a company's total implied valuation, typically constituting between 60% and 80%, and frequently up to 75% of the total implied enterprise value. Because the terminal value compresses decades of future cash flows beyond the explicit projection window into a single figure, small adjustments to terminal-year assumptions can result in massive swings in valuation. For instance, a minor $100,000 reduction in normalised operating cash flow in the terminal year can translate into a $1,000,000 reduction in implied enterprise value when utilising a standard 10x exit multiple. This report provides an institutional grade analysis of how terminal value is formulated, adjusted and reconciled for healthtech, medtech, and digital health companies. Foundations of Terminal Value in Healthcare Valuations In corporate finance, the terminal value represents the present value of all free cash flows a business will generate beyond the explicit forecast period (typically five to ten years) under the assumption of a going concern. This value is estimated using two primary methods, each anchored in different financial theories and market inputs. The Perpetuity Growth (Gordon Growth) Model The perpetuity growth model treats a business as a growing perpetuity that generates cash flows at a constant, sustainable rate forever. The mathematical formulation is expressed as: TV = \frac{FCF_{terminal} \times (1 + g)}{WACC - g} Where: TV$ is the terminal value at the end of the explicit forecast period (t = n). $FCF_{terminal} is the normalised free cash flow in the final projected year of the explicit forecast period. g is the perpetuity growth rate, which must be lower than the discount rate to ensure mathematical convergence. $WACC$ is the Weighted Average Cost of Capital, representing the discount rate. The resulting terminal value must then be discounted back to the present day using the following formula: PV(TV) = \frac{TV}{(1 + WACC)^n} Where n represents the total number of years in the explicit forecast period. In practice, the perpetuity growth rate (g) is anchored to long-term macroeconomic metrics, typically ranging between 2% and 4% to reflect sustainable, long-run nominal GDP and inflation expectations. The Exit Multiple Approach The exit multiple approach is a market-relative method that assumes the business will be valued or sold at the end of the projection horizon at a multiple of a key financial metric. It is structurally simpler and highly favoured by investment banking practitioners because it incorporates real-time market sentiment. The terminal value under this approach is formulated as: TV = EBITDA_{terminal} \times \text{Exit Multiple} Where: EBITDA_{terminal} is the normalised Earnings Before Interest, Taxes, Depreciation, and Amortisation in the final year of the explicit projection. \text{Exit Multiple} is a valuation multiple (such as Enterprise Value to EBITDA) derived from comparable public trading companies or precedent transactions in relevant sub sectors. Valuation Divergence: The Medtech Lifecycle and the Biopharma Patent Cliff A fundamental risk in evaluating medtech and healthtech assets is the misapplication of generalised corporate valuation methodologies to highly specialised product lines. In particular, a sharp divergence exists between the cash flow profiles of medical devices and biopharmaceuticals. Commercial-stage pharmaceutical models are heavily influenced by the "patent cliff" or loss of exclusivity (LOE). When a blockbuster drug's patent protection expires, generic or biosimilar competition floods the market, causing a rapid and severe erosion of 80% to 90% of the branded drug's revenue within two to three years. A classic historical benchmark is Pfizer's Lipitor, which generated $13 Billion in annual revenue at its peak but lost over $10 Billion in revenue within just two years of patent expiration. Because a drug's commercial viability is strictly time-limited, applying a standard perpetuity growth rate of 2% to 4% is dangerous and systematically overstates the terminal value. Instead, analysts valuing biopharma portfolios utilise a Sum-of-the-Parts (SOTP) framework, projecting product-level cash flows directly through their respective LOE dates and modelling explicit, steep decay curves that transition the terminal value of that specific product to zero. To evaluate whether a pharmaceutical company's developmental portfolio can replace the revenue lost to upcoming patent expirations, healthcare analysts utilise the pipeline coverage ratio. This metric compares the probability-weighted peak sales of pipeline assets to the revenue at risk from LOE over the next five to seven years. A ratio below 1.0x signals a looming revenue gap that typically forces the company to engage in strategic M&A to acquire commercial-stage assets. For example, the pipeline coverage ratio for Merck's Keytruda, representing approximately $25 Billion in annual revenue at risk of patent expiration between 2028 and 2030, is a central focal point in healthcare equity research and serves as a major driver of strategic acquisition activity. In contrast, medical device (medtech) products do not generally experience binary legal patent cliffs that trigger instantaneous generic entry. While medical devices have significant development timelines (typically 3 to 10 years) and regulatory barriers to entry, they are characterised by evolutionary engineering. Rather than facing a sudden 90% drop in cash flows, a mature medical device is slowly superseded by newer, technologically superior iterations or incremental product-line extensions. Furthermore, medtech companies often rely on high-barrier moats, such as proprietary platforms with steep switching costs (the "installed base moat") or behavioural lock-in driven by specialised surgical training (the "behavioural moat"). Consequently, mature medical device companies can support a standard perpetuity growth rate or a stable exit multiple in their terminal year, provided their technology has been successfully commercialised and integrated into healthcare workflows. Feature / Dimension Biopharmaceutical Products Medtech & Medical Device Products Healthtech & Digital Health Terminal Value Approach Sum-of-the-Parts (SOTP) with zero/minimal terminal value per drug; cash flows modeled to explicit decay Standard going-concern TV (perpetuity or exit multiple) applied to consolidated commercial platforms Standard going-concern TV, heavily focused on recurring revenue and SaaS-based multiples Exclusivity Profile Binary patent cliffs; high risk of immediate 80-90% generic erosion at LOE Gradual technological obsolescence; protected by proprietary platforms and physician preference Low clinical obsolescence; primary risk is SaaS platform switching and rapid software iterations Reinvestment Intensity Extremely high R&D to replace expiring pipelines; heavy reliance on clinical trial capital Moderate capital expenditures for specialized tooling, localized manufacturing, and line extensions Low physical CapEx; high development expensing (capitalized software) to support continuous platform updates Typical Cash Flow Moat Intellectual property, regulatory exclusivity, and clinical publications "Razor/blade" recurring consumables, surgical training, and installed hardware bases High switching costs, system-wide workflow integrations, and proprietary data structures Illustrative Sum-of-the-Parts (SOTP) Valuation Framework For diversified healthcare and pharmaceutical companies, corporate-level DCF models are highly insufficient because they obscure these divergent lifecycles. Instead, a Sum-of-the-Parts (SOTP) framework is utilised, which breaks the enterprise down into distinct commercial, pipeline, and corporate segments: \text{SOTP Value} = \sum(\text{Commercial Product DCFs}) + \sum(\text{Pipeline rNPVs}) + \text{Platform Value} - \text{Net Debt} The table below outlines a standard institutional implementation of a SOTP framework for a mid-sized healthcare enterprise with a mixed commercial and developmental portfolio: Portfolio Component Operational Parameters & Exclusivity Profile Implied SOTP Value ($B) Percentage of Total Enterprise Value Product A (Commercial) Peak sales of $4B; LOE cliff in 2027; currently experiencing declining commercial cash flows 12.00 28.24% Product B (Commercial) Peak sales of $2B; LOE cliff in 2031; currently in high-growth commercialization phase 10.00 23.53% Product C (Commercial) Early launch stage; estimated peak sales of $3B; LOE cliff expected in 2036 15.00 35.29% Pipeline Asset 1 (Clinical) Phase III oncology asset; 60% transition Probability of Success (PoS); est. peak sales of $2.5B 4.00 9.41% Pipeline Asset 2 (Clinical) Phase II rare disease asset; 25% transition PoS; est. peak sales of $1.5B 1.50 3.53% Early Pipeline (Pre-clinical) Aggregated preclinical and Phase I assets, conservatively valued 1.00 2.35% Corporate Overhead NPV Net present value of unallocated G&A, corporate R&D, and structural costs -3.00 -7.06% Aggregated Enterprise Value Total intrinsic value of the operating enterprise 40.50 95.29% Corporate Cash & Debt Bridge Plus: Cash and cash equivalents ($2.0B) 2.00 4.71% Implied Equity Value Total net asset value allocable to equity shareholders 42.50 100.00% Multiple Dispersion and Sector Benchmarks (2025–2026) When applying the Exit Multiple Approach to medtech and healthtech entities, comparable company trading multiples serve as the primary baseline. However, the medtech market is highly heterogeneous; a cardiovascular implant manufacturer and a commoditised hospital supply distributor operate under fundamentally different margin profiles, growth rates, and regulatory risk categories. Applying a generalised industry multiple is a common and severe valuation error. Rather, the multiple must be tailored based on the company's size, sub sector and underlying growth profile. Scale-Based and Sub sector Valuation Multiples In the medtech and healthtech markets of 2025 and 2026, enterprise multiples demonstrate a clear positive correlation with company scale, which is often termed the "size premium". Larger entities command premium multiples because of their diverse product portfolios, established distribution channels and lower execution risk. Conversely, in the broader healthcare space, service-oriented businesses have experienced multiple contraction, with median public healthcare services EV/EBITDA multiples declining to approximately 11.5x in 2026 from 14.5x in 2025. Scaled Financial Metric Pure-Play Medical Device Multiple Medtech Software / Digital Health Multiple $1M – $3M EBITDA 6.7x EV/EBITDA 8.2x EV/EBITDA $3M – $5M EBITDA 8.3x EV/EBITDA 10.2x EV/EBITDA $5M – $10M EBITDA 10.4x EV/EBITDA 14.4x EV/EBITDA $10M+ EBITDA (Mid-Market) 10.0x – 15.0x EV/EBITDA 14.0x – 18.0x EV/EBITDA $100M+ EBITDA (Large-Cap) 15.0x – 21.0x EV/EBITDA 18.0x – 25.0x EV/EBITDA $1M – $5M Revenue 3.6x EV/Revenue 5.0x – 8.0x EV/Revenue $6M – $10M Revenue 4.4x EV/Revenue 6.0x – 10.0x EV/Revenue $10M – $50M Revenue 5.0x EV/Revenue 8.0x – 12.0x+ EV/Revenue $50M+ Revenue 5.0x – 7.0x EV/Revenue 10.0x – 15.0x+ EV/Revenue When assessing unprofitable or early-stage digital health systems, valuations heavily rely on forward-looking revenue multiples. In the lower-market wellness sector, multiples remain conservative, with the median EV/Revenue multiple for wellness and health companies sitting at 1.1x in early 2026, slightly below pre-pandemic levels. Underperforming or unprofitable European startups trade at highly discounted ranges of 3.0x to 4.0x revenue, while general medtech in Europe commands 4.0x to 6.0x revenue, and AI-driven healthcare solutions trade at premiums of 6.0x to 8.0x+ revenue. Public trading reference benchmarks as of Q2 2025 illustrate the wide dispersion of multiples across different medtech business models: Intuitive Surgical: Command a highly premium valuation exceeding 20.0x EV/Revenue and 50.0x EV/EBITDA (with forward EBITDA multiples exceeding 40.0x), reflecting its dominant monopoly in robotic-assisted surgery and robust recurring software/service stream. Boston Scientific: Trades at 9.2x EV/Revenue and 35.0x EV/EBITDA (25.4x forward EBITDA), driven by its high-growth interventional cardiology portfolio. Stryker: Trades at approximately 7.0x EV/Revenue and 25.0x EV/EBITDA (22.0x forward EBITDA), representing a diversified orthopaedic and surgical player. Medtronic: Trades at approximately 4.0x EV/Revenue and 16.0x EV/EBITDA (14.0x forward EBITDA), reflecting slower organic growth. Baxter International: Trades at a discounted multiple of 2.2x EV/Revenue and 12.1x EV/EBITDA (9.2x forward EBITDA) due to lower growth profiles and more commoditised hospital hardware lines. Align Technology: Trades at 3.3x EV/Revenue and 15.2x EV/EBITDA (11.6x forward EBITDA). Peer Group Construction and Premium Drivers To avoid the "peer group trap," valuation specialists must construct comparable sets along three specific operational dimensions: Device Category Alignment (separating orthopaedic implants from cardiovascular devices, which have entirely different clinical margins and procedure volumes), Growth Profile Matching (grouping companies by organic growth rates, such as sub-3%, 3-6%, 6-10%, or 10%+), and Business Model Type (separating capital equipment-heavy companies from consumable-heavy razor/blade companies). The organic growth rate remains the single strongest predictor of multiple dispersion. For every percentage point of organic growth achieved above the industry average of 5% to 6%, a medtech company typically commands an additional 1 to 2 turns of EV/EBITDA. This relationship is non-linear and accelerates rapidly above 10% growth. This explains why Edwards Lifesciences, growing in the high-teens due to its transcatheter aortic valve replacement (TAVR) portfolio, historically trades at 20x to 25x EBITDA, representing 3 to 4 times the trading multiple of Medtronic, which is constrained by low-single-digit organic growth. Furthermore, the market rewards the recurring, high-visibility "razor/blade" business model with an additional 3 to 5 EBITDA turns relative to capital-equipment heavy peers. Finally, devices backed by regulatory barriers such as Premarket Approval (PMA) command significant premium multiples compared to those utilising the highly commoditised 510(k) pathway, which typically faces intense competitor density. Precedent Transactions and M&A Valuation Structuring In the medtech and healthtech sectors, strategic transaction multiples complement public comparable trading analyses by reflecting control premiums, cost and revenue synergies, and strategic asset positioning. Target Company Acquiring Strategic Entity Announced / Close Date Transaction Value ($B) Implied Revenue Multiple Implied EBITDA Multiple Key Strategic Catalyst & Valuation Premium Drivers Exact Sciences Abbott Laboratories 2025–2026 $21.0B ~7.0x N/A Cancer diagnostics leadership; capture of the highly valuable Cologuard franchise asset Penumbra Boston Scientific 2025–2026 $14.5B ~13.0x N/A High-growth thrombectomy market position; platform premium for vascular intervention portfolio Shockwave Medical Johnson & Johnson 2024 $13.1B ~18.0x ~54.0x High-growth Intravascular Lithotripsy (IVL) technology platform; strong margin profile Masimo Danaher Corporation 2025–2026 $9.9B ~6.6x ~18.0x (2027E) Leadership in pulse oximetry; valued at 15.0x on a post-synergized basis Wright Medical Stryker Corporation 2020 ~$5.4B ~5.0x – 6.0x ~35.0x Rapid expansion of extremities orthopedic portfolio; integration of localized sales forces Inari Medical Stryker Corporation 2025–2026 $4.9B ~8.0x N/A Capture of high-growth venous thromboembolism (VTE) clinical technology; 58% growth trajectory Intelerad GE HealthCare 2025–2026 $2.3B N/A N/A AI-powered enterprise imaging software; SaaS-based clinical workflow integration BTG plc Boston Scientific 2019 ~$4.2B ~7.0x ~25.0x Creation of a global interventional medicine platform; specialized drug-eluting bead technology Valuation Risk Mitigation: Earn-Outs and Contingent Value Rights Because medtech and healthtech companies are highly sensitive to regulatory clearances and clinical trial outcomes, M&A transactions frequently employ advanced structuring mechanisms to bridge valuation gaps between buyers and sellers. These mechanisms directly impact the cash flows projected in a transaction-based DCF. In life sciences and medical device transactions, earn-outs often comprise approximately 40% of the total potential deal value. Under these structures, a portion of the purchase price is held back and paid post-close only upon the achievement of specified clinical, regulatory, or commercial milestones. An example includes Medtronic's acquisition of CathWorks, which structured up to $585 Million in post-close milestone payments. Similarly, Boston Scientific completed an acquisition featuring a $15 Million upfront payment coupled with a $10 Million milestone tied to achieving FDA 510(k) clearance, a $15 Million milestone tied to commercial execution, and ongoing commercial royalties. Contingent Value Rights (CVRs), securities representing future payouts if specific technical or commercial milestones are met, are also widely used. CVRs were utilised in approximately two-thirds of all 2025 life science deals, averaging over one-third of the total transaction value. For corporate carve-outs and tax-free parent divestitures of non-core medtech divisions, companies utilise a Reverse Morris Trust (RMT). A notable example is the $17.5 Billion transaction separating Becton Dickinson’s Biosciences & Diagnostic Solutions via an RMT structure with Waters. Terminal Year Normalisation and Reinvestment Mechanics A frequent error in DCF modelling is the failure to properly normalise the cash flow of the target company in the terminal year. The terminal year represents a "steady state" where the company's financial performance has leveled out to a sustainable, predictable growth rate. Projecting unadjusted or lumpy cash flows into perpetuity results in highly distorted valuations. Normalising Capital Expenditures and Depreciation A common modelling practice is setting Capital Expenditures (CapEx) equal to Depreciation and Amortisation (D&A) in the terminal year (CapEx = D\&A) under the assumption that a mature firm only needs to replace its existing asset base. In institutional practice, this is mathematically inconsistent and fundamentally incorrect for three reasons: Inflationary Disconnect: Depreciation is an accounting metric based on historical, unadjusted acquisition costs. CapEx represents current and future outlays. Because of inflation, the future cost to replace physical manufacturing assets or specialised cleanrooms will always exceed historical depreciation. Growth-Support Requirements: If a company's free cash flow is projected to grow in perpetuity (g > 0), it must expand its physical or capitalised asset base to support that growth. A business cannot grow its revenue and production volume forever without expanding its physical cleanroom footprint, tooling, or database servers. Productivity and Cost Curves: Physical equipment becomes more efficient and technology costs decline over time. However, this productivity gain rarely offsets the combined effects of inflation and the capacity expansion required for growth. To resolve this, the steady-state reinvestment rate (RR) must be explicitly tied to the perpetuity growth rate (g) and the expected Return on Invested Capital (ROIC): RR = \frac{g}{ROIC} Once this rate is established, the normalised Capital Expenditures in the terminal year must be modelled as slightly lower than the hyper-growth projection years (reflecting lower reinvestment) but must mathematically remain above Depreciation and Amortisation to support the perpetual growth rate: $$CapEx_{terminal} = D\&A_{terminal} + \left( Net \ Revenue_{terminal} \times RR \right)$$ In healthtech and SaaS-enabled digital health platforms, physical CapEx is typically low, but research and development (R&D) and capitalised software development behave as the operational equivalent of CapEx. Analysts must ensure that capitalised software development costs are normalised and offset by appropriate amortisation in the terminal year, avoiding the assumption that software can be maintained without continuous capitalised engineering investment. Valuation Architectures in Healthtech and Medtech: Discounted Cash Flow and Terminal Value Frameworks Normalising Net Operating Losses (NOLs) and Tax Rates Medtech and healthtech startups frequently accumulate substantial Net Operating Losses (NOLs) and research tax credits during their clinical trial and early commercialisation phases. These tax shields often result in an artificially low or zero cash tax rate during the explicit projection period. However, in the terminal year, these historical NOLs are typically exhausted. Modeling a low cash tax rate into perpetuity will overstate the terminal value. Institutional analysts utilise one of three solutions to normalize terminal-year tax structures: Projection Extension: Extend the explicit projection period until the accumulated NOLs are fully utilised, allowing the cash tax rate to naturally step up to the standard marginal corporate rate in the final years before calculating the terminal value. Immediate Terminal Normalisation: Assume that NOLs do not exist in the normalised steady state, modelling the full marginal cash tax rate (typically 21% for US entities) starting immediately in the terminal year. Enterprise Value Adjustment: Ignore the NOL tax shields within the free cash flow projections (modelling standard marginal taxes throughout the explicit period) and instead add the standalone net present value of the NOL tax shields as a non-operating asset in the final Enterprise Value-to-Equity Value bridge. Elimination of Amortisation and Non-Recurring Items To normalise the terminal year free cash flow, analysts must eliminate non-recurring restructuring charges, lumpy working capital movements and the Amortisation of Intangibles. Because the terminal period assumes a steady-state going concern with no further finite-lived acquisition activities, amortisation of acquired intangibles should be removed from the terminal year cash flow. This ensures that the terminal FCF growth rate is normalised to a realistic 2% to 4% range, rather than carrying over an unsustainable 15% to 20% growth rate from the explicit projection period. Alternative Approaches for Pre-Revenue and Early Stage Valuations For clinical-stage medtech firms and pre-revenue digital health platforms, traditional corporate-level DCF models fail because they cannot handle negative EBITDA and high binary clinical or regulatory risks. Instead, valuation professionals rely on two primary alternative frameworks: Risk-Adjusted Net Present Value (rNPV) The rNPV framework is the gold-standard methodology for clinical-stage assets. Instead of adjusting for binary developmental risk by inflating the discount rate to an arbitrary venture-capital level (which can double-count risk), the rNPV model directly adjusts the projected commercial cash flows by the historical probability of achieving regulatory success at each phase gate. The rNPV is formulated as: rNPV = \sum_{t=0}^{N} \frac{CF_t \times P(success\_to\_year\_t)}{(1 + r)^t} Where: CF_t is the projected commercial cash flow in year t (incorporating R&D and clinical costs as negative cash flows, and commercial revenues as positive cash flows). P(success\_to\_year\_t) is the cumulative probability that the asset will survive all intervening clinical and regulatory hurdles to remain active in year t. r is a moderate, risk-adjusted discount rate (typically 8% to 12%), reflecting only the cost of capital and market risk, since clinical failure risk is already captured in the probability weights. Applying a high venture-stage discount rate (15% to 30%) alongside probability weightings is a common valuation error that systematically understates the pipeline asset's value. The probability adjustments in these models are based on historical transition success rates, which vary by therapeutic area and regulatory pathway: Development and Regulatory Milestone Phase Transition Success Rate Cumulative Probability from Pre-Clinical Pre-Clinical Development ~60.0% 60.0% First-in-Human / Phase I Trial ~65.0% ~39.0% Pivotal Trial / Phase II Trial ~35.0% ~14.0% FDA Submission / Phase III Trial ~60.0% ~9.6% (IND to Approval) FDA 510(k) Clearance / Approval 85.0% – 95.0% ~8.0% – 9.0% Intangible Asset and Comparable Financing Valuations When pre-revenue startups lack the visibility to build reliable cash flow projections, alternative asset-based or market-based approaches are utilised: Intangible Asset Valuations: This approach values the company based on its intellectual property portfolio, pending or approved regulatory dossiers (such as a 510(k) clearance or CE mark technical files), and clinically published safety and efficacy records. For example, a cleared 510(k) regulatory asset has an established direct value of $5 Million to $50 Million+ based on avoided development costs and speed-to-market. Comparable Financing Valuations: This approach benchmarks the company's valuation against recent financing rounds (such as Series A or Series B rounds) completed by similar peers in the same clinical sub sector. Terminal Value Growth Rate Assumptions and Analytical Reconciliations In corporate finance, terminal growth rates (g) must be set at or below the long-run nominal growth rate of the host economy to prevent the business from mathematically outgrowing the entire economy in perpetuity. While standard models default to 2% to 3% for mature businesses, actual institutional valuation research reveals a wider dispersion of growth assumptions depending on the specific asset profile: The Standard 2% Baseline: Zacks Small Cap Research's valuation of Cosmos Health (focusing on digital health services and integrated wellness models) utilises a 2.0% terminal growth rate. This is in line with standard macroeconomic inflation targets and long-term GDP growth. The 3% Institutional Consensus: Equity research analysts at ABG Sundal Collier (ABGSC) consistently employ a 3.0% terminal growth rate in their medtech valuations. For example, in their coverage of Ossdsign (scaling towards profitability), ABGSC applied a 3.0% terminal growth rate coupled with a 10.0% WACC. Similarly, their valuation of Q-Free (traffic management and tolling technology) utilised a 3.0% terminal growth rate. The 3.6% High-Growth Scenario: PIU Medical's reference DCF model utilizes a 3.6% base case terminal growth rate. This sits significantly above the standard 2.0% to 3.0% range, reflecting the premium growth dynamics of specialised pharma and medical device divisions. The 4% GuruFocus Earnings Stage: GuruFocus utilises a default 4.0% terminal growth rate within a secondary 10-year terminal stage in its two-stage discounted earnings model. To handle fast-growers and abnormal growth patterns, the growth rate during the initial stage is capped between 5.0% and 20.0%. Explicit Mathematical Reconciliation To ensure internal consistency, analysts must reconcile the implied perpetuity growth rate (g_{implied}) from a chosen exit multiple, or conversely, extract the implied multiple from an assumed perpetuity growth rate. This reconciliation acts as a vital sanity check. To calculate the implied perpetuity growth rate from a chosen EV/EBITDA multiple, the perpetuity growth equation is rearranged: g_{implied} = \frac{WACC \times Multiple - \left(\frac{FCF_{terminal}}{EBITDA_{terminal}}\right)}{Multiple + \left(\frac{FCF_{terminal}}{EBITDA_{terminal}}\right)} Where: Multiple is the target EV/EBITDA exit multiple. \frac{FCF_{terminal}}{EBITDA_{terminal}} is the free cash flow conversion ratio of the company in the terminal year, representing how efficiently the firm converts operating earnings into distributable cash. Consider a high-growth medtech software platform valued at a 15x EV/EBITDA exit multiple, with a WACC of 8.0% and a terminal FCF conversion ratio of 65%: g_{implied} = \frac{0.08 \times 15 - 0.65}{15 + 0.65} = \frac{1.20 - 0.65}{15.65} = \frac{0.55}{15.65} \approx 3.51% The resulting implied perpetuity growth rate of 3.51% is realistic and sustainable, sitting at the upper bound of long-term nominal GDP growth and justified by the platform's recurring SaaS revenue streams. If, however, a commoditised orthopaedic company with a lower-margin profile is valued at a 12x exit multiple, with a WACC of 10.0% and a terminal FCF conversion of 40%: g_{implied} = \frac{0.10 \times 12 - 0.40}{12 + 0.40} = \frac{1.20 - 0.40}{12.40} = \frac{0.80}{12.40} \approx 6.45\% A perpetual growth rate of 6.45% is highly unrealistic, as it implies the low-margin company will eventually grow to become larger than the entire economy. This signals a fundamental mismatch: either the exit multiple is too high, the WACC is miscalculated, or the terminal-year cash flow normalisation is flawed. By continuously cross-checking these two terminal value methodologies, equity analysts and investment bankers can construct mathematically coherent, risk-adjusted valuation models that reflect the unique operational and regulatory characteristics of the healthtech and medtech sectors. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk